Adverse Event,Category,Trial Id,URL,Condition,Intervention,Total-affected,Total-at risk,Serious/Other,Arm#,Arm Title,Arm-affected,Arm-at risk
Hypersensitivity,Immune_system_disorders,NCT00014911,https://clinicaltrials.gov/show/NCT00014911,Diabetes_Mellitus_Insulin-Dependent,Islet_Transplantation|Sirolimus|Tacrolimus|Daclizumab|Sulfamethoxazole|Ganciclovir|Trimethoprim|Pentamidine|,2,36,other_events,arm0,Islet Transplantation,2,36
Hypersensitivity,Immune_system_disorders,NCT00023452,https://clinicaltrials.gov/show/NCT00023452,Tuberculosis,RPT_+_INH_once_weekly_for_3_months_given_by_DOT|Isoniazid_(INH)_daily_for_9_months|,179,15598,other_events,arm1,3RPT/INH,153,4040
Hypersensitivity,Immune_system_disorders,NCT00023452,https://clinicaltrials.gov/show/NCT00023452,Tuberculosis,RPT_+_INH_once_weekly_for_3_months_given_by_DOT|Isoniazid_(INH)_daily_for_9_months|,179,15598,other_events,arm0,9INH,17,3759
Hypersensitivity,Immune_system_disorders,NCT00023452,https://clinicaltrials.gov/show/NCT00023452,Tuberculosis,RPT_+_INH_once_weekly_for_3_months_given_by_DOT|Isoniazid_(INH)_daily_for_9_months|,179,15598,serious_events,arm1,3RPT/INH,8,4040
Hypersensitivity,Immune_system_disorders,NCT00023452,https://clinicaltrials.gov/show/NCT00023452,Tuberculosis,RPT_+_INH_once_weekly_for_3_months_given_by_DOT|Isoniazid_(INH)_daily_for_9_months|,179,15598,serious_events,arm0,9INH,1,3759
HYPERSENSITIVITY,Immune_system_disorders,NCT00035932,https://clinicaltrials.gov/show/NCT00035932,HIV_Infections,Atazanavir_+_ritonavir_+_tenofovir_+_nucleoside|Atazanavir_+_saquinavir_+_tenofovir_+_nucleoside|Lopinavir/ritonavir_+_tenofovir_+_nucleoside|,10,457,serious_events,arm1,ATV400/SQV,1,110
HYPERSENSITIVITY,Immune_system_disorders,NCT00035932,https://clinicaltrials.gov/show/NCT00035932,HIV_Infections,Atazanavir_+_ritonavir_+_tenofovir_+_nucleoside|Atazanavir_+_saquinavir_+_tenofovir_+_nucleoside|Lopinavir/ritonavir_+_tenofovir_+_nucleoside|,10,457,other_events,arm2,LPV/RTV,2,118
HYPERSENSITIVITY,Immune_system_disorders,NCT00035932,https://clinicaltrials.gov/show/NCT00035932,HIV_Infections,Atazanavir_+_ritonavir_+_tenofovir_+_nucleoside|Atazanavir_+_saquinavir_+_tenofovir_+_nucleoside|Lopinavir/ritonavir_+_tenofovir_+_nucleoside|,10,457,other_events,arm1,ATV400/SQV,6,110
HYPERSENSITIVITY,Immune_system_disorders,NCT00035932,https://clinicaltrials.gov/show/NCT00035932,HIV_Infections,Atazanavir_+_ritonavir_+_tenofovir_+_nucleoside|Atazanavir_+_saquinavir_+_tenofovir_+_nucleoside|Lopinavir/ritonavir_+_tenofovir_+_nucleoside|,10,457,serious_events,arm0,ATV300/RTV,1,119
Hypersensitivity,Immune_system_disorders,NCT00036270,https://clinicaltrials.gov/show/NCT00036270,Breast_Neoplasms,exemestane_(Aromasin)|tamoxifen_+_exemestane|,5,9666,serious_events,arm1,Exemestane,4,4852
Hypersensitivity,Immune_system_disorders,NCT00036270,https://clinicaltrials.gov/show/NCT00036270,Breast_Neoplasms,exemestane_(Aromasin)|tamoxifen_+_exemestane|,5,9666,serious_events,arm0,Tamoxifen Followed by Exemestane,1,4814
Hypersensitivity,Immune_system_disorders,NCT00038103,https://clinicaltrials.gov/show/NCT00038103,Breast_Neoplasms,Exemestane|Celecoxib_+_Exemestane|,1,53,other_events,arm0,Exemestane (Exemestane Alone),1,53
Hypersensitivity,Immune_system_disorders,NCT00039130,https://clinicaltrials.gov/show/NCT00039130,Leukemia|Lymphoma|,filgrastim|rituximab|cyclophosphamide|cytarabine|dexamethasone|doxorubicin_hydrochloride|etoposide|ifosfamide|leucovorin_calcium|methotrexate|prednisone|vincristine_sulfate|Allopurinol|,7,210,other_events,arm0,Rituximab With High Intensity Chemotherapy,6,105
Hypersensitivity,Immune_system_disorders,NCT00039130,https://clinicaltrials.gov/show/NCT00039130,Leukemia|Lymphoma|,filgrastim|rituximab|cyclophosphamide|cytarabine|dexamethasone|doxorubicin_hydrochloride|etoposide|ifosfamide|leucovorin_calcium|methotrexate|prednisone|vincristine_sulfate|Allopurinol|,7,210,serious_events,arm0,Rituximab With High Intensity Chemotherapy,1,105
Hypersensitivity,Immune_system_disorders,NCT00038467,https://clinicaltrials.gov/show/NCT00038467,Breast_Neoplasms,Tamoxifen|Exemestane|,4,4658,serious_events,arm0,Exemestane,2,2320
Hypersensitivity,Immune_system_disorders,NCT00038467,https://clinicaltrials.gov/show/NCT00038467,Breast_Neoplasms,Tamoxifen|Exemestane|,4,4658,serious_events,arm1,Tamoxifen,2,2338
Hypersensitivity,Immune_system_disorders,NCT00043186,https://clinicaltrials.gov/show/NCT00043186,Low_Bone_Mineral_Density,Placebo|Denosumab|Alendronate|,8,235,other_events,arm4,Denosumab 14 mg Q6M,1,53
Hypersensitivity,Immune_system_disorders,NCT00043186,https://clinicaltrials.gov/show/NCT00043186,Low_Bone_Mineral_Density,Placebo|Denosumab|Alendronate|,8,235,other_events,arm1,Denosumab 6 mg Q3M,2,43
Hypersensitivity,Immune_system_disorders,NCT00043186,https://clinicaltrials.gov/show/NCT00043186,Low_Bone_Mineral_Density,Placebo|Denosumab|Alendronate|,8,235,other_events,arm8,Alendronate 70 mg,1,46
Hypersensitivity,Immune_system_disorders,NCT00043186,https://clinicaltrials.gov/show/NCT00043186,Low_Bone_Mineral_Density,Placebo|Denosumab|Alendronate|,8,235,other_events,arm0,Placebo,1,46
Hypersensitivity,Immune_system_disorders,NCT00043186,https://clinicaltrials.gov/show/NCT00043186,Low_Bone_Mineral_Density,Placebo|Denosumab|Alendronate|,8,235,other_events,arm5,Denosumab 60 mg Q6M,3,47
Hypersensitivity,Immune_system_disorders,NCT00046891,https://clinicaltrials.gov/show/NCT00046891,Breast_Cancer|Neurotoxicity|,Ginkgo_Biloba|Placebo|,2,104,other_events,arm0,Ginkgo Biloba,2,104
Hypersensitivity,Immune_system_disorders,NCT00048542,https://clinicaltrials.gov/show/NCT00048542,Arthritis_Juvenile_Idiopathic,Double-Blind_Adalimumab/Placebo_+_MTX|Double-Blind_Adalimumab/Placebo|OLE_BSA_Adalimumab_+/-_MTX|OLE_FD_Adalimumab_+/-_MTX|,9,174,other_events,arm6,Open-Label Extension FD Adalimumab + MTX,2,59
Hypersensitivity,Immune_system_disorders,NCT00048542,https://clinicaltrials.gov/show/NCT00048542,Arthritis_Juvenile_Idiopathic,Double-Blind_Adalimumab/Placebo_+_MTX|Double-Blind_Adalimumab/Placebo|OLE_BSA_Adalimumab_+/-_MTX|OLE_FD_Adalimumab_+/-_MTX|,9,174,other_events,arm0,Double-Blind Adalimumab + MTX,2,38
Hypersensitivity,Immune_system_disorders,NCT00048542,https://clinicaltrials.gov/show/NCT00048542,Arthritis_Juvenile_Idiopathic,Double-Blind_Adalimumab/Placebo_+_MTX|Double-Blind_Adalimumab/Placebo|OLE_BSA_Adalimumab_+/-_MTX|OLE_FD_Adalimumab_+/-_MTX|,9,174,other_events,arm2,Double-Blind Adalimumab,2,30
Hypersensitivity,Immune_system_disorders,NCT00048542,https://clinicaltrials.gov/show/NCT00048542,Arthritis_Juvenile_Idiopathic,Double-Blind_Adalimumab/Placebo_+_MTX|Double-Blind_Adalimumab/Placebo|OLE_BSA_Adalimumab_+/-_MTX|OLE_FD_Adalimumab_+/-_MTX|,9,174,other_events,arm7,Open-Label Extension FD Adalimumab,3,47
Hypersensitivity,Immune_system_disorders,NCT00049127,https://clinicaltrials.gov/show/NCT00049127,Adult_Anaplastic_Oligodendroglioma|Adult_Mixed_Glioma|Adult_Oligodendroglioma|Recurrent_Adult_Brain_Tumor|,imatinib_mesylate|laboratory_biomarker_analysis|pharmacological_study|,1,39,other_events,arm1,Study 2 Arm B,1,39
Hypersensitivity,Immune_system_disorders,NCT00057330,https://clinicaltrials.gov/show/NCT00057330,Herpes_Simplex_Infection,HSV_vaccine_or_SB208141_GSK_Biologicals'_glycoprotein_D_(gD)-Alum/3-deacylated_form_of_Monophosphoryl_Lipid_A_(MPL)_candidate_genital_herpes_vaccine|Havrix‰ã¢_GlaxoSmithKline_(GSK)_Biologicals'_licensed_Hepatitis_A_vaccine|,2,8150,serious_events,arm0,Herpes Simplex Virus Group,1,4488
Hypersensitivity,Immune_system_disorders,NCT00057330,https://clinicaltrials.gov/show/NCT00057330,Herpes_Simplex_Infection,HSV_vaccine_or_SB208141_GSK_Biologicals'_glycoprotein_D_(gD)-Alum/3-deacylated_form_of_Monophosphoryl_Lipid_A_(MPL)_candidate_genital_herpes_vaccine|Havrix‰ã¢_GlaxoSmithKline_(GSK)_Biologicals'_licensed_Hepatitis_A_vaccine|,2,8150,serious_events,arm1,Havrix Group,1,3662
Hypersensitivity,Immune_system_disorders,NCT00059332,https://clinicaltrials.gov/show/NCT00059332,Cerebrovascular_Accident,Magnesium_Sulfate|Normal_Saline|,2,843,serious_events,arm0,Normal Saline,2,843
Hypersensitivity,Immune_system_disorders,NCT00061945,https://clinicaltrials.gov/show/NCT00061945,Acute_Undifferentiated_Leukemia|B-cell_Adult_Acute_Lymphoblastic_Leukemia|B-cell_Childhood_Acute_Lymphoblastic_Leukemia|L1_Adult_Acute_Lymphoblastic_Leukemia|L1_Childhood_Acute_Lymphoblastic_Leukemia|L2_Adult_Acute_Lymphoblastic_Leukemia|L2_Childhood_Acute_Lymphoblastic_Leukemia|Philadelphia_Chromosome_Negative_Adult_Precursor_Acute_Lymphoblastic_Leukemia|Philadelphia_Chromosome_Positive_Adult_Precursor_Acute_Lymphoblastic_Leukemia|Philadelphia_Chromosome_Positive_Childhood_Precursor_Acute_Lymphoblastic_Leukemia|T-cell_Adult_Acute_Lymphoblastic_Leukemia|T-cell_Childhood_Acute_Lymphoblastic_Leukemia|Untreated_Adult_Acute_Lymphoblastic_Leukemia|Untreated_Childhood_Acute_Lymphoblastic_Leukemia|,allopurinol|cyclophosphamide|daunorubicin_hydrochloride|vincristine_sulfate|dexamethasone|asparaginase|filgrastim|imatinib_mesylate|methotrexate|cytarabine|trimethoprim-sulfamethoxazole|mercaptopurine|leucovorin_calcium|alemtuzumab|acyclovir|laboratory_biomarker_analysis|pharmacological_study|,19,600,serious_events,arm0,Phase I - Alemtuzumab and Combination Chemotherapy,1,119
Hypersensitivity,Immune_system_disorders,NCT00061945,https://clinicaltrials.gov/show/NCT00061945,Acute_Undifferentiated_Leukemia|B-cell_Adult_Acute_Lymphoblastic_Leukemia|B-cell_Childhood_Acute_Lymphoblastic_Leukemia|L1_Adult_Acute_Lymphoblastic_Leukemia|L1_Childhood_Acute_Lymphoblastic_Leukemia|L2_Adult_Acute_Lymphoblastic_Leukemia|L2_Childhood_Acute_Lymphoblastic_Leukemia|Philadelphia_Chromosome_Negative_Adult_Precursor_Acute_Lymphoblastic_Leukemia|Philadelphia_Chromosome_Positive_Adult_Precursor_Acute_Lymphoblastic_Leukemia|Philadelphia_Chromosome_Positive_Childhood_Precursor_Acute_Lymphoblastic_Leukemia|T-cell_Adult_Acute_Lymphoblastic_Leukemia|T-cell_Childhood_Acute_Lymphoblastic_Leukemia|Untreated_Adult_Acute_Lymphoblastic_Leukemia|Untreated_Childhood_Acute_Lymphoblastic_Leukemia|,allopurinol|cyclophosphamide|daunorubicin_hydrochloride|vincristine_sulfate|dexamethasone|asparaginase|filgrastim|imatinib_mesylate|methotrexate|cytarabine|trimethoprim-sulfamethoxazole|mercaptopurine|leucovorin_calcium|alemtuzumab|acyclovir|laboratory_biomarker_analysis|pharmacological_study|,19,600,other_events,arm0,Phase I - Alemtuzumab and Combination Chemotherapy,6,119
Hypersensitivity,Immune_system_disorders,NCT00061945,https://clinicaltrials.gov/show/NCT00061945,Acute_Undifferentiated_Leukemia|B-cell_Adult_Acute_Lymphoblastic_Leukemia|B-cell_Childhood_Acute_Lymphoblastic_Leukemia|L1_Adult_Acute_Lymphoblastic_Leukemia|L1_Childhood_Acute_Lymphoblastic_Leukemia|L2_Adult_Acute_Lymphoblastic_Leukemia|L2_Childhood_Acute_Lymphoblastic_Leukemia|Philadelphia_Chromosome_Negative_Adult_Precursor_Acute_Lymphoblastic_Leukemia|Philadelphia_Chromosome_Positive_Adult_Precursor_Acute_Lymphoblastic_Leukemia|Philadelphia_Chromosome_Positive_Childhood_Precursor_Acute_Lymphoblastic_Leukemia|T-cell_Adult_Acute_Lymphoblastic_Leukemia|T-cell_Childhood_Acute_Lymphoblastic_Leukemia|Untreated_Adult_Acute_Lymphoblastic_Leukemia|Untreated_Childhood_Acute_Lymphoblastic_Leukemia|,allopurinol|cyclophosphamide|daunorubicin_hydrochloride|vincristine_sulfate|dexamethasone|asparaginase|filgrastim|imatinib_mesylate|methotrexate|cytarabine|trimethoprim-sulfamethoxazole|mercaptopurine|leucovorin_calcium|alemtuzumab|acyclovir|laboratory_biomarker_analysis|pharmacological_study|,19,600,serious_events,arm1,Phase II - Alemtuzumab and Combination Chemotherapy,2,181
Hypersensitivity,Immune_system_disorders,NCT00061945,https://clinicaltrials.gov/show/NCT00061945,Acute_Undifferentiated_Leukemia|B-cell_Adult_Acute_Lymphoblastic_Leukemia|B-cell_Childhood_Acute_Lymphoblastic_Leukemia|L1_Adult_Acute_Lymphoblastic_Leukemia|L1_Childhood_Acute_Lymphoblastic_Leukemia|L2_Adult_Acute_Lymphoblastic_Leukemia|L2_Childhood_Acute_Lymphoblastic_Leukemia|Philadelphia_Chromosome_Negative_Adult_Precursor_Acute_Lymphoblastic_Leukemia|Philadelphia_Chromosome_Positive_Adult_Precursor_Acute_Lymphoblastic_Leukemia|Philadelphia_Chromosome_Positive_Childhood_Precursor_Acute_Lymphoblastic_Leukemia|T-cell_Adult_Acute_Lymphoblastic_Leukemia|T-cell_Childhood_Acute_Lymphoblastic_Leukemia|Untreated_Adult_Acute_Lymphoblastic_Leukemia|Untreated_Childhood_Acute_Lymphoblastic_Leukemia|,allopurinol|cyclophosphamide|daunorubicin_hydrochloride|vincristine_sulfate|dexamethasone|asparaginase|filgrastim|imatinib_mesylate|methotrexate|cytarabine|trimethoprim-sulfamethoxazole|mercaptopurine|leucovorin_calcium|alemtuzumab|acyclovir|laboratory_biomarker_analysis|pharmacological_study|,19,600,other_events,arm1,Phase II - Alemtuzumab and Combination Chemotherapy,10,181
Hypersensitivity,Immune_system_disorders,NCT00062647,https://clinicaltrials.gov/show/NCT00062647,Gram-Positive_Bacterial_Infections,Telavancin|Vancomycin_nafcillin_oxacillin_or_cloxacillin|,1,29,serious_events,arm1,Standard Therapy,1,29
HYPERSENSITIVITY,Immune_system_disorders,NCT00063154,https://clinicaltrials.gov/show/NCT00063154,Non-small_Cell_Lung_Cancer,Pertuzumab,1,43,serious_events,arm0,Pertuzumab,1,43
Hypersensitivity,Immune_system_disorders,NCT00063570,https://clinicaltrials.gov/show/NCT00063570,Breast_Cancer|Breast_Neoplasms|,Pemetrexed|Gemcitabine|Gemcitabine|Pemetrexed|,3,52,other_events,arm0,Bi-Weekly Schedule,3,52
HYPERSENSITIVITY,Immune_system_disorders,NCT00069121,https://clinicaltrials.gov/show/NCT00069121,Colorectal_Cancer,capecitabine_[Xeloda]|Oxaliplatin|Oxaliplatin|Leucovorin|5_FU|,2,938,serious_events,arm2,XELOX,2,938
Hypersensitivity,Immune_system_disorders,NCT00072475,https://clinicaltrials.gov/show/NCT00072475,Leukemia|Myelodysplastic_Syndromes|Myelodysplastic/Myeloproliferative_Neoplasms|,vatalanib,2,306,serious_events,arm0,Vatalanib,1,153
Hypersensitivity,Immune_system_disorders,NCT00072475,https://clinicaltrials.gov/show/NCT00072475,Leukemia|Myelodysplastic_Syndromes|Myelodysplastic/Myeloproliferative_Neoplasms|,vatalanib,2,306,other_events,arm0,Vatalanib,1,153
Hypersensitivity,Immune_system_disorders,NCT00072566,https://clinicaltrials.gov/show/NCT00072566,Primary_Peritoneal_Carcinoma|Recurrent_Ovarian_Carcinoma|Stage_IV_Ovarian_Cancer|,Bevacizumab|Cyclophosphamide|Laboratory_Biomarker_Analysis|,3,70,other_events,arm0,Treatment (Bevacizumab Cyclophosphamide),3,70
Hypersensitivity,Immune_system_disorders,NCT00074984,https://clinicaltrials.gov/show/NCT00074984,Fabry_Disease,Fabrazyme_(agalsidase_beta)|Placebo|,4,133,other_events,arm2,Total,2,82
Hypersensitivity,Immune_system_disorders,NCT00074984,https://clinicaltrials.gov/show/NCT00074984,Fabry_Disease,Fabrazyme_(agalsidase_beta)|Placebo|,4,133,other_events,arm0,Fabrazyme (Agalsidase Beta),2,51
Hypersensitivity,Immune_system_disorders,NCT00075218,https://clinicaltrials.gov/show/NCT00075218,Gastrointestinal_Stromal_Tumor,Placebo|SU011248|,1,114,other_events,arm1,Placebo Double-Blind Treatment,1,114
Hypersensitivity,Immune_system_disorders,NCT00078559,https://clinicaltrials.gov/show/NCT00078559,Kidney_Transplantation|Kidney_Disease|,Alemtuzumab|Sirolimus|Tacrolimus|Kidney_transplant|Methylprednisolone_(or_equivalent)|Acetaminophen|Diphenhydramine|Trimethoprim_(TMP)/Sulfa_(Bactrim_Septra)|Valgancyclovir|Acyclovir|Pentamidine|Clotrimazole|Nystatin|,1,10,other_events,arm0,Alemtuzumab,1,10
Hypersensitivity,Immune_system_disorders,NCT00079001,https://clinicaltrials.gov/show/NCT00079001,Metastatic_Cancer|Prostate_Cancer|,zoledronic_acid|placebo|androgen_deprivation_therapy|GnRH_agonist|Calcium_supplement|Vitamin_D|,14,618,other_events,arm1,Placebo + Androgen Deprivation Therapy,6,308
Hypersensitivity,Immune_system_disorders,NCT00079001,https://clinicaltrials.gov/show/NCT00079001,Metastatic_Cancer|Prostate_Cancer|,zoledronic_acid|placebo|androgen_deprivation_therapy|GnRH_agonist|Calcium_supplement|Vitamin_D|,14,618,other_events,arm0,Zoledronic Acid + Androgen Deprivation Therapy,8,310
Hypersensitivity,Immune_system_disorders,NCT00079274,https://clinicaltrials.gov/show/NCT00079274,Adenocarcinoma_of_the_Colon|Stage_III_Colon_Cancer|,irinotecan_hydrochloride|oxaliplatin|leucovorin_calcium|fluorouracil|cetuximab|Locally_Directed_Therapy|,117,5602,other_events,arm2,Arm C (Combination Chemotherapy),2,108
Hypersensitivity,Immune_system_disorders,NCT00079274,https://clinicaltrials.gov/show/NCT00079274,Adenocarcinoma_of_the_Colon|Stage_III_Colon_Cancer|,irinotecan_hydrochloride|oxaliplatin|leucovorin_calcium|fluorouracil|cetuximab|Locally_Directed_Therapy|,117,5602,other_events,arm0,Arm A (Combination Chemotherapy),28,1378
Hypersensitivity,Immune_system_disorders,NCT00079274,https://clinicaltrials.gov/show/NCT00079274,Adenocarcinoma_of_the_Colon|Stage_III_Colon_Cancer|,irinotecan_hydrochloride|oxaliplatin|leucovorin_calcium|fluorouracil|cetuximab|Locally_Directed_Therapy|,117,5602,other_events,arm5,Arm F (Combination Chemotherapy Monoclonal Antibody),1,44
Hypersensitivity,Immune_system_disorders,NCT00079274,https://clinicaltrials.gov/show/NCT00079274,Adenocarcinoma_of_the_Colon|Stage_III_Colon_Cancer|,irinotecan_hydrochloride|oxaliplatin|leucovorin_calcium|fluorouracil|cetuximab|Locally_Directed_Therapy|,117,5602,serious_events,arm0,Arm A (Combination Chemotherapy),6,1378
Hypersensitivity,Immune_system_disorders,NCT00079274,https://clinicaltrials.gov/show/NCT00079274,Adenocarcinoma_of_the_Colon|Stage_III_Colon_Cancer|,irinotecan_hydrochloride|oxaliplatin|leucovorin_calcium|fluorouracil|cetuximab|Locally_Directed_Therapy|,117,5602,other_events,arm4,Arm E (Combination Chemotherapy Monoclonal Antibody),1,42
Hypersensitivity,Immune_system_disorders,NCT00079274,https://clinicaltrials.gov/show/NCT00079274,Adenocarcinoma_of_the_Colon|Stage_III_Colon_Cancer|,irinotecan_hydrochloride|oxaliplatin|leucovorin_calcium|fluorouracil|cetuximab|Locally_Directed_Therapy|,117,5602,other_events,arm3,Arm D (Combination Chemotherapy Monoclonal Antibody),62,1326
Hypersensitivity,Immune_system_disorders,NCT00079274,https://clinicaltrials.gov/show/NCT00079274,Adenocarcinoma_of_the_Colon|Stage_III_Colon_Cancer|,irinotecan_hydrochloride|oxaliplatin|leucovorin_calcium|fluorouracil|cetuximab|Locally_Directed_Therapy|,117,5602,serious_events,arm3,Arm D (Combination Chemotherapy Monoclonal Antibody),17,1326
Hypersensitivity,Immune_system_disorders,NCT00081497,https://clinicaltrials.gov/show/NCT00081497,Fabry_Disease,agalsidase_beta,2,106,other_events,arm2,Total,1,67
Hypersensitivity,Immune_system_disorders,NCT00081497,https://clinicaltrials.gov/show/NCT00081497,Fabry_Disease,agalsidase_beta,2,106,other_events,arm0,Fabrazyme/Fabrazyme,1,39
HYPERSENSITIVITY,Immune_system_disorders,NCT00081770,https://clinicaltrials.gov/show/NCT00081770,Hepatitis_C_Chronic,PegIntron_(peginterferon_alfa-2b;_SCH_54031)|PegIntron_(peginterferon_alfa-2b;_SCH_54031)|REBETOL_(ribavirin;_SCH_18908)|PEGASYS_(peginterferon_alfa-2a)|COPEGUS_(ribavirin)|,1,1019,serious_events,arm0,PegIntron 1.5 ug/kg/wk Plus REBETOL,1,1019
HYPERSENSITIVITY,Immune_system_disorders,NCT00082433,https://clinicaltrials.gov/show/NCT00082433,Cancer|Breast_Cancer|,Ixabepilone_+_Capecitabine|Capecitabine|,4,595,serious_events,arm1,Ixabepilone + Capecitabine,4,595
Hypersensitivity,Immune_system_disorders,NCT00083122,https://clinicaltrials.gov/show/NCT00083122,Recurrent_Ovarian_Epithelial_Cancer|Recurrent_Primary_Peritoneal_Cavity_Cancer|Stage_IIIA_Ovarian_Epithelial_Cancer|Stage_IIIA_Primary_Peritoneal_Cavity_Cancer|Stage_IIIB_Ovarian_Epithelial_Cancer|Stage_IIIB_Primary_Peritoneal_Cavity_Cancer|Stage_IIIC_Ovarian_Epithelial_Cancer|Stage_IIIC_Primary_Peritoneal_Cavity_Cancer|Stage_IV_Ovarian_Epithelial_Cancer|Stage_IV_Primary_Peritoneal_Cavity_Cancer|,cisplatin|alvocidib|cisplatin/flavopiridol|,3,45,serious_events,arm0,Group 1 and Group 2 Combined,3,45
Hypersensitivity,Immune_system_disorders,NCT00083616,https://clinicaltrials.gov/show/NCT00083616,Colorectal_Cancer|Metastatic_Cancer|,Panitumumab,1,182,serious_events,arm0,Panitumumab,1,182
Hypersensitivity,Immune_system_disorders,NCT00083720,https://clinicaltrials.gov/show/NCT00083720,Colorectal_Neoplasms|Metastases|Neoplasm|,cetuximab,1,85,serious_events,arm0,Cetuximab,1,85
Hypersensitivity,Immune_system_disorders,NCT00084136,https://clinicaltrials.gov/show/NCT00084136,HIV_Infections,Atazanavir|Didanosine_(enteric-coated)|Efavirenz|Emtricitabine|Emtricitabine/Tenofovir_disoproxil_fumarate|Lamivudine/Zidovudine|,1,526,serious_events,arm2,TDF/FTC+EFV,1,526
Hypersensitivity,Immune_system_disorders,NCT00086502,https://clinicaltrials.gov/show/NCT00086502,Diabetes_Mellitus_Type_2,Comparator:_Sitagliptin|Comparator:_Placebo|Comparator:_Pioglitazone|Metformin|,1,175,serious_events,arm0,Sitagliptin 100 mg,1,175
Hypersensitivity,Immune_system_disorders,NCT00086580,https://clinicaltrials.gov/show/NCT00086580,B-Cell_Chronic_Lymphocytic_Leukemia,FluCAM_[Fludara_+_Campath]|fludarabine_phosphate|,6,329,other_events,arm0,Combination Arm (FluCAM),5,164
Hypersensitivity,Immune_system_disorders,NCT00086580,https://clinicaltrials.gov/show/NCT00086580,B-Cell_Chronic_Lymphocytic_Leukemia,FluCAM_[Fludara_+_Campath]|fludarabine_phosphate|,6,329,other_events,arm1,Fludarabine Alone,1,165
Hypersensitivity,Immune_system_disorders,NCT00086684,https://clinicaltrials.gov/show/NCT00086684,Interstitial_Cystitis,Pentosan_polysulfate_sodium_100_mg|Placebo|Pentosan_polysulfate_sodium_100_mg|,2,246,other_events,arm0,PLACEBO,1,118
Hypersensitivity,Immune_system_disorders,NCT00086684,https://clinicaltrials.gov/show/NCT00086684,Interstitial_Cystitis,Pentosan_polysulfate_sodium_100_mg|Placebo|Pentosan_polysulfate_sodium_100_mg|,2,246,other_events,arm1,Pentosan Polysulfate Sodium (ELMIRON) 100MG QD,1,128
Hypersensitivity,Immune_system_disorders,NCT00087555,https://clinicaltrials.gov/show/NCT00087555,Fibromyalgia,Xyrem_(sodium_oxybate)_oral_solution|Xyrem_(sodium_oxybate)_oral_solution|Placebo|,1,67,other_events,arm2,Xyrem (Sodium Oxybate) 6.0g,1,67
Hypersensitivity,Immune_system_disorders,NCT00087490,https://clinicaltrials.gov/show/NCT00087490,Skin/Soft_Tissue_Infections|Methicillin_Resistant_Staphylococcus_Aureus_(MRSA)|,linezolid|vancomycin|,1,515,other_events,arm1,Vancomycin,1,515
Hypersensitivity,Immune_system_disorders,NCT00089635,https://clinicaltrials.gov/show/NCT00089635,Colorectal_Cancer|Metastases|,ABX-EGF_(panitumumab),1,203,serious_events,arm0,Panitumumab,1,203
Hypersensitivity,Immune_system_disorders,NCT00090051,https://clinicaltrials.gov/show/NCT00090051,Chronic_Lymphocytic_Leukemia,Rituximab|Fludarabine_Phosphate|Cyclophosphamide|,1,272,serious_events,arm0,Fludarabine+Cyclophosphamide (FC),1,272
Hypersensitivity,Immune_system_disorders,NCT00090285,https://clinicaltrials.gov/show/NCT00090285,Condylomata_Acuminata,(Gardasil‰ã¢)_human_papillomavirus_(types_6_11_16_18)_recombinant_vaccine|Comparator:_placebo_(unspecified)|,1,2020,serious_events,arm0,qHPV Vaccine: Base Study,1,2020
Hypersensitivity,Immune_system_disorders,NCT00090233,https://clinicaltrials.gov/show/NCT00090233,Rotavirus_Infections,Rotateq‰ã¢|Comparator:_Placebo|,2,69766,serious_events,arm0,RotaTeq‰ã¢,1,34904
Hypersensitivity,Immune_system_disorders,NCT00090233,https://clinicaltrials.gov/show/NCT00090233,Rotavirus_Infections,Rotateq‰ã¢|Comparator:_Placebo|,2,69766,serious_events,arm1,Placebo,1,34862
Hypersensitivity,Immune_system_disorders,NCT00090259,https://clinicaltrials.gov/show/NCT00090259,Heart_Failure,Losartan_50_mg|Losartan_150_mg|,1,1913,serious_events,arm0,Losartan 50 mg,1,1913
HYPERSENSITIVITY,Immune_system_disorders,NCT00091572,https://clinicaltrials.gov/show/NCT00091572,Melanoma,Temozolomide|Dacarbazine|,2,421,serious_events,arm1,Dacarbazine,2,421
Hypersensitivity,Immune_system_disorders,NCT00091819,https://clinicaltrials.gov/show/NCT00091819,Staphylococcal_Skin_Infection,Telavancin|Vancomycin|,1,429,serious_events,arm1,Vancomycin,1,429
Hypersensitivity,Immune_system_disorders,NCT00092456,https://clinicaltrials.gov/show/NCT00092456,Rotavirus_Infections,rotavirus_vaccine_live_oral_pentavalent|Placebo|,6,679,other_events,arm1,RotaTeq‰ã¢ Lot 2,3,224
Hypersensitivity,Immune_system_disorders,NCT00092456,https://clinicaltrials.gov/show/NCT00092456,Rotavirus_Infections,rotavirus_vaccine_live_oral_pentavalent|Placebo|,6,679,other_events,arm0,RotaTeq‰ã¢ Lot 1,1,226
Hypersensitivity,Immune_system_disorders,NCT00092456,https://clinicaltrials.gov/show/NCT00092456,Rotavirus_Infections,rotavirus_vaccine_live_oral_pentavalent|Placebo|,6,679,other_events,arm2,RotaTeq‰ã¢ Lot 3,2,229
Hypersensitivity,Immune_system_disorders,NCT00093015,https://clinicaltrials.gov/show/NCT00093015,Kidney_Disease|Diabetes_Mellitus|Anemia|,Placebo|darbepoetin_alfa|,4,4023,serious_events,arm1,Darbepoetin Alfa,2,2004
Hypersensitivity,Immune_system_disorders,NCT00093015,https://clinicaltrials.gov/show/NCT00093015,Kidney_Disease|Diabetes_Mellitus|Anemia|,Placebo|darbepoetin_alfa|,4,4023,serious_events,arm0,Placebo,2,2019
Hypersensitivity,Immune_system_disorders,NCT00093756,https://clinicaltrials.gov/show/NCT00093756,Recurrent_Non-small_Cell_Lung_Cancer|Stage_IIIA_Non-small_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|,3-dimensional_conformal_radiation_therapy|bortezomib|paclitaxel|carboplatin|,2,27,other_events,arm1,PhaseII,2,27
Hypersensitivity,Immune_system_disorders,NCT00094835,https://clinicaltrials.gov/show/NCT00094835,Lung_Cancer|Non-Small_Cell_Lung_Cancer|,Panitumumab|Motesanib_diphosphate|Paclitaxel|Carboplatin|,2,12,other_events,arm2,Paclitaxel/Carboplatin + Motesanib 75 mg BID,1,6
Hypersensitivity,Immune_system_disorders,NCT00094835,https://clinicaltrials.gov/show/NCT00094835,Lung_Cancer|Non-Small_Cell_Lung_Cancer|,Panitumumab|Motesanib_diphosphate|Paclitaxel|Carboplatin|,2,12,other_events,arm6,Panitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD,1,6
Hypersensitivity,Immune_system_disorders,NCT00095199,https://clinicaltrials.gov/show/NCT00095199,Non_Small_Cell_Lung_Cancer,Pemetrexed|Cetuximab|Docetaxel|,6,600,serious_events,arm3,Docetaxel,1,149
Hypersensitivity,Immune_system_disorders,NCT00095199,https://clinicaltrials.gov/show/NCT00095199,Non_Small_Cell_Lung_Cancer,Pemetrexed|Cetuximab|Docetaxel|,6,600,serious_events,arm2,Cetuximab and Docetaxel,2,159
Hypersensitivity,Immune_system_disorders,NCT00095199,https://clinicaltrials.gov/show/NCT00095199,Non_Small_Cell_Lung_Cancer,Pemetrexed|Cetuximab|Docetaxel|,6,600,serious_events,arm0,Cetuximab & Pemetrexed,3,292
Hypersensitivity,Immune_system_disorders,NCT00096226,https://clinicaltrials.gov/show/NCT00096226,Lung_Cancer,Induction_Carboplatin|Induction_Paclitaxel|Resection|Consolidation_Carboplatin|Radiation_Therapy|Consolidation_Paclitaxel|,8,114,other_events,arm0,Chemoradiation Surgery Chemotherapy,7,57
Hypersensitivity,Immune_system_disorders,NCT00096226,https://clinicaltrials.gov/show/NCT00096226,Lung_Cancer,Induction_Carboplatin|Induction_Paclitaxel|Resection|Consolidation_Carboplatin|Radiation_Therapy|Consolidation_Paclitaxel|,8,114,serious_events,arm0,Chemoradiation Surgery Chemotherapy,1,57
Hypersensitivity,Immune_system_disorders,NCT00096954,https://clinicaltrials.gov/show/NCT00096954,Asthma,omalizumab_(Xolair)|placebo|,1,171,serious_events,arm1,Placebo,1,171
HYPERSENSITIVITY,Immune_system_disorders,NCT00096993,https://clinicaltrials.gov/show/NCT00096993,Ovarian_Cancer|Peritoneal_Cancer|Fallopian_Tube_Cancer|,Placebo|Gemcitabine|Pertuzumab|,6,195,other_events,arm1,Pertuzumab + Gemcitabine,4,65
HYPERSENSITIVITY,Immune_system_disorders,NCT00096993,https://clinicaltrials.gov/show/NCT00096993,Ovarian_Cancer|Peritoneal_Cancer|Fallopian_Tube_Cancer|,Placebo|Gemcitabine|Pertuzumab|,6,195,serious_events,arm1,Pertuzumab + Gemcitabine,1,65
HYPERSENSITIVITY,Immune_system_disorders,NCT00096993,https://clinicaltrials.gov/show/NCT00096993,Ovarian_Cancer|Peritoneal_Cancer|Fallopian_Tube_Cancer|,Placebo|Gemcitabine|Pertuzumab|,6,195,other_events,arm0,Placebo + Gemcitabine,1,65
Hypersensitivity,Immune_system_disorders,NCT00097591,https://clinicaltrials.gov/show/NCT00097591,Coronary_Arteriosclerosis|Acute_Coronary_Syndromes|,Prasugrel|Clopidogrel|,5,13457,serious_events,arm1,Clopidogrel,2,6716
Hypersensitivity,Immune_system_disorders,NCT00097591,https://clinicaltrials.gov/show/NCT00097591,Coronary_Arteriosclerosis|Acute_Coronary_Syndromes|,Prasugrel|Clopidogrel|,5,13457,serious_events,arm0,Prasugrel,3,6741
Hypersensitivity,Immune_system_disorders,NCT00097786,https://clinicaltrials.gov/show/NCT00097786,Diabetes_Mellitus_Type_2,Valsartan_160_mg_+_nateglinide_60_mg|Valsartan_160_mg_+_nateglinide_placebo|Nateglinide_60_mg_+_valsartan_placebo|Valsartan_placebo_+_nateglinide_placebo|,3,4588,serious_events,arm2,Nateglinide 60 mg ac + Placebo Valsartan,2,2305
Hypersensitivity,Immune_system_disorders,NCT00097786,https://clinicaltrials.gov/show/NCT00097786,Diabetes_Mellitus_Type_2,Valsartan_160_mg_+_nateglinide_60_mg|Valsartan_160_mg_+_nateglinide_placebo|Nateglinide_60_mg_+_valsartan_placebo|Valsartan_placebo_+_nateglinide_placebo|,3,4588,serious_events,arm1,Valsartan 160 mg od + Placebo Nateglinide,1,2283
Hypersensitivity,Immune_system_disorders,NCT00098293,https://clinicaltrials.gov/show/NCT00098293,HIV-1,Maraviroc_+_Zidovudine/Lamivudine|Efavirenz_+_Zidovudine/Lamivudine|Maraviroc_(UK-427857)_+_Zidovudine/Lamivudine|,1,361,serious_events,arm2,Efavirenz Once Daily + CBV (DB and OL),1,361
Hypersensitivity,Immune_system_disorders,NCT00098670,https://clinicaltrials.gov/show/NCT00098670,B-cell_Chronic_Lymphocytic_Leukemia|Stage_I_Chronic_Lymphocytic_Leukemia|Stage_II_Chronic_Lymphocytic_Leukemia|Stage_III_Chronic_Lymphocytic_Leukemia|Stage_IV_Chronic_Lymphocytic_Leukemia|,alemtuzumab|rituximab|fludarabine_phosphate|,15,262,other_events,arm1,Alemtuzumab Consolidation,4,58
Hypersensitivity,Immune_system_disorders,NCT00098670,https://clinicaltrials.gov/show/NCT00098670,B-cell_Chronic_Lymphocytic_Leukemia|Stage_I_Chronic_Lymphocytic_Leukemia|Stage_II_Chronic_Lymphocytic_Leukemia|Stage_III_Chronic_Lymphocytic_Leukemia|Stage_IV_Chronic_Lymphocytic_Leukemia|,alemtuzumab|rituximab|fludarabine_phosphate|,15,262,other_events,arm0,FR Induction,9,102
Hypersensitivity,Immune_system_disorders,NCT00098670,https://clinicaltrials.gov/show/NCT00098670,B-cell_Chronic_Lymphocytic_Leukemia|Stage_I_Chronic_Lymphocytic_Leukemia|Stage_II_Chronic_Lymphocytic_Leukemia|Stage_III_Chronic_Lymphocytic_Leukemia|Stage_IV_Chronic_Lymphocytic_Leukemia|,alemtuzumab|rituximab|fludarabine_phosphate|,15,262,serious_events,arm0,FR Induction,2,102
Hypersensitivity,Immune_system_disorders,NCT00098774,https://clinicaltrials.gov/show/NCT00098774,Lymphoma,filgrastim|rituximab|cytarabine|etoposide|leucovorin_calcium|methotrexate|temozolomide|,2,44,other_events,arm0,Intensive Combination Chemo & Immunotherapy,2,44
Hypersensitivity,Immune_system_disorders,NCT00098748,https://clinicaltrials.gov/show/NCT00098748,HIV_Infections,Optimized_Background_Therapy_(OBT)|maraviroc_(UK-427857)|Optimized_Background_Therapy_(OBT)|maraviroc_(UK-427857)|Optimized_Background_Therapy_(OBT)|,2,123,serious_events,arm1,Maraviroc BID,1,62
Hypersensitivity,Immune_system_disorders,NCT00098748,https://clinicaltrials.gov/show/NCT00098748,HIV_Infections,Optimized_Background_Therapy_(OBT)|maraviroc_(UK-427857)|Optimized_Background_Therapy_(OBT)|maraviroc_(UK-427857)|Optimized_Background_Therapy_(OBT)|,2,123,serious_events,arm2,Placebo,1,61
Hypersensitivity,Immune_system_disorders,NCT00101582,https://clinicaltrials.gov/show/NCT00101582,Mucositis|Solid_Tumors|Stomatitis|Head_and_Neck_Cancer|Squamous_Cell_Carcinoma|,Placebo|palifermin|cisplatin_chemotherapy|Radiotherapy|,1,94,serious_events,arm1,Palifermin,1,94
HYPERSENSITIVITY,Immune_system_disorders,NCT00101660,https://clinicaltrials.gov/show/NCT00101660,Chronic_Myeloid_Leukemia|Philadelphia-Positive_Myeloid_Leukemia|,Dasatinib,3,387,serious_events,arm0,Intolerant,1,99
HYPERSENSITIVITY,Immune_system_disorders,NCT00101660,https://clinicaltrials.gov/show/NCT00101660,Chronic_Myeloid_Leukemia|Philadelphia-Positive_Myeloid_Leukemia|,Dasatinib,3,387,serious_events,arm1,Resistant,2,288
Hypersensitivity,Immune_system_disorders,NCT00101686,https://clinicaltrials.gov/show/NCT00101686,Colorectal_Neoplasms,Modified_Bolus_5-FU/LV_with_Irinotecan|FOLFIRI_+_bevacizumab|miFL_+_bevacizumab|Infusional_5-FU/LV_with_Irinotecan|Oral_Capecitabine_with_Irinotecan|,1,137,serious_events,arm0,FOLFIRI,1,137
Hypersensitivity,Immune_system_disorders,NCT00102804,https://clinicaltrials.gov/show/NCT00102804,Non-Small_Cell_Lung_Cancer,Pemetrexed|Placebo|Best_Supportive_Care|,7,656,other_events,arm0,Pemetrexed and BSC,6,438
Hypersensitivity,Immune_system_disorders,NCT00102804,https://clinicaltrials.gov/show/NCT00102804,Non-Small_Cell_Lung_Cancer,Pemetrexed|Placebo|Best_Supportive_Care|,7,656,other_events,arm1,Placebo and BSC,1,218
Hypersensitivity,Immune_system_disorders,NCT00103506,https://clinicaltrials.gov/show/NCT00103506,Multiple_Myeloma,Bortezomib_(VELCADE)|Bortezomib_(VELCADE)|Doxorubicin_hydrochloride_(DOXIL/CAELYX)|,1,318,serious_events,arm1,Doxil/Caelyx Plus Velcade (Bortezomib),1,318
Hypersensitivity,Immune_system_disorders,NCT00104299,https://clinicaltrials.gov/show/NCT00104299,Vasculitis|Wegener's_Granulomatosis|Microscopic_Polyangiitis|,Rituximab_plus_cyclophosphamide_placebo_(rituximab_group)|Cyclophosphamide_plus_rituximab_placebo_(control_group)|Azathioprine|Methylprednisolone_(or_other_glucocorticoid)|Prednisone|,1,99,serious_events,arm0,Rituximab,1,99
Hypersensitivity,Immune_system_disorders,NCT00105235,https://clinicaltrials.gov/show/NCT00105235,Liver_Disease|Liver_Transplantation|,Alemtuzumab|Cyclosporine|Mycophenolate_mofetil|Tacrolimus|Liver_transplant|Immunosuppression_withdrawal|,1,27,serious_events,arm0,Alemtuzumab,1,27
Hypersensitivity,Immune_system_disorders,NCT00105157,https://clinicaltrials.gov/show/NCT00105157,HIV_Infections|Acquired_Immunodeficiency_Syndrome|,Comparator:_MK0518|MK0518|MK0518|Placebo|,3,178,other_events,arm0,MK0518,2,133
Hypersensitivity,Immune_system_disorders,NCT00105157,https://clinicaltrials.gov/show/NCT00105157,HIV_Infections|Acquired_Immunodeficiency_Syndrome|,Comparator:_MK0518|MK0518|MK0518|Placebo|,3,178,other_events,arm1,Placebo,1,45
Hypersensitivity,Immune_system_disorders,NCT00105989,https://clinicaltrials.gov/show/NCT00105989,Depressive_Disorder_Major,Duloxetine|placebo|,4,109,other_events,arm2,Duloxetine 90 mg,3,45
Hypersensitivity,Immune_system_disorders,NCT00105989,https://clinicaltrials.gov/show/NCT00105989,Depressive_Disorder_Major,Duloxetine|placebo|,4,109,other_events,arm1,Duloxetine 60 mg,1,64
Hypersensitivity,Immune_system_disorders,NCT00106704,https://clinicaltrials.gov/show/NCT00106704,Diabetes_Mellitus_Type_2,Comparator:_Sitagliptin|Comparator:_Placebo|Comparator:_Pioglitazone|,1,219,serious_events,arm1,Placebo/ Pioglitazone,1,219
Hypersensitivity,Immune_system_disorders,NCT00106353,https://clinicaltrials.gov/show/NCT00106353,Adenocarcinoma|Neoplasms|,Torisel,2,19,other_events,arm5,Neuroblastoma: Part 2,2,19
Hypersensitivity,Immune_system_disorders,NCT00107315,https://clinicaltrials.gov/show/NCT00107315,Colorectal_Cancer,bevacizumab|capecitabine|,1,16,other_events,arm0,Combination of Capecitabine and Bevacizumab,1,16
Hypersensitivity,Immune_system_disorders,NCT00109031,https://clinicaltrials.gov/show/NCT00109031,Cancer|Lymphoma|Leukemia|,palifermin|Total_Body_Irradiation|Cyclophosphamide|Etoposide|Placebo|,1,11,other_events,arm1,Palifermin 180 ë_g/kg on Day ‰öÕ1 (B),1,11
Hypersensitivity,Immune_system_disorders,NCT00109473,https://clinicaltrials.gov/show/NCT00109473,Crohn's_Disease,growth_hormone|cortecosteroid|,1,10,other_events,arm0,Growth Hormone Plus Corticosteroid (CTX),1,10
Hypersensitivity,Immune_system_disorders,NCT00109967,https://clinicaltrials.gov/show/NCT00109967,Recurrent_Mantle_Cell_Lymphoma,rituximab|temsirolimus|,5,117,other_events,arm1,Group II: Rituximab Refractory,1,21
Hypersensitivity,Immune_system_disorders,NCT00109967,https://clinicaltrials.gov/show/NCT00109967,Recurrent_Mantle_Cell_Lymphoma,rituximab|temsirolimus|,5,117,other_events,arm0,Group I: Rituximab Sensitive,3,48
Hypersensitivity,Immune_system_disorders,NCT00109967,https://clinicaltrials.gov/show/NCT00109967,Recurrent_Mantle_Cell_Lymphoma,rituximab|temsirolimus|,5,117,serious_events,arm0,Group I: Rituximab Sensitive,1,48
Hypersensitivity,Immune_system_disorders,NCT00110084,https://clinicaltrials.gov/show/NCT00110084,Breast_Cancer,Gemcitabine|Paclitaxel_protein-bound_particles_for_injectable_suspension_(albumin-bound)|,1,50,other_events,arm0,Nab-paclitaxel/Gemcitabine,1,50
HYPERSENSITIVITY,Immune_system_disorders,NCT00110357,https://clinicaltrials.gov/show/NCT00110357,Cancer|Refractory_Solid_Tumor|,Cetuximab_+_Irinotecan|Cetuximab_+_Irinotecan|,5,39,serious_events,arm0,01 75 mg/m2 CET + 20 mg/m2 IRI,2,14
HYPERSENSITIVITY,Immune_system_disorders,NCT00110357,https://clinicaltrials.gov/show/NCT00110357,Cancer|Refractory_Solid_Tumor|,Cetuximab_+_Irinotecan|Cetuximab_+_Irinotecan|,5,39,other_events,arm2,03 150 mg/m2 CET + 16 mg/m2 IRI,1,3
HYPERSENSITIVITY,Immune_system_disorders,NCT00110357,https://clinicaltrials.gov/show/NCT00110357,Cancer|Refractory_Solid_Tumor|,Cetuximab_+_Irinotecan|Cetuximab_+_Irinotecan|,5,39,other_events,arm3,04 250 mg/m2 CET + 16 mg/m2 IRI,1,12
HYPERSENSITIVITY,Immune_system_disorders,NCT00110357,https://clinicaltrials.gov/show/NCT00110357,Cancer|Refractory_Solid_Tumor|,Cetuximab_+_Irinotecan|Cetuximab_+_Irinotecan|,5,39,serious_events,arm1,02 150 mg/m2 CET + 20 mg/m2 IRI,1,10
Hypersensitivity,Immune_system_disorders,NCT00110617,https://clinicaltrials.gov/show/NCT00110617,Sickle_Cell_Disease|Iron_Overload|Hemolytic_Anemia|,Deferasirox_(ICL670)|Deferoxamine_(DFO)|,10,188,other_events,arm3,Period 2 Deferoxamine (DFO) Then ICL670,3,53
Hypersensitivity,Immune_system_disorders,NCT00110617,https://clinicaltrials.gov/show/NCT00110617,Sickle_Cell_Disease|Iron_Overload|Hemolytic_Anemia|,Deferasirox_(ICL670)|Deferoxamine_(DFO)|,10,188,other_events,arm2,Period 2 Deferasirox (ICL670),7,135
Hypersensitivity,Immune_system_disorders,NCT00112294,https://clinicaltrials.gov/show/NCT00112294,Non-Small-Cell_Lung_Carcinoma,Paclitaxel_(Taxane)|Docetaxel_(Taxane)|Carboplatin|Cetuximab|,42,1290,serious_events,arm1,Taxane+Carboplatin,1,320
Hypersensitivity,Immune_system_disorders,NCT00112294,https://clinicaltrials.gov/show/NCT00112294,Non-Small-Cell_Lung_Carcinoma,Paclitaxel_(Taxane)|Docetaxel_(Taxane)|Carboplatin|Cetuximab|,42,1290,serious_events,arm0,Cetuximab+Taxane+Carboplatin,11,325
Hypersensitivity,Immune_system_disorders,NCT00112294,https://clinicaltrials.gov/show/NCT00112294,Non-Small-Cell_Lung_Carcinoma,Paclitaxel_(Taxane)|Docetaxel_(Taxane)|Carboplatin|Cetuximab|,42,1290,other_events,arm1,Taxane+Carboplatin,8,320
Hypersensitivity,Immune_system_disorders,NCT00112294,https://clinicaltrials.gov/show/NCT00112294,Non-Small-Cell_Lung_Carcinoma,Paclitaxel_(Taxane)|Docetaxel_(Taxane)|Carboplatin|Cetuximab|,42,1290,other_events,arm0,Cetuximab+Taxane+Carboplatin,22,325
Hypersensitivity,Immune_system_disorders,NCT00112840,https://clinicaltrials.gov/show/NCT00112840,Clear_Cell_Renal_Cell_Carcinoma|Recurrent_Renal_Cell_Cancer|Stage_IV_Renal_Cell_Cancer|,CCI-779|Bevacizumab|,3,45,other_events,arm2,Phase II,3,45
HYPERSENSITIVITY,Immune_system_disorders,NCT00113490,https://clinicaltrials.gov/show/NCT00113490,Motavizumab_Administration_for_a_Second_Season_for_RSV_Prophylaxis,motavizumab_(MEDI-524)|palivizumab_15_mg/kg|,1,66,serious_events,arm0,Motavizumab (MEDI-524) 15 mg/kg,1,66
Hypersensitivity,Immune_system_disorders,NCT00113607,https://clinicaltrials.gov/show/NCT00113607,Ovarian_Cancer,Trabectedin|DOXIL|Dexamethasone|,5,663,serious_events,arm1,DOXIL,3,330
Hypersensitivity,Immune_system_disorders,NCT00113607,https://clinicaltrials.gov/show/NCT00113607,Ovarian_Cancer,Trabectedin|DOXIL|Dexamethasone|,5,663,serious_events,arm0,Trabectedin/DOXIL,2,333
Hypersensitivity,Immune_system_disorders,NCT00113516,https://clinicaltrials.gov/show/NCT00113516,Non-small_Cell_Lung_Cancer,carboplatin|paclitaxel|sunitinib|,1,84,serious_events,arm0,Carboplatin Plus Paclitaxel 172-225 mg/m2 (Part 1),1,84
HYPERSENSITIVITY,Immune_system_disorders,NCT00113763,https://clinicaltrials.gov/show/NCT00113763,Colorectal_Cancer|Metastases|,Best_supportive_care|Panitumumab|,1,229,serious_events,arm0,Panitumumab Plus BSC,1,229
Hypersensitivity,Immune_system_disorders,NCT00114244,https://clinicaltrials.gov/show/NCT00114244,Stage_IV_Pancreatic_Cancer,sorafenib_tosylate|gemcitabine_hydrochloride|laboratory_biomarker_analysis|,1,15,other_events,arm0,Arm I (Sorafenib Tosylate),1,15
HYPERSENSITIVITY,Immune_system_disorders,NCT00115765,https://clinicaltrials.gov/show/NCT00115765,Colorectal_Cancer,Oxaliplatin_Based_Chemotherapy|Panitumumab|Irinotecan_Based_Chemotherapy|Bevacizumab|,5,1028,serious_events,arm0,Panit. Plus Bevacizumab With Chemotherapy,4,518
HYPERSENSITIVITY,Immune_system_disorders,NCT00115765,https://clinicaltrials.gov/show/NCT00115765,Colorectal_Cancer,Oxaliplatin_Based_Chemotherapy|Panitumumab|Irinotecan_Based_Chemotherapy|Bevacizumab|,5,1028,serious_events,arm1,Bevacizumab With Chemotherapy,1,510
Hypersensitivity,Immune_system_disorders,NCT00117962,https://clinicaltrials.gov/show/NCT00117962,Lung_Cancer,cetuximab|carboplatin|pemetrexed_disodium|radiation_therapy|,8,206,serious_events,arm0,Std Tx + Pemetrexed,1,50
Hypersensitivity,Immune_system_disorders,NCT00117962,https://clinicaltrials.gov/show/NCT00117962,Lung_Cancer,cetuximab|carboplatin|pemetrexed_disodium|radiation_therapy|,8,206,serious_events,arm1,Std Tx + Pemetrexed and Cetuximab,3,53
Hypersensitivity,Immune_system_disorders,NCT00117962,https://clinicaltrials.gov/show/NCT00117962,Lung_Cancer,cetuximab|carboplatin|pemetrexed_disodium|radiation_therapy|,8,206,other_events,arm1,Std Tx + Pemetrexed and Cetuximab,3,53
Hypersensitivity,Immune_system_disorders,NCT00117962,https://clinicaltrials.gov/show/NCT00117962,Lung_Cancer,cetuximab|carboplatin|pemetrexed_disodium|radiation_therapy|,8,206,other_events,arm0,Std Tx + Pemetrexed,1,50
Hypersensitivity,Immune_system_disorders,NCT00118144,https://clinicaltrials.gov/show/NCT00118144,Adenocarcinoma_of_the_Lung|Bronchoalveolar_Cell_Lung_Cancer|Non-small_Cell_Lung_Cancer|Recurrent_Non-small_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|Stage_IV_Non-small_Cell_Lung_Cancer|,bortezomib,1,42,other_events,arm0,Arm I,1,42
Hypersensitivity,Immune_system_disorders,NCT00118755,https://clinicaltrials.gov/show/NCT00118755,Colorectal_Cancer,capecitabine|Oxaliplatin|bevacizumab|capecitabine|Oxaliplatin|bevacizumab|,1,208,serious_events,arm0,XELOX Q3W + Bevacizumab,1,208
Hypersensitivity,Immune_system_disorders,NCT00118742,https://clinicaltrials.gov/show/NCT00118742,Liver_Transplantation,mycophenolate_mofetil_[CellCept]|Tacrolimus|Cyclosporine|Sirolimus|,1,148,serious_events,arm1,CellCept + Sirolimus,1,148
Hypersensitivity,Immune_system_disorders,NCT00122460,https://clinicaltrials.gov/show/NCT00122460,Head_and_Neck_Cancer,Cetuximab_+_Platinum_(Cisplatin_or_Carboplatin)_+_5Fluorouracil_(5-FU)|Platinum_(Cisplatin_or_Carboplatin)_+_5-FU|,4,219,serious_events,arm0,Cetuximab Plus Chemotherapy,4,219
Hypersensitivity,Immune_system_disorders,NCT00122681,https://clinicaltrials.gov/show/NCT00122681,Infections_Papillomavirus,Cervarix‰ã¢|Havrix‰ã¢-based_investigational_formulation|,7,18644,serious_events,arm0,Havrix Group,5,9325
Hypersensitivity,Immune_system_disorders,NCT00122681,https://clinicaltrials.gov/show/NCT00122681,Infections_Papillomavirus,Cervarix‰ã¢|Havrix‰ã¢-based_investigational_formulation|,7,18644,serious_events,arm1,Cervarix Group,2,9319
Hypersensitivity,Immune_system_disorders,NCT00123474,https://clinicaltrials.gov/show/NCT00123474,Myeloid_Leukemia_Chronic_Chronic-Phase,dasatinib|dasatinib|dasatinib|dasatinib|,2,330,serious_events,arm1,140mg QD,1,163
Hypersensitivity,Immune_system_disorders,NCT00123474,https://clinicaltrials.gov/show/NCT00123474,Myeloid_Leukemia_Chronic_Chronic-Phase,dasatinib|dasatinib|dasatinib|dasatinib|,2,330,serious_events,arm3,70mg BID,1,167
Hypersensitivity,Immune_system_disorders,NCT00124618,https://clinicaltrials.gov/show/NCT00124618,Lung_Cancer,cetuximab|radiation_therapy|,4,58,other_events,arm0,Cetuximab/Radiation,4,58
Hypersensitivity,Immune_system_disorders,NCT00124709,https://clinicaltrials.gov/show/NCT00124709,Atopic_Dermatitis,Pimecrolimus|Corticosteroid|,1,543,serious_events,arm0,Pimecrolimus (Elidel) Treatment Group,1,543
HYPERSENSITIVITY,Immune_system_disorders,NCT00125034,https://clinicaltrials.gov/show/NCT00125034,Neoplasm_Metastasis|Colorectal_Cancer|,Cetuximab|Oxaliplatin|,21,676,other_events,arm0,Cetuximab Plus FOLFOX-4,13,170
HYPERSENSITIVITY,Immune_system_disorders,NCT00125034,https://clinicaltrials.gov/show/NCT00125034,Neoplasm_Metastasis|Colorectal_Cancer|,Cetuximab|Oxaliplatin|,21,676,serious_events,arm1,FOLFOX-4 Alone,2,168
HYPERSENSITIVITY,Immune_system_disorders,NCT00125034,https://clinicaltrials.gov/show/NCT00125034,Neoplasm_Metastasis|Colorectal_Cancer|,Cetuximab|Oxaliplatin|,21,676,serious_events,arm0,Cetuximab Plus FOLFOX-4,5,170
HYPERSENSITIVITY,Immune_system_disorders,NCT00125034,https://clinicaltrials.gov/show/NCT00125034,Neoplasm_Metastasis|Colorectal_Cancer|,Cetuximab|Oxaliplatin|,21,676,other_events,arm1,FOLFOX-4 Alone,1,168
Hypersensitivity,Immune_system_disorders,NCT00127101,https://clinicaltrials.gov/show/NCT00127101,Lymphoma,vorinostat|Comparator:_bexarotene|,1,5,serious_events,arm1,Cohort 2,1,5
HYPERSENSITIVITY,Immune_system_disorders,NCT00129766,https://clinicaltrials.gov/show/NCT00129766,Respiratory_Syncytial_Virus_Infections,motavizumab_(MEDI-524)|palivizumab|,1,3315,serious_events,arm1,Motavizumab,1,3315
Hypersensitivity,Immune_system_disorders,NCT00131911,https://clinicaltrials.gov/show/NCT00131911,Gastrinoma|Glucagonoma|Insulinoma|Metastatic_Gastrointestinal_Carcinoid_Tumor|Neuroendocrine_Tumor|Pancreatic_Polypeptide_Tumor|Recurrent_Gastrointestinal_Carcinoid_Tumor|Recurrent_Islet_Cell_Carcinoma|Somatostatinoma|WDHA_Syndrome|,sorafenib_tosylate,2,186,serious_events,arm0,All Patients,1,93
Hypersensitivity,Immune_system_disorders,NCT00131911,https://clinicaltrials.gov/show/NCT00131911,Gastrinoma|Glucagonoma|Insulinoma|Metastatic_Gastrointestinal_Carcinoid_Tumor|Neuroendocrine_Tumor|Pancreatic_Polypeptide_Tumor|Recurrent_Gastrointestinal_Carcinoid_Tumor|Recurrent_Islet_Cell_Carcinoma|Somatostatinoma|WDHA_Syndrome|,sorafenib_tosylate,2,186,other_events,arm0,All Patients,1,93
Hypersensitivity,Immune_system_disorders,NCT00132808,https://clinicaltrials.gov/show/NCT00132808,Osteopenia,Zoledronic_Acid|Placebo|,1,198,serious_events,arm0,Zoledronic Acid 2x5 mg,1,198
Hypersensitivity,Immune_system_disorders,NCT00133575,https://clinicaltrials.gov/show/NCT00133575,Smallpox,MVA_Smallpox_Vaccine|MVA_Smallpox_Vaccine|Placebo|Placebo|MVA_Smallpox_Vaccine|Live_vaccinia_virus_vaccine|Placebo|,1,10,other_events,arm1,10^7 TCID50 MVA IM,1,10
Hypersensitivity,Immune_system_disorders,NCT00137436,https://clinicaltrials.gov/show/NCT00137436,Prostatic_Neoplasms,Docetaxel|Prednisone|SU011248|,1,55,serious_events,arm0,SU011248 37.5 mg + Docetaxel 75 mg/m^2 + Prednisone 5 mg,1,55
Hypersensitivity,Immune_system_disorders,NCT00139776,https://clinicaltrials.gov/show/NCT00139776,Osteoarthritis_Knee|Osteoarthritis_Hip|,Celecoxib|Celecoxib|,1,427,other_events,arm1,Celecoxib 200mg Intermittent Use,1,427
HYPERSENSITIVITY,Immune_system_disorders,NCT00142298,https://clinicaltrials.gov/show/NCT00142298,Chronic_Hepatitis_B,Telbivudine_(LdT),5,856,other_events,arm9,Group C : Other Feeder Studies,1,13
HYPERSENSITIVITY,Immune_system_disorders,NCT00142298,https://clinicaltrials.gov/show/NCT00142298,Chronic_Hepatitis_B,Telbivudine_(LdT),5,856,other_events,arm0,Group A : LdT Pool 2302/015,2,655
HYPERSENSITIVITY,Immune_system_disorders,NCT00142298,https://clinicaltrials.gov/show/NCT00142298,Chronic_Hepatitis_B,Telbivudine_(LdT),5,856,other_events,arm7,Group C : LdT Pool 2302/015,1,66
HYPERSENSITIVITY,Immune_system_disorders,NCT00142298,https://clinicaltrials.gov/show/NCT00142298,Chronic_Hepatitis_B,Telbivudine_(LdT),5,856,other_events,arm3,Group A: Feeder 2401,1,122
Hypersensitivity,Immune_system_disorders,NCT00143247,https://clinicaltrials.gov/show/NCT00143247,Diabetes_Mellitus,Exuberaå¨_(inhaled_insulin),8,173,other_events,arm0,Inhaled Insulin,8,173
Hypersensitivity,Immune_system_disorders,NCT00144300,https://clinicaltrials.gov/show/NCT00144300,Parkinson_Disease,Mirapex|Requip|,1,121,serious_events,arm0,Pramipexole,1,121
Hypersensitivity,Immune_system_disorders,NCT00145249,https://clinicaltrials.gov/show/NCT00145249,Cryptococcal_Meningitis,Amphotericin_B|Fluconazole|,1,45,serious_events,arm0,AmphoB Standard,1,45
Hypersensitivity,Immune_system_disorders,NCT00144339,https://clinicaltrials.gov/show/NCT00144339,Pulmonary_Disease_Chronic_Obstructive,tiotropium|placebo|,2,2986,serious_events,arm1,Tiotropium Bromide Inhalation Capsules 18 mcg,2,2986
Hypersensitivity,Immune_system_disorders,NCT00145327,https://clinicaltrials.gov/show/NCT00145327,Osteoporosis,Zoledronic_Acid|Placebo|,3,1837,serious_events,arm1,Zoledronic Acid 3 Placebo 3,1,616
Hypersensitivity,Immune_system_disorders,NCT00145327,https://clinicaltrials.gov/show/NCT00145327,Osteoporosis,Zoledronic_Acid|Placebo|,3,1837,serious_events,arm2,Placebo 3 Zoledronic Acid 3,2,1221
Hypersensitivity,Immune_system_disorders,NCT00147537,https://clinicaltrials.gov/show/NCT00147537,Carcinoma_Non-Small-Cell_Lung,CP-751871|paclitaxel|carboplatin|CP-751871|paclitaxel|carboplatin|erlotinib|,6,219,other_events,arm10,Paclitaxel + Carboplatin (Phase 2),1,56
Hypersensitivity,Immune_system_disorders,NCT00147537,https://clinicaltrials.gov/show/NCT00147537,Carcinoma_Non-Small-Cell_Lung,CP-751871|paclitaxel|carboplatin|CP-751871|paclitaxel|carboplatin|erlotinib|,6,219,other_events,arm9,CP-751871 + Paclitaxel + Carboplatin (Phase 2),5,163
Hypersensitivity,Immune_system_disorders,NCT00148798,https://clinicaltrials.gov/show/NCT00148798,Non_Small_Cell_Lung_Cancer_(NSCLC),cetuximab_+_cisplatin_+_vinorelbine|cisplatin_+_vinorelbine|,6,1110,serious_events,arm0,Cetuximab Plus Chemotherapy,5,548
Hypersensitivity,Immune_system_disorders,NCT00148798,https://clinicaltrials.gov/show/NCT00148798,Non_Small_Cell_Lung_Cancer_(NSCLC),cetuximab_+_cisplatin_+_vinorelbine|cisplatin_+_vinorelbine|,6,1110,serious_events,arm1,Chemotherapy Alone,1,562
Hypersensitivity,Immune_system_disorders,NCT00149890,https://clinicaltrials.gov/show/NCT00149890,Liver_Transplantation|Infection|,Basiliximab|Cyclosporine/cyclosporine_microemulsion|Steroid|,1,38,serious_events,arm1,Without Intraoperative Steroids,1,38
Hypersensitivity,Immune_system_disorders,NCT00153062,https://clinicaltrials.gov/show/NCT00153062,Stroke,Aggrenox|Aggrenox|Clopidogrel_placebo|Clopidogrel_placebo|Micardis|Micardis|Aggrenox_placebo|Aggrenox_placebo|Clopidogrel|Clopidogrel|Micardis_placebo|Micardis_placebo|,9,15047,serious_events,arm2,Clopidogrel / Telmisartan,1,5000
Hypersensitivity,Immune_system_disorders,NCT00153062,https://clinicaltrials.gov/show/NCT00153062,Stroke,Aggrenox|Aggrenox|Clopidogrel_placebo|Clopidogrel_placebo|Micardis|Micardis|Aggrenox_placebo|Aggrenox_placebo|Clopidogrel|Clopidogrel|Micardis_placebo|Micardis_placebo|,9,15047,serious_events,arm3,Clopidogrel / Placebo,5,5023
Hypersensitivity,Immune_system_disorders,NCT00153062,https://clinicaltrials.gov/show/NCT00153062,Stroke,Aggrenox|Aggrenox|Clopidogrel_placebo|Clopidogrel_placebo|Micardis|Micardis|Aggrenox_placebo|Aggrenox_placebo|Clopidogrel|Clopidogrel|Micardis_placebo|Micardis_placebo|,9,15047,serious_events,arm1,Aspirin + Extended Release Dipyridamole / Placebo,3,5024
Hypersensitivity,Immune_system_disorders,NCT00154063,https://clinicaltrials.gov/show/NCT00154063,Migraine_Prophylaxis,E2007|Placebo|,2,206,other_events,arm1,E2007,1,102
Hypersensitivity,Immune_system_disorders,NCT00154063,https://clinicaltrials.gov/show/NCT00154063,Migraine_Prophylaxis,E2007|Placebo|,2,206,other_events,arm0,Placebo,1,104
HYPERSENSITIVITY,Immune_system_disorders,NCT00154102,https://clinicaltrials.gov/show/NCT00154102,Epidermal_Growth_Factor_Receptor_(EGFR)_Expressing_Metastatic_Colorectal_Cancer,Cetuximab|FOLFIRI_(5-Fluorouracil_Folinic_acid_Irinotecan)|,4,600,serious_events,arm0,Cetuximab Plus FOLFIRI,4,600
Hypersensitivity,Immune_system_disorders,NCT00158600,https://clinicaltrials.gov/show/NCT00158600,Pompe_Disease_(Late-onset)|Glycogen_Storage_Disease_Type_II_(GSD-II)|Acid_Maltase_Deficiency_Disease|Glycogenosis_2|,alglucosidase_alfa|Placebo|,8,300,serious_events,arm0,Alglucosidase Alfa,2,60
Hypersensitivity,Immune_system_disorders,NCT00158600,https://clinicaltrials.gov/show/NCT00158600,Pompe_Disease_(Late-onset)|Glycogen_Storage_Disease_Type_II_(GSD-II)|Acid_Maltase_Deficiency_Disease|Glycogenosis_2|,alglucosidase_alfa|Placebo|,8,300,other_events,arm0,Alglucosidase Alfa,2,60
Hypersensitivity,Immune_system_disorders,NCT00158600,https://clinicaltrials.gov/show/NCT00158600,Pompe_Disease_(Late-onset)|Glycogen_Storage_Disease_Type_II_(GSD-II)|Acid_Maltase_Deficiency_Disease|Glycogenosis_2|,alglucosidase_alfa|Placebo|,8,300,serious_events,arm2,Overall,2,90
Hypersensitivity,Immune_system_disorders,NCT00158600,https://clinicaltrials.gov/show/NCT00158600,Pompe_Disease_(Late-onset)|Glycogen_Storage_Disease_Type_II_(GSD-II)|Acid_Maltase_Deficiency_Disease|Glycogenosis_2|,alglucosidase_alfa|Placebo|,8,300,other_events,arm2,Overall,2,90
Hypersensitivity,Immune_system_disorders,NCT00159861,https://clinicaltrials.gov/show/NCT00159861,Pulmonary_Hypertension,Sildenafil_citrate,3,134,other_events,arm1,Sildenafil/Sildenafil,3,134
Hypersensitivity,Immune_system_disorders,NCT00162123,https://clinicaltrials.gov/show/NCT00162123,Melanoma,Ipilimumab,6,177,other_events,arm0,First Reinduction: Ipilimumab 10 to 10 mg/kg,1,53
Hypersensitivity,Immune_system_disorders,NCT00162123,https://clinicaltrials.gov/show/NCT00162123,Melanoma,Ipilimumab,6,177,serious_events,arm5,Extended Maintenance Only: Ipilimumab 3 mg/kg,1,12
Hypersensitivity,Immune_system_disorders,NCT00162123,https://clinicaltrials.gov/show/NCT00162123,Melanoma,Ipilimumab,6,177,other_events,arm1,First Reinduction: Ipilimumab 3 to 10 mg/kg,1,34
Hypersensitivity,Immune_system_disorders,NCT00162123,https://clinicaltrials.gov/show/NCT00162123,Melanoma,Ipilimumab,6,177,other_events,arm5,Extended Maintenance Only: Ipilimumab 3 mg/kg,1,12
Hypersensitivity,Immune_system_disorders,NCT00162123,https://clinicaltrials.gov/show/NCT00162123,Melanoma,Ipilimumab,6,177,other_events,arm4,Extended Maintenance Only: Ipilimumab 10 mg/kg,1,33
Hypersensitivity,Immune_system_disorders,NCT00162123,https://clinicaltrials.gov/show/NCT00162123,Melanoma,Ipilimumab,6,177,serious_events,arm4,Extended Maintenance Only: Ipilimumab 10 mg/kg,1,33
Hypersensitivity,Immune_system_disorders,NCT00163189,https://clinicaltrials.gov/show/NCT00163189,Growth_Hormone_Deficiency,Somatropin,2,196,serious_events,arm0,Genotonorm,1,98
Hypersensitivity,Immune_system_disorders,NCT00163189,https://clinicaltrials.gov/show/NCT00163189,Growth_Hormone_Deficiency,Somatropin,2,196,other_events,arm0,Genotonorm,1,98
Hypersensitivity,Immune_system_disorders,NCT00166205,https://clinicaltrials.gov/show/NCT00166205,Obesity_Morbid,Swedish_Adjustable_Gastric_Band,1,276,serious_events,arm0,Swedish Adjustable Gastric Band (SAGB),1,276
Hypersensitivity,Immune_system_disorders,NCT00168818,https://clinicaltrials.gov/show/NCT00168818,Thromboembolism|Arthroplasty_Replacement_Hip|,dabigatran_etexilate|dabigatran_etexilate|enoxaparin|,1,1154,serious_events,arm2,Enoxaparin,1,1154
Hypersensitivity,Immune_system_disorders,NCT00170157,https://clinicaltrials.gov/show/NCT00170157,Prostatic_Neoplasms,Combination_Androgen_Ablative_Therapy|MDX-010_therapy|,4,220,serious_events,arm0,Entire Study Population,1,110
Hypersensitivity,Immune_system_disorders,NCT00170157,https://clinicaltrials.gov/show/NCT00170157,Prostatic_Neoplasms,Combination_Androgen_Ablative_Therapy|MDX-010_therapy|,4,220,other_events,arm0,Entire Study Population,3,110
Hypersensitivity,Immune_system_disorders,NCT00170950,https://clinicaltrials.gov/show/NCT00170950,Hypertension,Benazepril/amlodipine_20/5_mg_-_Dose_Level_1_from_Day_1_to_Month_1|Benazepril/amlodipine_40/5_mg_-_Dose_Level_2_from_Month_1_to_Month_2|Benazepril/amlodipine_40/10_mg_-_Dose_Level_3_from_Month_2_to_Month_3_and_thereafter|Benazepril/hydrochlorothiazide_20/12.5_mg_-_Dose_Level_1_from_Day_1_to_Month_1|Benazepril/hydrochlorothiazide_40/12.5_mg_-_Dose_Level_2_from_Month_1_to_Month_2|Benazepril/hydrochlorothiazide_40/25_mg_-_Dose_Level_3_from_Month_2_to_Month_3_and_thereafter|,3,11497,serious_events,arm1,Benazepril / HCTZ,1,5757
Hypersensitivity,Immune_system_disorders,NCT00170950,https://clinicaltrials.gov/show/NCT00170950,Hypertension,Benazepril/amlodipine_20/5_mg_-_Dose_Level_1_from_Day_1_to_Month_1|Benazepril/amlodipine_40/5_mg_-_Dose_Level_2_from_Month_1_to_Month_2|Benazepril/amlodipine_40/10_mg_-_Dose_Level_3_from_Month_2_to_Month_3_and_thereafter|Benazepril/hydrochlorothiazide_20/12.5_mg_-_Dose_Level_1_from_Day_1_to_Month_1|Benazepril/hydrochlorothiazide_40/12.5_mg_-_Dose_Level_2_from_Month_1_to_Month_2|Benazepril/hydrochlorothiazide_40/25_mg_-_Dose_Level_3_from_Month_2_to_Month_3_and_thereafter|,3,11497,serious_events,arm0,Benazepril / Amlodipine,2,5740
Hypersensitivity,Immune_system_disorders,NCT00171340,https://clinicaltrials.gov/show/NCT00171340,Bone_Loss|Breast_Cancer|,Zoledronic_acid|Letrozole|,1,535,serious_events,arm1,Zolendronic Acid 4mg Delayed,1,535
Hypersensitivity,Immune_system_disorders,NCT00171834,https://clinicaltrials.gov/show/NCT00171834,Carcinoma_Non-Small-Cell_Lung,Patupilone,1,6,other_events,arm0,Patupilone ‰ä_7.0 mg/m^2 (Phase I),1,6
Hypersensitivity,Immune_system_disorders,NCT00174187,https://clinicaltrials.gov/show/NCT00174187,Endocrine_System_Diseases,Somatropin,1,21,other_events,arm2,Somatropin- After Year 3,1,21
Hypersensitivity,Immune_system_disorders,NCT00174785,https://clinicaltrials.gov/show/NCT00174785,Atrial_Fibrillation|Atrial_Flutter|,dronedarone_(SR33589)|placebo|,1,2291,serious_events,arm0,Dronedarone 400mg Bid,1,2291
Hypersensitivity,Immune_system_disorders,NCT00184548,https://clinicaltrials.gov/show/NCT00184548,Acquired_Bleeding_Disorder|Trauma|,eptacog_alfa_(activated)|placebo|,2,224,serious_events,arm0,rFVIIa Blunt Trauma,2,224
Hypersensitivity,Immune_system_disorders,NCT00190671,https://clinicaltrials.gov/show/NCT00190671,Breast_Cancer,pemetrexed|cyclophosphamide|pemetrexed|,3,42,other_events,arm0,Pemetrexed 600mg/m2,3,42
Hypersensitivity,Immune_system_disorders,NCT00191282,https://clinicaltrials.gov/show/NCT00191282,Diabetes_Mellitus_Type_2|Acute_Myocardial_Infarction|,Insulin_lispro|Human_insulin_isophane_suspension_(NPH)|Insulin_glargine|Human_insulin_isophane_suspension|Human_insulin_30/70|,1,557,serious_events,arm0,Postprandial,1,557
Hypersensitivity,Immune_system_disorders,NCT00191451,https://clinicaltrials.gov/show/NCT00191451,Breast_Cancer,Gemcitabine|Carboplatin|Herceptin|,1,48,serious_events,arm1,HER2- (Taxane-),1,48
Hypersensitivity,Immune_system_disorders,NCT00191984,https://clinicaltrials.gov/show/NCT00191984,Metastatic_Colorectal_Cancer,pemetrexed|irinotecan|,1,44,serious_events,arm0,Pemetrexed + Irinotecan,1,44
Hypersensitivity,Immune_system_disorders,NCT00193258,https://clinicaltrials.gov/show/NCT00193258,Clear_Cell_Renal_Cell_Carcinoma,Bevacizumab|Erlotinib|Imatinib|,5,94,other_events,arm0,Bevacizumab/Erlotinib/Imatinib,5,94
Hypersensitivity,Immune_system_disorders,NCT00195650,https://clinicaltrials.gov/show/NCT00195650,Rheumatoid_Arthritis,Adalimumab,2,846,serious_events,arm0,Adalimumab,2,846
Hypersensitivity,Immune_system_disorders,NCT00195715,https://clinicaltrials.gov/show/NCT00195715,Crohn's_Disease,Adalimumab,1,777,serious_events,arm0,Open-label Adalimumab,1,777
Hypersensitivity,Immune_system_disorders,NCT00195663,https://clinicaltrials.gov/show/NCT00195663,Early_Rheumatoid_Arthritis,Adalimumab|Methotrexate|Adalimumab_placebo|Methotrexate_placebo|,3,971,serious_events,arm3,Any Adalimumab,2,697
Hypersensitivity,Immune_system_disorders,NCT00195663,https://clinicaltrials.gov/show/NCT00195663,Early_Rheumatoid_Arthritis,Adalimumab|Methotrexate|Adalimumab_placebo|Methotrexate_placebo|,3,971,serious_events,arm1,Adalimumab,1,274
Hypersensitivity,Immune_system_disorders,NCT00195702,https://clinicaltrials.gov/show/NCT00195702,Rheumatoid_Arthritis,Adalimumab|Adalimumab|Placebo|Adalimumab|Adalimumab|Adalimumab|,1,553,serious_events,arm3,Any Adalimumab Through Year 10,1,553
Hypersensitivity,Immune_system_disorders,NCT00205803,https://clinicaltrials.gov/show/NCT00205803,Healthy_Subjects|Pneumococcal_Infections|,13-Valent_Pneumococcal_Conjugate_Vaccine_(13vPnC)|7-Valent_Pneumococcal_Conjugate_Vaccine_(7vPnC)|,1,120,other_events,arm0,13vPnC Infant Series,1,120
HYPERSENSITIVITY,Immune_system_disorders,NCT00207090,https://clinicaltrials.gov/show/NCT00207090,Advanced_Solid_Tumors|Neoplasms|,ixabepilone|Rifampin|,2,30,serious_events,arm0,All Participants,1,15
HYPERSENSITIVITY,Immune_system_disorders,NCT00207090,https://clinicaltrials.gov/show/NCT00207090,Advanced_Solid_Tumors|Neoplasms|,ixabepilone|Rifampin|,2,30,other_events,arm0,All Participants,1,15
Hypersensitivity,Immune_system_disorders,NCT00213135,https://clinicaltrials.gov/show/NCT00213135,Multiple_Sclerosis_Relapsing-Remitting,Cladribine_5.25_mg/kg|Cladribine_3.5_mg/kg|Placebo|,2,454,serious_events,arm0,Cladribine 5.25 mg/kg,2,454
Hypersensitivity,Immune_system_disorders,NCT00214526,https://clinicaltrials.gov/show/NCT00214526,Asthma,Bronchial_thermoplasty_with_the_Alair_System|Conventional_therapy_with_ICS+LABA|,7,218,other_events,arm3,Control (Post-Treatment Period),3,54
Hypersensitivity,Immune_system_disorders,NCT00214526,https://clinicaltrials.gov/show/NCT00214526,Asthma,Bronchial_thermoplasty_with_the_Alair_System|Conventional_therapy_with_ICS+LABA|,7,218,other_events,arm0,Alair (Treatment Period),1,55
Hypersensitivity,Immune_system_disorders,NCT00214526,https://clinicaltrials.gov/show/NCT00214526,Asthma,Bronchial_thermoplasty_with_the_Alair_System|Conventional_therapy_with_ICS+LABA|,7,218,other_events,arm2,Alair (Post-Treatment Period),2,55
Hypersensitivity,Immune_system_disorders,NCT00214526,https://clinicaltrials.gov/show/NCT00214526,Asthma,Bronchial_thermoplasty_with_the_Alair_System|Conventional_therapy_with_ICS+LABA|,7,218,other_events,arm1,Control (Treatment Period),1,54
Hypersensitivity,Immune_system_disorders,NCT00214539,https://clinicaltrials.gov/show/NCT00214539,Asthma,Bronchial_Thermoplasty_with_the_Alair_System|Control|,2,32,other_events,arm5,Control (Steroid Wean and Reduced Steroid Phases),1,17
Hypersensitivity,Immune_system_disorders,NCT00214539,https://clinicaltrials.gov/show/NCT00214539,Asthma,Bronchial_Thermoplasty_with_the_Alair_System|Control|,2,32,other_events,arm4,Alair (Steroid Wean and Reduced Steroid Phases),1,15
Hypersensitivity,Immune_system_disorders,NCT00219557,https://clinicaltrials.gov/show/NCT00219557,Pancreatic_Neoplasms,Gemcitabine|AG-013736|Gemcitabine|,2,99,other_events,arm2,Gemcitabine,1,31
Hypersensitivity,Immune_system_disorders,NCT00219557,https://clinicaltrials.gov/show/NCT00219557,Pancreatic_Neoplasms,Gemcitabine|AG-013736|Gemcitabine|,2,99,other_events,arm1,Axitinib + Gemcitabine,1,68
hypersensitivity,Immune_system_disorders,NCT00225147,https://clinicaltrials.gov/show/NCT00225147,Hereditary_Angioedema|Angioneurotic_Edema|,Recombinant_Human_C1_Inhibitor|placebo|,1,62,serious_events,arm3,"50 IU/kg Open-label ""rhC1INH""",1,62
Hypersensitivity,Immune_system_disorders,NCT00227266,https://clinicaltrials.gov/show/NCT00227266,Spinal_Muscular_Atrophy,Valproic_Acid_and_Levocarnitine|Placebo|,1,31,other_events,arm0,Cohort 1a Sitters Placebo Then Treatment,1,31
Hypersensitivity,Immune_system_disorders,NCT00229723,https://clinicaltrials.gov/show/NCT00229723,Neoplasms_Squamous_Cell,gefitinib_(Iressa)|cisplatin|radiotherapy|Gefitinib_(Iressa)|,1,34,serious_events,arm5,Placebo/250mg,1,34
Hypersensitivity,Immune_system_disorders,NCT00234884,https://clinicaltrials.gov/show/NCT00234884,Rheumatoid_Arthritis,adalimumab,1,3435,serious_events,arm0,Adalimumab,1,3435
Hypersensitivity,Immune_system_disorders,NCT00235391,https://clinicaltrials.gov/show/NCT00235391,Thalassemia|Sickle_Cell_Disease|Diamond_Blackfan_Anemia|Myelofibrosis|,Deferasirox,1,1683,serious_events,arm0,All Participants,1,1683
Hypersensitivity,Immune_system_disorders,NCT00240994,https://clinicaltrials.gov/show/NCT00240994,Kidney_Failure_Chronic|Kidney_Transplantation|Immunosuppression|,Alemtuzumab|Tacrolimus|Mycophenolate_mofetil|Sirolimus|,1,35,serious_events,arm0,Alemtuzumab (Campath),1,35
Hypersensitivity,Immune_system_disorders,NCT00242710,https://clinicaltrials.gov/show/NCT00242710,Endometrial_Hyperplasia|Osteoporosis|,Bazedoxifene/Conjugated_Estrogen|Bazedoxifene/Conjugated_Estrogen|CE_0.45_mg/MPA_1.5mg|Placebo|,24,1061,other_events,arm1,Bazedoxifene 20 mg/Conjugated Estrogen 0.625 mg,9,349
Hypersensitivity,Immune_system_disorders,NCT00242710,https://clinicaltrials.gov/show/NCT00242710,Endometrial_Hyperplasia|Osteoporosis|,Bazedoxifene/Conjugated_Estrogen|Bazedoxifene/Conjugated_Estrogen|CE_0.45_mg/MPA_1.5mg|Placebo|,24,1061,other_events,arm3,Placebo,2,172
Hypersensitivity,Immune_system_disorders,NCT00242710,https://clinicaltrials.gov/show/NCT00242710,Endometrial_Hyperplasia|Osteoporosis|,Bazedoxifene/Conjugated_Estrogen|Bazedoxifene/Conjugated_Estrogen|CE_0.45_mg/MPA_1.5mg|Placebo|,24,1061,other_events,arm2,Conjugated Estrogen 0.45 mg/Medroxyprogesterone Acetate 1.5mg,3,179
Hypersensitivity,Immune_system_disorders,NCT00242710,https://clinicaltrials.gov/show/NCT00242710,Endometrial_Hyperplasia|Osteoporosis|,Bazedoxifene/Conjugated_Estrogen|Bazedoxifene/Conjugated_Estrogen|CE_0.45_mg/MPA_1.5mg|Placebo|,24,1061,other_events,arm0,Bazedoxifene 20 mg/Conjugated Estrogen 0.45 mg,10,361
Hypersensitivity,Immune_system_disorders,NCT00244712,https://clinicaltrials.gov/show/NCT00244712,HIV_Infection,emtricitabine/tenofovir|abacavir/lamivudine|,2,343,serious_events,arm0,Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV),2,343
Hypersensitivity,Immune_system_disorders,NCT00245466,https://clinicaltrials.gov/show/NCT00245466,Prostate_Cancer,Degarelix|Degarelix|Degarelix|,1,46,serious_events,arm1,Degarelix 40/40 + 40,1,46
Hypersensitivity,Immune_system_disorders,NCT00246012,https://clinicaltrials.gov/show/NCT00246012,Melanoma,Intetumumab|Dacarbazine|Placebo|,1,32,serious_events,arm8,Dacarbazine + Intetumumab 10 mg/kg [Phase 2],1,32
Hypersensitivity,Immune_system_disorders,NCT00246571,https://clinicaltrials.gov/show/NCT00246571,Breast_Neoplasms,SU011248|Chemotherapy|,1,110,other_events,arm0,Sunitinib,1,110
Hypersensitivity,Immune_system_disorders,NCT00248170,https://clinicaltrials.gov/show/NCT00248170,Breast_Cancer,Letrozole|Anastrozole|,1,2049,serious_events,arm0,Letrozole,1,2049
Hypersensitivity,Immune_system_disorders,NCT00249873,https://clinicaltrials.gov/show/NCT00249873,Atrial_Fibrillation|Vascular_Risk|,clopidogrel_(SR25990C)|placebo|,4,7554,serious_events,arm1,Placebo + ASA,2,3782
Hypersensitivity,Immune_system_disorders,NCT00249873,https://clinicaltrials.gov/show/NCT00249873,Atrial_Fibrillation|Vascular_Risk|,clopidogrel_(SR25990C)|placebo|,4,7554,serious_events,arm0,Clopidogrel + ASA,2,3772
HYPERSENSITIVITY,Immune_system_disorders,NCT00252564,https://clinicaltrials.gov/show/NCT00252564,Colorectal_Cancer_Metastatic,Bevacizumab|Oxaliplatin|Leucovorin|Fluorouracil|Cetuximab|,20,118,other_events,arm0,Arm A,20,118
Hypersensitivity,Immune_system_disorders,NCT00252733,https://clinicaltrials.gov/show/NCT00252733,Type_1_Diabetes,candesartan_cilexetil,2,710,serious_events,arm1,Placebo,2,710
Hypersensitivity,Immune_system_disorders,NCT00252694,https://clinicaltrials.gov/show/NCT00252694,Type_2_Diabetes,candesartan,2,953,serious_events,arm1,Placebo,2,953
Hypersensitivity,Immune_system_disorders,NCT00257010,https://clinicaltrials.gov/show/NCT00257010,Migraine,Almotriptan_Malate,6,420,other_events,arm0,Almotriptan Malate,6,420
Hypersensitivity,Immune_system_disorders,NCT00256997,https://clinicaltrials.gov/show/NCT00256997,Schizophrenia,Risperidone_long-acting_injection_(LAI)|Oral_atypical_Antipsychotic|,4,167,other_events,arm0,Risperidone Long-Acting Injection (LAI),2,81
Hypersensitivity,Immune_system_disorders,NCT00256997,https://clinicaltrials.gov/show/NCT00256997,Schizophrenia,Risperidone_long-acting_injection_(LAI)|Oral_atypical_Antipsychotic|,4,167,other_events,arm1,Oral Atypical Antipsychotic,2,86
Hypersensitivity,Immune_system_disorders,NCT00262067,https://clinicaltrials.gov/show/NCT00262067,Metastatic_Breast_Cancer,Bevacizumab|Placebo|Chemotherapy|,1,413,serious_events,arm0,Bevacizumab 15 mg/kg + Taxane or Anthracycline-based Regimen,1,413
Hypersensitivity,Immune_system_disorders,NCT00262522,https://clinicaltrials.gov/show/NCT00262522,Human_Immunodeficiency_Virus_Infections,lopinavir/ritonavir_(LPV/r)_(tablet_or_capsule)_with_nucleoside_reverse_transcriptase_inhibitors_(NRTIs)|lopinavir/ritonavir_(LPV/r)_(tablet_or_capsule)_with_nucleoside_reverse_transcriptase_inhibitors_(NRTIs)|lopinavir/ritonavir_(LPV/r)_(tablet_or_capsule)_with_nucleoside_reverse_transcriptase_inhibitors_(NRTIs)|lopinavir/ritonavir_(LPV/r)_(tablet_or_capsule)_with_nucleoside_reverse_transcriptase_inhibitors_(NRTIs)|,1,333,serious_events,arm0,LPV/r 800/200 mg QD Tablet,1,333
Hypersensitivity,Immune_system_disorders,NCT00262600,https://clinicaltrials.gov/show/NCT00262600,Atrial_Fibrillation|Stroke|,warfarin|Dabigatran_dose_1|Dabigatran_dose_2|,2,11981,serious_events,arm2,Warfarin,1,5998
Hypersensitivity,Immune_system_disorders,NCT00262600,https://clinicaltrials.gov/show/NCT00262600,Atrial_Fibrillation|Stroke|,warfarin|Dabigatran_dose_1|Dabigatran_dose_2|,2,11981,serious_events,arm0,Dabigatran 110 mg,1,5983
Hypersensitivity,Immune_system_disorders,NCT00263328,https://clinicaltrials.gov/show/NCT00263328,Kidney_Transplantation,Tacrolimus|CP-690550|CP-690550|,1,13,other_events,arm2,Tofacitinib 30-15-10 mg BID,1,13
Hypersensitivity,Immune_system_disorders,NCT00263887,https://clinicaltrials.gov/show/NCT00263887,Alpha_1-Antitrypsin_Deficiency,Alpha1-Proteinase_Inhibitor_(Human)|Albumin_(Human)_20_PERCENT_United_States_Pharmacopeia_(USP)|,3,77,other_events,arm0,Prolastin (60 mg/kg Body Weight),2,38
Hypersensitivity,Immune_system_disorders,NCT00263887,https://clinicaltrials.gov/show/NCT00263887,Alpha_1-Antitrypsin_Deficiency,Alpha1-Proteinase_Inhibitor_(Human)|Albumin_(Human)_20_PERCENT_United_States_Pharmacopeia_(USP)|,3,77,other_events,arm1,Placebo,1,39
HYPERSENSITIVITY,Immune_system_disorders,NCT00265395,https://clinicaltrials.gov/show/NCT00265395,Hepatitis_C_Chronic,Combination_of_pegylated_interferon_alfa-2b_(PEG-Intronå¨)_and_ribavirin_(Rebetolå¨)|Combination_of_pegylated_interferon_alfa-2b_and_ribavirin|,1,1427,serious_events,arm0,Standard Therapy (48-week Treatment),1,1427
Hypersensitivity,Immune_system_disorders,NCT00265317,https://clinicaltrials.gov/show/NCT00265317,Carcinoma_Non-Small-Cell_Lung,erlotinib|sunitinib|erlotinib|placebo|,2,64,other_events,arm2,Sunitinib + Erlotinib,2,64
HYPERSENSITIVITY,Immune_system_disorders,NCT00266799,https://clinicaltrials.gov/show/NCT00266799,Breast_Cancer,Pegylated_liposomal_doxorubicin_(SCH_200746)|Capecitabine|,13,298,other_events,arm0,Pegylated Liposomal Doxorubicin (PLD),10,98
HYPERSENSITIVITY,Immune_system_disorders,NCT00266799,https://clinicaltrials.gov/show/NCT00266799,Breast_Cancer,Pegylated_liposomal_doxorubicin_(SCH_200746)|Capecitabine|,13,298,other_events,arm1,Capecitabine,1,102
HYPERSENSITIVITY,Immune_system_disorders,NCT00266799,https://clinicaltrials.gov/show/NCT00266799,Breast_Cancer,Pegylated_liposomal_doxorubicin_(SCH_200746)|Capecitabine|,13,298,serious_events,arm0,Pegylated Liposomal Doxorubicin (PLD),2,98
Hypersensitivity,Immune_system_disorders,NCT00267748,https://clinicaltrials.gov/show/NCT00267748,Carcinoma_Renal_Cell,Sunitinib_Malate_Continuous_Daily_Dosing|Sunitinib_Malate_Schedule_4/2|,1,143,serious_events,arm2,Sunitinib 37.5 mg,1,143
Hypersensitivity,Immune_system_disorders,NCT00268203,https://clinicaltrials.gov/show/NCT00268203,Lymphoma_Non-Hodgkin,Iodine_I_131_Tositumomab_Therapeutic_Regimen,4,765,other_events,arm0,Tositumomab and Iodine I-131 Tositumomab,4,765
Hypersensitivity,Immune_system_disorders,NCT00268983,https://clinicaltrials.gov/show/NCT00268983,Lymphoma_Non-Hodgkin,Tositumomab_and_Iodine_I_131_Tositumomab|Rituximab|,1,8,serious_events,arm1,TST/I-131 TST,1,8
Hypersensitivity,General_disorders,NCT00271154,https://clinicaltrials.gov/show/NCT00271154,Heart_Failure,Cardiac_Resynchronization_Therapy_(CRT)_Device_or_Implantable_Cardioverter_Defibrillator_(ICD)_with_CRT,1,419,serious_events,arm1,CRT ON,1,419
HYPERSENSITIVITY,Immune_system_disorders,NCT00272779,https://clinicaltrials.gov/show/NCT00272779,HIV_Infections,ATV|RTV|Tenofovi-Emtricitabine_(TDF/FTC)_tablet|LPV|,1,441,serious_events,arm0,ATV/RTV/Tenofovir/Emtricitabine,1,441
Hypersensitivity,Nervous_system_disorders,NCT00272987,https://clinicaltrials.gov/show/NCT00272987,Neoplasms_Breast,lapatinib|paclitaxel|trastuzumab|,1,14,other_events,arm1,Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg,1,14
Hypersensitivity,Immune_system_disorders,NCT00273858,https://clinicaltrials.gov/show/NCT00273858,Ankylosing_Spondylitis|Arthritis_Psoriatic|Arthritis_Rheumatoid|Spondylitis_Ankylosing|,There_is_no_Intervention._The_study_is_observational.,2,880,other_events,arm0,Etanercept,2,880
Hypersensitivity,Immune_system_disorders,NCT00274261,https://clinicaltrials.gov/show/NCT00274261,Pregnancy,C31G|nonoxynol-9_(N-9)|,1,560,serious_events,arm1,Conceptrol,1,560
Hypersensitivity,Immune_system_disorders,NCT00274456,https://clinicaltrials.gov/show/NCT00274456,Metastatic_Breast_Cancer,ABI-007|Docetaxel|,1,76,serious_events,arm1,ABI-007 100 mg/m^2 Weekly,1,76
Hypersensitivity,Immune_system_disorders,NCT00274651,https://clinicaltrials.gov/show/NCT00274651,Cutaneous_T-Cell_Lymphoma|Peripheral_T-Cell_Lymphoma|Non-Hodgkin's_Lymphoma|,belinostat,2,24,other_events,arm1,Arm B (PTCL ITT Population),2,24
Hypersensitivity,Immune_system_disorders,NCT00279201,https://clinicaltrials.gov/show/NCT00279201,Diabetes_Mellitus_Type_2,Insulin_glargine|Lispro_Low_Mix|Lispro_Mid_Mix|Lispro|,1,1045,serious_events,arm1,Lispro LM Initiation,1,1045
Hypersensitivity,Immune_system_disorders,NCT00281528,https://clinicaltrials.gov/show/NCT00281528,Breast_Neoplasms|Neoplasm_Metastasis|,ABI-007_(Abraxane)|bevacizumab|,4,129,other_events,arm1,260 mg/m^2 ABI-007 Every 2 Weeks,3,54
Hypersensitivity,Immune_system_disorders,NCT00281528,https://clinicaltrials.gov/show/NCT00281528,Breast_Neoplasms|Neoplasm_Metastasis|,ABI-007_(Abraxane)|bevacizumab|,4,129,other_events,arm0,260 mg/m^2 ABI-007 Every 3 Weeks,1,75
Hypersensitivity,Immune_system_disorders,NCT00282087,https://clinicaltrials.gov/show/NCT00282087,Leiomyosarcoma|Uterine_Neoplasm|,gemcitabine_docetaxel_doxorubicin,10,47,other_events,arm0,Women Treated With Adjuvant Regimen for High Risk Uterine LMS,10,47
Hypersensitivity,Immune_system_disorders,NCT00282048,https://clinicaltrials.gov/show/NCT00282048,Kidney_Neoplasms|Carcinoma_Renal_Cell|,AG-013736_(axitinib),3,62,other_events,arm0,Axitinib,3,62
Hypersensitivity,Immune_system_disorders,NCT00283062,https://clinicaltrials.gov/show/NCT00283062,Prostatic_Neoplasms,Docetaxel_(TAXOTEREå¨)_Chemotherapy|Leuprolide_acetate_(_ELIGARDå¨)_Hormonal_Therapy|Docetaxel_(TAXOTEREå¨)_Chemotherapy|Leuprolide_acetate_(_ELIGARDå¨)_Hormonal_Therapy|Leuprolide_acetate_(_ELIGARDå¨)_Hormonal_Therapy|,1,50,other_events,arm0,Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT),1,50
Hypersensitivity,Immune_system_disorders,NCT00286429,https://clinicaltrials.gov/show/NCT00286429,Diabetes_Mellitus,Alogliptin_and_insulin|Alogliptin_and_insulin|Insulin|,1,129,serious_events,arm2,Alogliptin 25 mg QD,1,129
Hypersensitivity,Immune_system_disorders,NCT00289783,https://clinicaltrials.gov/show/NCT00289783,Meningococcal_Infection|Haemophilus_Influenzae_Type_b_Infection|,GSK_Biologicals'_Haemophilus_influenzae_type_b_and_Neisseria_meningitidis_792014_vaccine|ActHIB|PedvaxHIB|Pediarix|Prevnar|M-M-R_II|Varivax|,2,5905,serious_events,arm0,Menhibrix Group,1,2769
Hypersensitivity,Immune_system_disorders,NCT00292188,https://clinicaltrials.gov/show/NCT00292188,Neuralgia,pregabalin|Placebo|,1,127,other_events,arm1,Double-Blind Pregabalin,1,127
Hypersensitivity,Immune_system_disorders,NCT00293254,https://clinicaltrials.gov/show/NCT00293254,HIV_Infections,raltegravir_potassium|Comparator:_placebo|,1,230,serious_events,arm0,Raltegravir 400 mg b.i.d. Plus OBT,1,230
Hypersensitivity,Immune_system_disorders,NCT00293267,https://clinicaltrials.gov/show/NCT00293267,HIV_Infections,raltegravir_potassium|Comparator:_Placebo|,1,232,serious_events,arm0,Raltegravir 400 mg b.i.d Plus OBT,1,232
Hypersensitivity,Immune_system_disorders,NCT00294047,https://clinicaltrials.gov/show/NCT00294047,Infections_Papillomavirus,Cervarix|Placebo_control|,1,2877,serious_events,arm0,Cervarix Group,1,2877
Hypersensitivity,Immune_system_disorders,NCT00296491,https://clinicaltrials.gov/show/NCT00296491,Asthma,fluticasone_propionate/salmeterol_(FSC)|montelukast_(MON)|fluticasone_propionate_(FP)|placebo_nasal|ADVAIR_DISKUS|placebo_capsule|placebo_DISKUS|,1,182,other_events,arm0,Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS),1,182
Hypersensitivity,Immune_system_disorders,NCT00296816,https://clinicaltrials.gov/show/NCT00296816,Ovarian_Cancer,Bevacizumab_(Avastinå¨)|Docetaxel_(Taxotereå¨)|Oxaliplatin_(Eloxatinå¨)|,8,132,other_events,arm0,Oxaliplatin/Docetaxel/Bevacizumab,8,132
Hypersensitivity,Immune_system_disorders,NCT00298363,https://clinicaltrials.gov/show/NCT00298363,Chronic_Hepatitis_B,Tenofovir_disoproxil_fumarate_(tenofovir_DF;_TDF)|Emtricitabine/tenofovir_disoproxil_fumarate_(FTC/TDF)|Entecavir_(ETV)|TDF_placebo|FTC/TDF_placebo|ETV_placebo|,2,138,serious_events,arm1,Double Blind FTC/TDF,1,45
Hypersensitivity,Immune_system_disorders,NCT00298363,https://clinicaltrials.gov/show/NCT00298363,Chronic_Hepatitis_B,Tenofovir_disoproxil_fumarate_(tenofovir_DF;_TDF)|Emtricitabine/tenofovir_disoproxil_fumarate_(FTC/TDF)|Entecavir_(ETV)|TDF_placebo|FTC/TDF_placebo|ETV_placebo|,2,138,serious_events,arm4,All TDF,1,93
Hypersensitivity,Immune_system_disorders,NCT00300274,https://clinicaltrials.gov/show/NCT00300274,Graft_Rejection,everolimus|mycophenolate_mofetil|cyclosporine|corticosteroids|,1,279,serious_events,arm0,Everolimus 1.5 mg,1,279
Hypersensitivity,Immune_system_disorders,NCT00301821,https://clinicaltrials.gov/show/NCT00301821,Lymphoma,epratuzumab|rituximab|cyclophosphamide|doxorubicin_hydrochloride|prednisone|vincristine_sulfate|,2,106,other_events,arm0,Epratuzumab + Rituximab + CHOP,2,106
HYPERSENSITIVITY,Immune_system_disorders,NCT00303459,https://clinicaltrials.gov/show/NCT00303459,Pulmonary_Arterial_Hypertension,bosentan|placebo|,1,174,serious_events,arm1,Placebo,1,174
Hypersensitivity,Immune_system_disorders,NCT00303472,https://clinicaltrials.gov/show/NCT00303472,Thrombocytopenia|MDS|Myelodysplastic_Syndromes|Refractory_Cytopenias|,Romiplostim,3,32,other_events,arm4,Part B: 750 åµg Romiplostim SC QW,1,11
Hypersensitivity,Immune_system_disorders,NCT00303472,https://clinicaltrials.gov/show/NCT00303472,Thrombocytopenia|MDS|Myelodysplastic_Syndromes|Refractory_Cytopenias|,Romiplostim,3,32,other_events,arm3,Part A: 1500 åµg Romiplostim,1,16
Hypersensitivity,Immune_system_disorders,NCT00303472,https://clinicaltrials.gov/show/NCT00303472,Thrombocytopenia|MDS|Myelodysplastic_Syndromes|Refractory_Cytopenias|,Romiplostim,3,32,serious_events,arm6,Part B: 750 åµg Romiplostim IV Q2W,1,5
Hypersensitivity,Immune_system_disorders,NCT00306592,https://clinicaltrials.gov/show/NCT00306592,Multiple_Sclerosis_Relapsing-Remitting,BG00002_(natalizumab),2,1094,serious_events,arm0,300 mg Natalizumab IV Monthly,2,1094
Hypersensitivity,Immune_system_disorders,NCT00308087,https://clinicaltrials.gov/show/NCT00308087,Lymphoma_Follicular,Sargramostim_(Leukine)|Rituximab|,4,75,other_events,arm0,Rituximab,1,37
Hypersensitivity,Immune_system_disorders,NCT00308087,https://clinicaltrials.gov/show/NCT00308087,Lymphoma_Follicular,Sargramostim_(Leukine)|Rituximab|,4,75,other_events,arm1,Rituximab + Sargramostim,3,38
Hypersensitivity,Immune_system_disorders,NCT00310466,https://clinicaltrials.gov/show/NCT00310466,Allergy,Sublingual_immunotherapy|Placebo|,4,226,other_events,arm0,SLITone Birch,1,113
Hypersensitivity,Immune_system_disorders,NCT00310466,https://clinicaltrials.gov/show/NCT00310466,Allergy,Sublingual_immunotherapy|Placebo|,4,226,other_events,arm1,Placebo,3,113
Hypersensitivity,Immune_system_disorders,NCT00312845,https://clinicaltrials.gov/show/NCT00312845,Non-Hodgkin's_Lymphoma,Bortezomib_+_Rituximab|Rituximab|,5,673,serious_events,arm1,Rituximab,1,339
Hypersensitivity,Immune_system_disorders,NCT00312845,https://clinicaltrials.gov/show/NCT00312845,Non-Hodgkin's_Lymphoma,Bortezomib_+_Rituximab|Rituximab|,5,673,serious_events,arm0,Bortezomib + Rituximab,4,334
Hypersensitivity,Immune_system_disorders,NCT00313144,https://clinicaltrials.gov/show/NCT00313144,Alpha_1-Antitrypsin_(AAT)_Deficiency,ARALAST_Alpha1-Proteinase_Inhibitor,13,127,other_events,arm0,Overall Study,13,127
Hypersensitivity,Immune_system_disorders,NCT00313781,https://clinicaltrials.gov/show/NCT00313781,Prostatic_Neoplasms,CP-751871|docetaxel|prednisone|docetaxel|prednisone|,4,296,serious_events,arm1,Docetaxel+Prednisone,1,102
Hypersensitivity,Immune_system_disorders,NCT00313781,https://clinicaltrials.gov/show/NCT00313781,Prostatic_Neoplasms,CP-751871|docetaxel|prednisone|docetaxel|prednisone|,4,296,other_events,arm0,CP-751871+Docetaxel+Prednisone,2,97
Hypersensitivity,Immune_system_disorders,NCT00313781,https://clinicaltrials.gov/show/NCT00313781,Prostatic_Neoplasms,CP-751871|docetaxel|prednisone|docetaxel|prednisone|,4,296,serious_events,arm0,CP-751871+Docetaxel+Prednisone,1,97
Hypersensitivity,Immune_system_disorders,NCT00314106,https://clinicaltrials.gov/show/NCT00314106,Metastatic_Melanoma,Melanoma_Reactive_TIL|Cyclophosphamide|IL-2|Fludarabine|1200_total_body_irradiation_(TBI)|,1,18,serious_events,arm0,TBI 1200 cGy + TIL +HD IL-2 Prior IL-2,1,18
Hypersensitivity,Immune_system_disorders,NCT00315731,https://clinicaltrials.gov/show/NCT00315731,Lymphoma_Follicular,Follicular_Lymphoma,1,15,other_events,arm0,Tositumomab and Fission-derived Iodine I-131 Tositumomab,1,15
Hypersensitivity,Immune_system_disorders,NCT00316914,https://clinicaltrials.gov/show/NCT00316914,Colorectal_Cancer|Neurotoxicity|,calcium_gluconate|magnesium_sulfate|placebo|,4,50,other_events,arm0,Ca/Mg,4,50
Hypersensitivity,Immune_system_disorders,NCT00318370,https://clinicaltrials.gov/show/NCT00318370,Ovarian_Cancer|Fallopian_Tube_Cancer|Peritoneal_Neoplasms|,Farletuzumab|Chemo_Plus_Far|,3,54,other_events,arm0,Far Only and Chemo Plus Far and Maintenance Far Only,3,54
Hypersensitivity,Injury_poisoning_and_procedural_complications,NCT00320411,https://clinicaltrials.gov/show/NCT00320411,Neoplasms_Breast,lapatinib,1,58,other_events,arm0,Lapatinib Monotherapy,1,58
Hypersensitivity,Immune_system_disorders,NCT00321711,https://clinicaltrials.gov/show/NCT00321711,MDS|Myelodysplastic_Syndromes|Thrombocytopenia|,Placebo|AMG_531_(Romiplostim)|Azacitidine|Decitabine|,2,28,other_events,arm2,Part A Romiplostim 750 åµg,1,14
Hypersensitivity,Immune_system_disorders,NCT00321711,https://clinicaltrials.gov/show/NCT00321711,MDS|Myelodysplastic_Syndromes|Thrombocytopenia|,Placebo|AMG_531_(Romiplostim)|Azacitidine|Decitabine|,2,28,serious_events,arm2,Part A Romiplostim 750 åµg,1,14
HYPERSENSITIVITY,Immune_system_disorders,NCT00322374,https://clinicaltrials.gov/show/NCT00322374,Metastatic_Breast_Cancer,Ixabepilone|Epirubicin|,4,36,serious_events,arm0,Ixabepilone 25 mg^m2 + Epirubicin 75 mg^m2,1,6
HYPERSENSITIVITY,Immune_system_disorders,NCT00322374,https://clinicaltrials.gov/show/NCT00322374,Metastatic_Breast_Cancer,Ixabepilone|Epirubicin|,4,36,other_events,arm1,Ixabepilone 30 mg^m2 + Epirubicin 75 mg^m2,3,30
Hypersensitivity,Immune_system_disorders,NCT00323609,https://clinicaltrials.gov/show/NCT00323609,Vertebral_Body_Compression_Fractures,Vertebroplasty|Kyphoplasty|,2,381,serious_events,arm1,Vertebroplasty,1,190
Hypersensitivity,Immune_system_disorders,NCT00323609,https://clinicaltrials.gov/show/NCT00323609,Vertebral_Body_Compression_Fractures,Vertebroplasty|Kyphoplasty|,2,381,serious_events,arm0,Kyphoplasty,1,191
Hypersensitivity,Immune_system_disorders,NCT00324155,https://clinicaltrials.gov/show/NCT00324155,Melanoma,Ipilimumab|Placebo|Dacarbazine|,21,745,other_events,arm1,Placebo + Dacarbazine,6,251
Hypersensitivity,Immune_system_disorders,NCT00324155,https://clinicaltrials.gov/show/NCT00324155,Melanoma,Ipilimumab|Placebo|Dacarbazine|,21,745,other_events,arm0,10 mg/kg Ipilimumab + Dacarbazine,13,247
Hypersensitivity,Immune_system_disorders,NCT00324155,https://clinicaltrials.gov/show/NCT00324155,Melanoma,Ipilimumab|Placebo|Dacarbazine|,21,745,serious_events,arm0,10 mg/kg Ipilimumab + Dacarbazine,2,247
hypersensitivity,General_disorders,NCT00325442,https://clinicaltrials.gov/show/NCT00325442,Pulmonary_Hypertension,Oral_treprostinil_(UT-15C)_sustained_release_tablets|Placebo|,1,176,serious_events,arm0,Placebo Arm,1,176
Hypersensitivity,Immune_system_disorders,NCT00326872,https://clinicaltrials.gov/show/NCT00326872,Neurofibromatosis_Type_1|Plexiform_Neurofibroma|Spinal_Cord_Neurofibroma|,Cediranib_Maleate,1,26,other_events,arm0,Treatment (Cediranib Maleate),1,26
Hypersensitivity,Immune_system_disorders,NCT00327470,https://clinicaltrials.gov/show/NCT00327470,Age_Related_Macular_Degeneration_(AMD)|Macular_Degeneration|Choroidal_Neovascularization_(CNV)|,Pegaptanib_Sodium_0.3_mg,1,179,other_events,arm1,Established AMD,1,179
Hypersensitivity,Immune_system_disorders,NCT00328198,https://clinicaltrials.gov/show/NCT00328198,B-Cell_Chronic_Lymphocytic_Leukemia_(B-CLL),Alemtuzumab|Alemtuzumab|,2,172,serious_events,arm0,Alemtuzumab 30mg,1,86
Hypersensitivity,Immune_system_disorders,NCT00328198,https://clinicaltrials.gov/show/NCT00328198,B-Cell_Chronic_Lymphocytic_Leukemia_(B-CLL),Alemtuzumab|Alemtuzumab|,2,172,other_events,arm0,Alemtuzumab 30mg,1,86
hypersensitivity,Immune_system_disorders,NCT00329108,https://clinicaltrials.gov/show/NCT00329108,Acute_Mania|Bipolar_Disorder_Manic|,ziprasidone_hydrochloride|olanzapine|,1,14,other_events,arm1,Olanzapine,1,14
Hypersensitivity,Immune_system_disorders,NCT00329238,https://clinicaltrials.gov/show/NCT00329238,Thromboembolism,Dabigatran|Warfarin|,1,1426,serious_events,arm1,Warfarin,1,1426
Hypersensitivity,General_disorders,NCT00330161,https://clinicaltrials.gov/show/NCT00330161,Recurrent_Prostate_Cancer|Stage_IV_Prostate_Cancer|,vorinostat|laboratory_biomarker_analysis|,2,29,other_events,arm0,Treatment (Vorinostat),2,29
Hypersensitivity,Immune_system_disorders,NCT00330759,https://clinicaltrials.gov/show/NCT00330759,Bone_Metastases,Denosumab|Zoledronic_Acid|,1,878,serious_events,arm1,Denosumab 120 mg Q4W,1,878
Hypersensitivity,Immune_system_disorders,NCT00337103,https://clinicaltrials.gov/show/NCT00337103,Metastatic_Breast_Cancer,Eribulin_Mesylate|Capecitabine|,2,1090,serious_events,arm0,Eribulin Mesylate 1.4 mg/m^2,1,544
Hypersensitivity,Immune_system_disorders,NCT00337103,https://clinicaltrials.gov/show/NCT00337103,Metastatic_Breast_Cancer,Eribulin_Mesylate|Capecitabine|,2,1090,serious_events,arm1,Capecitabine 2.5 g/m^2/Day,1,546
Hypersensitivity,Immune_system_disorders,NCT00337194,https://clinicaltrials.gov/show/NCT00337194,Adult_Lymphocyte_Depletion_Hodgkin_Lymphoma|Adult_Lymphocyte_Predominant_Hodgkin_Lymphoma|Adult_Mixed_Cellularity_Hodgkin_Lymphoma|Adult_Nodular_Sclerosis_Hodgkin_Lymphoma|Recurrent_Adult_Hodgkin_Lymphoma|,monoclonal_antibody_SGN-30|placebo|vinorelbine_tartrate|pegylated_liposomal_doxorubicin_hydrochloride|gemcitabine_hydrochloride|laboratory_biomarker_analysis|pharmacological_study|,2,23,other_events,arm0,Arm I (SGN-30 Chemotherapy),2,23
Hypersensitivity,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,11,232,serious_events,arm1,Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3),3,58
Hypersensitivity,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,11,232,serious_events,arm0,Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6),1,58
Hypersensitivity,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,11,232,other_events,arm0,Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6),2,58
Hypersensitivity,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,11,232,other_events,arm1,Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3),5,58
Hypersensitivity,Immune_system_disorders,NCT00345540,https://clinicaltrials.gov/show/NCT00345540,Ovarian_Cancer,NOV-002|Carboplatin|,2,15,other_events,arm0,NOV-002 Plus Carboplatin,2,15
Hypersensitivity,Immune_system_disorders,NCT00346398,https://clinicaltrials.gov/show/NCT00346398,Asthma|Allergic_Sensitization|,Oral_mucosal_immunoprophylaxis_(OMIP)|Placebo|,13,51,other_events,arm0,OMIP With Timothy Grass Cat and House Dust Mite Allergens,7,25
Hypersensitivity,Immune_system_disorders,NCT00346398,https://clinicaltrials.gov/show/NCT00346398,Asthma|Allergic_Sensitization|,Oral_mucosal_immunoprophylaxis_(OMIP)|Placebo|,13,51,other_events,arm1,Placebo,6,26
Hypersensitivity,Immune_system_disorders,NCT00347919,https://clinicaltrials.gov/show/NCT00347919,Neoplasms_Breast,pazopanib_(GW786034)_400_mg|lapatinib_(GW572016)_1500_mg|lapatinib_(GW572016)_1000_mg|pazopanib_(GW786034)_800_mg|,1,76,serious_events,arm1,Cohort 1: Lapatinib 1000 mg/Pazopanib 400 mg,1,76
Hypersensitivity,Immune_system_disorders,NCT00349336,https://clinicaltrials.gov/show/NCT00349336,Colorectal_Cancer,bevacizumab_[Avastin]|XELOX|bevacizumab_[Avastin]|FOLFOX-4|,6,64,other_events,arm1,FOLFOX-4+Bevacizumab,4,32
Hypersensitivity,Immune_system_disorders,NCT00349336,https://clinicaltrials.gov/show/NCT00349336,Colorectal_Cancer,bevacizumab_[Avastin]|XELOX|bevacizumab_[Avastin]|FOLFOX-4|,6,64,serious_events,arm1,FOLFOX-4+Bevacizumab,2,32
Hypersensitivity,Immune_system_disorders,NCT00349349,https://clinicaltrials.gov/show/NCT00349349,Leukaemia_Lymphocytic_Chronic,ofatumumab,1,95,serious_events,arm0,2000 mg Ofatumumab + DR,1,95
Hypersensitivity,Immune_system_disorders,NCT00356135,https://clinicaltrials.gov/show/NCT00356135,Coronary_Arteriosclerosis|Acute_Coronary_Syndrome|,prasugrel_10_mg|clopidogrel|prasugrel_placebo|prasugrel_60_mg|clopidogrel_placebo|,1,47,other_events,arm0,Prasgurel 10/10 mg,1,47
HYPERSENSITIVITY,Immune_system_disorders,NCT00356122,https://clinicaltrials.gov/show/NCT00356122,Non-Small_Cell_Lung_Cancer,Docetaxel|Oxaliplatin|Bevacizumab|,5,52,other_events,arm0,Docetaxel/Oxaliplatin/Bevacizumab,5,52
Hypersensitivity,Immune_system_disorders,NCT00356811,https://clinicaltrials.gov/show/NCT00356811,Neoplasms_Breast,Lapatinib_oral_tablets|Paclitaxel_infusion|,4,57,other_events,arm0,Lapatinib Plus Paclitaxel,4,57
Hypersensitivity,Immune_system_disorders,NCT00357162,https://clinicaltrials.gov/show/NCT00357162,de_Novo_Myelodysplastic_Syndromes|Previously_Treated_Myelodysplastic_Syndromes|Secondary_Myelodysplastic_Syndromes|,belinostat,2,21,other_events,arm0,Treatment (Enzyme Inhibitor Therapy),2,21
Hypersensitivity,Immune_system_disorders,NCT00357968,https://clinicaltrials.gov/show/NCT00357968,Coronary_Artery_Disease,Prasugrel|Clopidogrel|Placebo_for_Prasugrel|Placebo_for_Clopidogrel|,1,99,other_events,arm1,Clopidogrel Before Cross-over,1,99
Hypersensitivity,Immune_system_disorders,NCT00359424,https://clinicaltrials.gov/show/NCT00359424,Stroke,IV_rt-PA_alone|endovascular_therapy|,1,434,other_events,arm0,Endovascular,1,434
Hypersensitivity,Immune_system_disorders,NCT00362882,https://clinicaltrials.gov/show/NCT00362882,Non-small_Cell_Lung_Cancer|Recurrent_Non-small_Cell_Lung_Cancer|Stage_IV_Non-small_Cell_Lung_Cancer|,docetaxel|bortezomib|laboratory_biomarker_analysis|immunoenzyme_technique|immunohistochemistry_staining_method|pharmacological_study|,1,41,other_events,arm1,Arm 2,1,41
Hypersensitivity,Immune_system_disorders,NCT00363415,https://clinicaltrials.gov/show/NCT00363415,Small_Cell_Lung_Cancer,pemetrexed|etoposide|carboplatin|,1,447,serious_events,arm1,Etoposide + Carboplatin,1,447
Hypersensitivity,Immune_system_disorders,NCT00364013,https://clinicaltrials.gov/show/NCT00364013,Metastatic_Colorectal_Cancer,Panitumumab|FOLFOX_regimen|,8,1169,serious_events,arm0,Panitumumab Plus FOLFOX,4,585
Hypersensitivity,Immune_system_disorders,NCT00364013,https://clinicaltrials.gov/show/NCT00364013,Metastatic_Colorectal_Cancer,Panitumumab|FOLFOX_regimen|,8,1169,serious_events,arm1,FOLFOX Alone,4,584
Hypersensitivity,Immune_system_disorders,NCT00364858,https://clinicaltrials.gov/show/NCT00364858,Gaucher_Disease_Type_1|Cerebroside_Lipidosis_Syndrome|Glucocerebrosidase_Deficiency_Disease|Glucosylceramide_Beta-Glucosidase_Deficiency_Disease|Gaucher_Disease_Non-Neuronopathic_Form|,Cerezyme,2,157,other_events,arm2,Total,1,95
Hypersensitivity,Immune_system_disorders,NCT00364858,https://clinicaltrials.gov/show/NCT00364858,Gaucher_Disease_Type_1|Cerebroside_Lipidosis_Syndrome|Glucocerebrosidase_Deficiency_Disease|Glucosylceramide_Beta-Glucosidase_Deficiency_Disease|Gaucher_Disease_Non-Neuronopathic_Form|,Cerezyme,2,157,other_events,arm1,Q4 Cerezyme,1,62
Hypersensitivity,Immune_system_disorders,NCT00365053,https://clinicaltrials.gov/show/NCT00365053,Advanced_Malignant_Mesothelioma|Epithelial_Mesothelioma|Recurrent_Malignant_Mesothelioma|Sarcomatous_Mesothelioma|,belinostat|laboratory_biomarker_analysis|,2,13,other_events,arm0,Treatment (Belinostat),2,13
Hypersensitivity,Immune_system_disorders,NCT00365456,https://clinicaltrials.gov/show/NCT00365456,Osteoporosis,Parathyroid_Hormone_(PTH)|Risedronate|,1,405,serious_events,arm0,PTH (1-84),1,405
Hypersensitivity,Immune_system_disorders,NCT00366548,https://clinicaltrials.gov/show/NCT00366548,Vaccines_Pneumococcal,13_valent_pneumococcal_conjugate_vaccine_with_Polysorbate_80|13_valent_pneumococcal_conjugate_vaccine_without_Polysorbate_80|,1,249,serious_events,arm0,13vPnC + P80 Infant Series,1,249
Hypersensitivity,Immune_system_disorders,NCT00369655,https://clinicaltrials.gov/show/NCT00369655,Metastatic_Breast_Cancer|Recurrent_Breast_Cancer|Stage_IV_Breast_Cancer|,ziv-aflibercept,1,21,other_events,arm0,Treatment (Ziv-afibercept),1,21
Hypersensitivity,Immune_system_disorders,NCT00372424,https://clinicaltrials.gov/show/NCT00372424,Breast_Cancer,Herceptin|Sunitinib|Taxotere|,2,25,other_events,arm0,Sunitinib + Docetaxel + Trastuzumab,2,25
Hypersensitivity,Immune_system_disorders,NCT00372996,https://clinicaltrials.gov/show/NCT00372996,Breast_Neoplasms,CP-751871|exemestane|exemestane|Fulvestrant|,1,115,serious_events,arm0,CP-751871 + Exemestane,1,115
Hypersensitivity,Immune_system_disorders,NCT00373113,https://clinicaltrials.gov/show/NCT00373113,Breast_Neoplasms,Capecitabine|Sunitinib_malate|,3,238,other_events,arm0,Sunitinib,3,238
Hypersensitivity,Immune_system_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,14,477,other_events,arm1,Bevacizumab + Paclitaxel,7,242
Hypersensitivity,Immune_system_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,14,477,other_events,arm0,Sunitinib + Paclitaxel,7,235
Hypersensitivity,Immune_system_disorders,NCT00373529,https://clinicaltrials.gov/show/NCT00373529,Acute_Myelogenous_Leukemia|Acute_Myeloid_Leukemia|,clofarabine,1,112,other_events,arm0,Clofarabine,1,112
Hypersensitivity,Immune_system_disorders,NCT00373958,https://clinicaltrials.gov/show/NCT00373958,Vaccines_Pneumococcal,13_valent_pneumococcal_conjugate_vaccine|7vPnc_pneumococcal_conjugate_vaccine|,3,921,other_events,arm2,13vPnC Post Infant Series,1,332
Hypersensitivity,Immune_system_disorders,NCT00373958,https://clinicaltrials.gov/show/NCT00373958,Vaccines_Pneumococcal,13_valent_pneumococcal_conjugate_vaccine|7vPnc_pneumococcal_conjugate_vaccine|,3,921,other_events,arm5,7vPnC Toddler Series,1,258
Hypersensitivity,Immune_system_disorders,NCT00373958,https://clinicaltrials.gov/show/NCT00373958,Vaccines_Pneumococcal,13_valent_pneumococcal_conjugate_vaccine|7vPnc_pneumococcal_conjugate_vaccine|,3,921,other_events,arm1,7vPnC Infant Series,1,331
Hypersensitivity,Immune_system_disorders,NCT00374322,https://clinicaltrials.gov/show/NCT00374322,Neoplasms_Breast,lapatinib|placebo|,1,1573,serious_events,arm0,Lapatinib 1500 mg,1,1573
HYPERSENSITIVITY,Immune_system_disorders,NCT00374907,https://clinicaltrials.gov/show/NCT00374907,Type_2_Diabetes,Saxagliptin|Placebo|Metformin_(blinded)|Metformin_(open-label)|,1,16,other_events,arm0,PLACEBO/METFORMIN,1,16
Hypersensitivity,Immune_system_disorders,NCT00375492,https://clinicaltrials.gov/show/NCT00375492,Type_2_Diabetes_Mellitus,exenatide|placebo|,1,98,serious_events,arm1,Group B (Placebo),1,98
Hypersensitivity,Immune_system_disorders,NCT00377572,https://clinicaltrials.gov/show/NCT00377572,Asthma,omalizumab|omalizumab_placebo|,1,211,serious_events,arm1,Placebo + Conventional Therapy,1,211
HYPERSENSITIVITY,Immune_system_disorders,NCT00378014,https://clinicaltrials.gov/show/NCT00378014,Liver_Transplantation,everolimus|basiliximab|CNI|,1,102,serious_events,arm1,Calcineurin Inhibitor (CNI),1,102
Hypersensitivity,Immune_system_disorders,NCT00379769,https://clinicaltrials.gov/show/NCT00379769,Diabetes_Mellitus_Type_2,Rosiglitazone|Sulfonylurea|Metformin|,4,2220,serious_events,arm0,RSG in Addition to Background MET,1,1117
Hypersensitivity,Immune_system_disorders,NCT00379769,https://clinicaltrials.gov/show/NCT00379769,Diabetes_Mellitus_Type_2,Rosiglitazone|Sulfonylurea|Metformin|,4,2220,serious_events,arm2,RSG in Addition to Background SU,3,1103
Hypersensitivity,Immune_system_disorders,NCT00379899,https://clinicaltrials.gov/show/NCT00379899,Chronic_Kidney_Disease|End_Stage_Renal_Disease|Coronary_Artery_Calcification|Vascular_Calcification|Calcification|Cardiovascular_Disease|Chronic_Renal_Failure|Hyperparathyroidism|Kidney_Disease|Nephrology|Secondary_Hyperparathyroidism|,cinacalcet,1,180,serious_events,arm0,Cinacalcet,1,180
Hypersensitivity,Immune_system_disorders,NCT00380874,https://clinicaltrials.gov/show/NCT00380874,Chemotherapy-Induced_Peripheral_Neuropathy,Pregabalin|Placebo|,2,61,other_events,arm0,Pregabalin,1,32
Hypersensitivity,Immune_system_disorders,NCT00380874,https://clinicaltrials.gov/show/NCT00380874,Chemotherapy-Induced_Peripheral_Neuropathy,Pregabalin|Placebo|,2,61,other_events,arm1,Placebo,1,29
Hypersensitivity,Immune_system_disorders,NCT00381303,https://clinicaltrials.gov/show/NCT00381303,HIV|Infectious|,darunavir|ritonavir|,2,429,serious_events,arm0,Female,1,287
Hypersensitivity,Immune_system_disorders,NCT00381303,https://clinicaltrials.gov/show/NCT00381303,HIV|Infectious|,darunavir|ritonavir|,2,429,serious_events,arm1,Male,1,142
Hypersensitivity,Immune_system_disorders,NCT00382174,https://clinicaltrials.gov/show/NCT00382174,Pressure_Ulcers,Placebo|Thymosin_Beta_4|,2,124,other_events,arm1,Të_4 at 3 Doses,1,53
Hypersensitivity,Immune_system_disorders,NCT00382174,https://clinicaltrials.gov/show/NCT00382174,Pressure_Ulcers,Placebo|Thymosin_Beta_4|,2,124,other_events,arm2,Placebo vs. Thymosin Beta 4 at 3 Doses,1,71
HYPERSENSITIVITY,Immune_system_disorders,NCT00383149,https://clinicaltrials.gov/show/NCT00383149,Metastatic_Pancreatic_Cancer,Ixabepilone|Cetuximab|,8,108,serious_events,arm0,Ixabepilone + Cetuximab,3,54
HYPERSENSITIVITY,Immune_system_disorders,NCT00383149,https://clinicaltrials.gov/show/NCT00383149,Metastatic_Pancreatic_Cancer,Ixabepilone|Cetuximab|,8,108,other_events,arm0,Ixabepilone + Cetuximab,5,54
Hypersensitivity,Immune_system_disorders,NCT00384930,https://clinicaltrials.gov/show/NCT00384930,Benign_Prostatic_Hyperplasia,tadalafil|tadalafil|tadalafil|tadalafil|placebo|,2,421,other_events,arm4,20 mg Tadalafil,1,209
Hypersensitivity,Immune_system_disorders,NCT00384930,https://clinicaltrials.gov/show/NCT00384930,Benign_Prostatic_Hyperplasia,tadalafil|tadalafil|tadalafil|tadalafil|placebo|,2,421,other_events,arm2,5 mg Tadalafil,1,212
Hypersensitivity,Immune_system_disorders,NCT00385944,https://clinicaltrials.gov/show/NCT00385944,Acute_Coronary_Syndrome,Prasugrel|Clopidogrel|,1,56,other_events,arm0,Clopidogrel 900 mg LD,1,56
Hypersensitivity,Immune_system_disorders,NCT00389441,https://clinicaltrials.gov/show/NCT00389441,Thyroid_Neoplasms,AG-013736,1,52,serious_events,arm0,Axitinib,1,52
Hypersensitivity,Immune_system_disorders,NCT00390858,https://clinicaltrials.gov/show/NCT00390858,Transfusional_Iron_Overload|ë_-thalassemia_Major|Pediatric_Rare_Anemia|,Deferasirox,1,20,other_events,arm0,Children (<12 Years),1,20
Hypersensitivity,Immune_system_disorders,NCT00391092,https://clinicaltrials.gov/show/NCT00391092,Breast_Cancer,bevacizumab_[Avastin]|Docetaxel|Herceptin|,25,627,serious_events,arm0,Trastuzumab + Docetaxel,1,206
Hypersensitivity,Immune_system_disorders,NCT00391092,https://clinicaltrials.gov/show/NCT00391092,Breast_Cancer,bevacizumab_[Avastin]|Docetaxel|Herceptin|,25,627,other_events,arm1,Trastuzumab + Bevacizumab + Docetaxel,10,215
Hypersensitivity,Immune_system_disorders,NCT00391092,https://clinicaltrials.gov/show/NCT00391092,Breast_Cancer,bevacizumab_[Avastin]|Docetaxel|Herceptin|,25,627,other_events,arm0,Trastuzumab + Docetaxel,14,206
Hypersensitivity,Immune_system_disorders,NCT00391625,https://clinicaltrials.gov/show/NCT00391625,Gaucher_Disease_Type_1,GA-GCB,1,10,other_events,arm0,GA-GCB,1,10
Hypersensitivity,Immune_system_disorders,NCT00391768,https://clinicaltrials.gov/show/NCT00391768,Influenza,oseltamivir_(Tamifluå¨),1,7,serious_events,arm2,Cohort IIA,1,7
Hypersensitivity,Immune_system_disorders,NCT00391872,https://clinicaltrials.gov/show/NCT00391872,Acute_Coronary_Syndrome,Ticagrelor|Clopidogrel|,3,18624,serious_events,arm0,TICAGRELOR,1,9333
Hypersensitivity,Immune_system_disorders,NCT00391872,https://clinicaltrials.gov/show/NCT00391872,Acute_Coronary_Syndrome,Ticagrelor|Clopidogrel|,3,18624,serious_events,arm1,CLOPIDOGREL,2,9291
Hypersensitivity,Immune_system_disorders,NCT00392925,https://clinicaltrials.gov/show/NCT00392925,Overweight|Obesity|,pramlintide_acetate_360_mcg|metreleptin|placebo-pramlintide_600_uL|placebo-metreleptin_1_mL|Pramlintide_acetate_180_mcg|,4,139,serious_events,arm2,Pramlintide + Metreleptin,1,56
Hypersensitivity,Immune_system_disorders,NCT00392925,https://clinicaltrials.gov/show/NCT00392925,Overweight|Obesity|,pramlintide_acetate_360_mcg|metreleptin|placebo-pramlintide_600_uL|placebo-metreleptin_1_mL|Pramlintide_acetate_180_mcg|,4,139,other_events,arm2,Pramlintide + Metreleptin,1,56
Hypersensitivity,Immune_system_disorders,NCT00392925,https://clinicaltrials.gov/show/NCT00392925,Overweight|Obesity|,pramlintide_acetate_360_mcg|metreleptin|placebo-pramlintide_600_uL|placebo-metreleptin_1_mL|Pramlintide_acetate_180_mcg|,4,139,other_events,arm0,Placebo + Metreleptin,2,27
Hypersensitivity,Immune_system_disorders,NCT00393523,https://clinicaltrials.gov/show/NCT00393523,Hepatitis_B,Comparator:_Modified_Process_Hepatitis_B_Vaccine|Comparator:_Comparator:_ENGERIX-B|,1,344,other_events,arm2,Modified Process Hepatitis B Vaccine Booster (Group 3),1,344
Hypersensitivity,Immune_system_disorders,NCT00393939,https://clinicaltrials.gov/show/NCT00393939,Breast_Neoplasms,Sunitinib_malate|Taxotere|,1,295,serious_events,arm0,Docetaxel + Sunitinib,1,295
Hypersensitivity,Immune_system_disorders,NCT00394836,https://clinicaltrials.gov/show/NCT00394836,Lymphoma_Follicular,Ofatumumab|Ofatumumab|,9,116,other_events,arm1,Ofatumumab 1000 mg,6,86
Hypersensitivity,Immune_system_disorders,NCT00394836,https://clinicaltrials.gov/show/NCT00394836,Lymphoma_Follicular,Ofatumumab|Ofatumumab|,9,116,other_events,arm0,Ofatumumab 500 mg,3,30
Hypersensitivity,Immune_system_disorders,NCT00396409,https://clinicaltrials.gov/show/NCT00396409,Allergic_Asthma,Depigoid|Omalizumab|Placebo|,9,242,other_events,arm0,Depigoid + Omalizumab 2007,3,65
Hypersensitivity,Immune_system_disorders,NCT00396409,https://clinicaltrials.gov/show/NCT00396409,Allergic_Asthma,Depigoid|Omalizumab|Placebo|,9,242,other_events,arm1,Depigoid + Omalizumab 2008,3,59
Hypersensitivity,Immune_system_disorders,NCT00396409,https://clinicaltrials.gov/show/NCT00396409,Allergic_Asthma,Depigoid|Omalizumab|Placebo|,9,242,other_events,arm2,Depigoid + Placebo 2007,2,63
Hypersensitivity,Immune_system_disorders,NCT00396409,https://clinicaltrials.gov/show/NCT00396409,Allergic_Asthma,Depigoid|Omalizumab|Placebo|,9,242,other_events,arm3,Depigoid + Placebo 2008,1,55
Hypersensitivity,Immune_system_disorders,NCT00396981,https://clinicaltrials.gov/show/NCT00396981,Intracranial_Aneurysms,Matrix_2å¨_coils_for_endovascular_aneurysm_occlusion|GDCå¨_coils_for_endovascular_aneurysm_occlusion|,1,315,other_events,arm1,GDCå¨ Coils for Endovascular Aneurysm Occlusion,1,315
Hypersensitivity,Immune_system_disorders,NCT00400829,https://clinicaltrials.gov/show/NCT00400829,Recurrent_Non-small_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|Stage_IV_Non-small_Cell_Lung_Cancer|,eribulin_mesylate,1,66,serious_events,arm0,Arm I,1,66
Hypersensitivity,Immune_system_disorders,NCT00403767,https://clinicaltrials.gov/show/NCT00403767,Atrial_Fibrillation|Stroke|Embolism|,Rivaroxaban|Warfarin|Matching_placebo_for_Rivaroxaban_arm_(Warfarin_placebo)|Matching_placebo_for_Warfarin_arm_(Rivaroxaban_placebo)|,3,7111,serious_events,arm0,Rivaroxaban,3,7111
Hypersensitivity,Immune_system_disorders,NCT00405756,https://clinicaltrials.gov/show/NCT00405756,Newly_Diagnosed_Multiple_Myeloma,Lenalidomide:_Double-blind_Induction|Melphalan|Prednisone|Aspirin|Placebo|Lenalidomide:_Double-blind_Maintenance|Lenalidomide:_Open-label|,1,150,serious_events,arm0,MPR+R,1,150
Hypersensitivity,Immune_system_disorders,NCT00407563,https://clinicaltrials.gov/show/NCT00407563,Epithelial_Ovarian_Cancer|Primary_Peritoneal_Carcinoma|,Bevacizumab|Abraxane|,2,48,other_events,arm0,Bevacizumab and Abraxane,2,48
Hypersensitivity,Immune_system_disorders,NCT00407537,https://clinicaltrials.gov/show/NCT00407537,Hypertension|Hypercholesterolemia|,Amlodipine_besylate/atorvastatin_calcium_single_pill_combination,1,779,other_events,arm0,Caduet,1,779
Hypersensitivity,Immune_system_disorders,NCT00408421,https://clinicaltrials.gov/show/NCT00408421,Osteoarthritis_Knee_Pain,Duloxetine|placebo|,1,120,other_events,arm0,Placebo,1,120
Hypersensitivity,Immune_system_disorders,NCT00410124,https://clinicaltrials.gov/show/NCT00410124,Metastatic_Renal_Cell_Carcinoma,RAD001|Placebo|,2,385,serious_events,arm1,Randomized to Placebo + BSC (Open Label),1,111
Hypersensitivity,Immune_system_disorders,NCT00410124,https://clinicaltrials.gov/show/NCT00410124,Metastatic_Renal_Cell_Carcinoma,RAD001|Placebo|,2,385,serious_events,arm0,Randomized to RAD001+ BSC ( Blinded + Open Label),1,274
HYPERSENSITIVITY,Immune_system_disorders,NCT00410410,https://clinicaltrials.gov/show/NCT00410410,Ulcerative_Colitis,abatacept_(ABA)|placebo|abatacept|,1,141,serious_events,arm0,ABA 30/~10 mg/kgIP1C,1,141
Hypersensitivity,Immune_system_disorders,NCT00412971,https://clinicaltrials.gov/show/NCT00412971,Bladder_Cancer,Hexvix|Standard_white_light_cystoscopy|,2,230,other_events,arm0,Hexvix Cystoscopy Group,1,112
Hypersensitivity,Immune_system_disorders,NCT00412971,https://clinicaltrials.gov/show/NCT00412971,Bladder_Cancer,Hexvix|Standard_white_light_cystoscopy|,2,230,other_events,arm1,White Light,1,118
Hypersensitivity,Immune_system_disorders,NCT00412893,https://clinicaltrials.gov/show/NCT00412893,Invasive_Fungal_Infection|Aspergillosis|,Isavuconazole|Voriconazole|,1,257,serious_events,arm0,Isavuconazole,1,257
HYPERSENSITIVITY,Immune_system_disorders,NCT00414440,https://clinicaltrials.gov/show/NCT00414440,Autosomal_Dominant_Polycystic_Kidney_Disease,Placebo|Everolimus|,1,214,serious_events,arm0,Everolimus,1,214
Hypersensitivity,Immune_system_disorders,NCT00415194,https://clinicaltrials.gov/show/NCT00415194,Head_and_Neck_Neoplasms,pemetrexed|cisplatin|placebo|,2,385,serious_events,arm1,Placebo/Cisplatin,2,385
Hypersensitivity,Immune_system_disorders,NCT00415532,https://clinicaltrials.gov/show/NCT00415532,Idiopathic_Thrombocytopenic_Purpura|Thrombocytopenia|Thrombocytopenia_in_Subjects_With_Immune_(Idiopathic)_Thrombocytopenic_Purpura_(ITP)|Thrombocytopenic_Purpura|,Medical_Standard_of_Care_for_ITP|Romiplostim|,8,385,serious_events,arm1,AMG 531,1,156
Hypersensitivity,Immune_system_disorders,NCT00415532,https://clinicaltrials.gov/show/NCT00415532,Idiopathic_Thrombocytopenic_Purpura|Thrombocytopenia|Thrombocytopenia_in_Subjects_With_Immune_(Idiopathic)_Thrombocytopenic_Purpura_(ITP)|Thrombocytopenic_Purpura|,Medical_Standard_of_Care_for_ITP|Romiplostim|,8,385,other_events,arm1,AMG 531,3,156
Hypersensitivity,Immune_system_disorders,NCT00415532,https://clinicaltrials.gov/show/NCT00415532,Idiopathic_Thrombocytopenic_Purpura|Thrombocytopenia|Thrombocytopenia_in_Subjects_With_Immune_(Idiopathic)_Thrombocytopenic_Purpura_(ITP)|Thrombocytopenic_Purpura|,Medical_Standard_of_Care_for_ITP|Romiplostim|,8,385,other_events,arm0,Standard of Care,4,73
Hypersensitivity,Immune_system_disorders,NCT00418886,https://clinicaltrials.gov/show/NCT00418886,Non_Small_Cell_Lung_Cancer|Lung_Cancer|,Vandetanib|Pemetrexed|,1,273,serious_events,arm1,Placebo Plus Pemetrexed,1,273
Hypersensitivity,Immune_system_disorders,NCT00420212,https://clinicaltrials.gov/show/NCT00420212,Relapsing-Remitting_Multiple_Sclerosis,BG00012|Placebo|,4,1652,serious_events,arm2,BG00012 240 mg 3 Times Daily (TID),1,416
Hypersensitivity,Immune_system_disorders,NCT00420212,https://clinicaltrials.gov/show/NCT00420212,Relapsing-Remitting_Multiple_Sclerosis,BG00012|Placebo|,4,1652,serious_events,arm1,BG00012 240 mg Twice Daily (BID),1,410
Hypersensitivity,Immune_system_disorders,NCT00420212,https://clinicaltrials.gov/show/NCT00420212,Relapsing-Remitting_Multiple_Sclerosis,BG00012|Placebo|,4,1652,serious_events,arm3,Total BG00012,2,826
Hypersensitivity,Immune_system_disorders,NCT00421889,https://clinicaltrials.gov/show/NCT00421889,Ovarian_Cancer|Epithelial_Ovarian_Cancer|Fallopian_Tube_Cancer|Bladder_Cancer|,belinostat|Paclitaxel|Carboplatin|,4,93,serious_events,arm1,Part B: Ovarian Cancer MTD (N=35),1,35
Hypersensitivity,Immune_system_disorders,NCT00421889,https://clinicaltrials.gov/show/NCT00421889,Ovarian_Cancer|Epithelial_Ovarian_Cancer|Fallopian_Tube_Cancer|Bladder_Cancer|,belinostat|Paclitaxel|Carboplatin|,4,93,other_events,arm0,Part A: Dose Escalation (N=23),1,23
Hypersensitivity,Immune_system_disorders,NCT00421889,https://clinicaltrials.gov/show/NCT00421889,Ovarian_Cancer|Epithelial_Ovarian_Cancer|Fallopian_Tube_Cancer|Bladder_Cancer|,belinostat|Paclitaxel|Carboplatin|,4,93,other_events,arm1,Part B: Ovarian Cancer MTD (N=35),2,35
Hypersensitivity,Immune_system_disorders,NCT00424190,https://clinicaltrials.gov/show/NCT00424190,Bacterial_Infections,IV_Vancomycin_plus_IV_Aztreonam|Ceftaroline|,2,698,serious_events,arm0,Ceftaroline Fosamil for Injection,1,351
Hypersensitivity,Immune_system_disorders,NCT00424190,https://clinicaltrials.gov/show/NCT00424190,Bacterial_Infections,IV_Vancomycin_plus_IV_Aztreonam|Ceftaroline|,2,698,serious_events,arm1,IV Vancomycin Plus IV Aztreonam,1,347
Hypersensitivity,Immune_system_disorders,NCT00426764,https://clinicaltrials.gov/show/NCT00426764,Peripheral_T-cell_Lymphoma,Romidepsin,1,131,serious_events,arm0,Romidepsin,1,131
Hypersensitivity,Immune_system_disorders,NCT00426660,https://clinicaltrials.gov/show/NCT00426660,Advanced_HIV_Infection,maraviroc,2,1032,other_events,arm0,Maraviroc,2,1032
Hypersensitivity,Immune_system_disorders,NCT00428584,https://clinicaltrials.gov/show/NCT00428584,Relapsing_Remitting_Multiple_Sclerosis_(RRMS),New_Formulation_of_rebif_-_human_interferon_beta-1a|Interferon_beta_-1b|,1,65,other_events,arm0,New Formulation of Rebif,1,65
Hypersensitivity,Immune_system_disorders,NCT00428844,https://clinicaltrials.gov/show/NCT00428844,Osteomyelitis,daptomycin|daptomycin|vancomycin|teicoplanin|nafcillin|oxacillin|flucloxacillin|,1,25,serious_events,arm2,Comparator,1,25
Hypersensitivity,Immune_system_disorders,NCT00430027,https://clinicaltrials.gov/show/NCT00430027,Esophageal_Adenocarcinoma,Capecitabine|Oxaliplatin|Cetuximab|,2,8,other_events,arm0,Capecitabine Oxaliplatin Cetuximab and Radiation Therapy,2,8
HYPERSENSITIVITY,Immune_system_disorders,NCT00430677,https://clinicaltrials.gov/show/NCT00430677,Systemic_Lupus_Erythematosus,Corticosteroids_(prednisone_or_prednisolone)|Abatacept|Abatacept|Mycophenolate_mofetil_(MMF)|Abatacept|,1,99,serious_events,arm0,Abatacept 30/10 mg/kg,1,99
Hypersensitivity,Immune_system_disorders,NCT00432159,https://clinicaltrials.gov/show/NCT00432159,Cervical_Degenerative_Disc_Disease,Cervical_TDR|ACDF_with_plate|,1,89,other_events,arm4,Training: 1 & 2-level Cervical TDR,1,89
Hypersensitivity,Immune_system_disorders,NCT00434252,https://clinicaltrials.gov/show/NCT00434252,Melanoma,bevacizumab|carboplatin|paclitaxel|placebo|,11,212,other_events,arm0,Carboplatin+Paclitaxel+Placebo,4,69
Hypersensitivity,Immune_system_disorders,NCT00434252,https://clinicaltrials.gov/show/NCT00434252,Melanoma,bevacizumab|carboplatin|paclitaxel|placebo|,11,212,other_events,arm1,Carboplatin+Paclitaxel+Bevacizumab,7,143
Hypersensitivity,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,30,960,serious_events,arm1,Carboplatin and Gemcitabine + Placebo,1,233
Hypersensitivity,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,30,960,other_events,arm0,Carboplatin and Gemcitabine + Bevacizumab,16,247
Hypersensitivity,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,30,960,serious_events,arm0,Carboplatin and Gemcitabine + Bevacizumab,1,247
Hypersensitivity,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,30,960,other_events,arm1,Carboplatin and Gemcitabine + Placebo,12,233
Hypersensitivity,Immune_system_disorders,NCT00435539,https://clinicaltrials.gov/show/NCT00435539,Vitreomacular_Traction,ocriplasmin|ocriplasmin|Sham_Comparator|,1,11,other_events,arm2,Ocriplasmin 175åµg Single Injection,1,11
Hypersensitivity,Immune_system_disorders,NCT00435409,https://clinicaltrials.gov/show/NCT00435409,Breast_Neoplasms,Sunitinib_+_Capecitabine|Capecitabine|,1,215,other_events,arm1,Capecitabine,1,215
Hypersensitivity,Immune_system_disorders,NCT00436566,https://clinicaltrials.gov/show/NCT00436566,Breast_Cancer|Cardiac_Toxicity|,trastuzumab|cyclophosphamide|doxorubicin_hydrochloride|lapatinib_ditosylate|paclitaxel|gene_expression_analysis|reverse_transcriptase-polymerase_chain_reaction|fluorophotometry|laboratory_biomarker_analysis|mass_spectrometry|adjuvant_therapy|quality-of-life_assessment|,1,108,other_events,arm0,AC/PTL,1,108
Hypersensitivity,Immune_system_disorders,NCT00436618,https://clinicaltrials.gov/show/NCT00436618,Leukemia|Lymphoma|Lymphoproliferative_Disorder|,Everolimus,1,114,serious_events,arm0,Relapsed Aggressive Non-Hodgkin Lymphoma,1,114
Hypersensitivity,Immune_system_disorders,NCT00436904,https://clinicaltrials.gov/show/NCT00436904,Leukemia,Alemtuzumab|Rituximab|,3,30,other_events,arm0,Alemtuzumab + Rituximab,3,30
Hypersensitivity,Immune_system_disorders,NCT00437203,https://clinicaltrials.gov/show/NCT00437203,Neoplasms,PF-00477736|gemcitabine|,1,4,serious_events,arm9,PF-00477736 225 mg 24 Hrs + Gemcitabine 1000 mg/m^2 (cohort10),1,4
Hypersensitivity,Immune_system_disorders,NCT00439335,https://clinicaltrials.gov/show/NCT00439335,Influenza,Inactivated_Influenza_A_Vaccine_A/H5N1|Inactivated_Influenza_A_Vaccine_A/H5N1|Placebo_(IM)|Placebo_(ID)|,9,227,other_events,arm1,H5 HA IM,2,114
Hypersensitivity,Immune_system_disorders,NCT00439335,https://clinicaltrials.gov/show/NCT00439335,Influenza,Inactivated_Influenza_A_Vaccine_A/H5N1|Inactivated_Influenza_A_Vaccine_A/H5N1|Placebo_(IM)|Placebo_(ID)|,9,227,other_events,arm0,H5 HA ID,7,113
Hypersensitivity,Immune_system_disorders,NCT00439270,https://clinicaltrials.gov/show/NCT00439270,Metastatic_Prostate_Cancer,Dasatinib|Docetaxel|,7,40,other_events,arm2,Dasatinib 50 mg + Docetaxel 60 mg/m^2,2,3
Hypersensitivity,Immune_system_disorders,NCT00439270,https://clinicaltrials.gov/show/NCT00439270,Metastatic_Prostate_Cancer,Dasatinib|Docetaxel|,7,40,other_events,arm3,Dasatinib 50 mg + Docetaxel 75 mg/m^2,1,3
Hypersensitivity,Immune_system_disorders,NCT00439270,https://clinicaltrials.gov/show/NCT00439270,Metastatic_Prostate_Cancer,Dasatinib|Docetaxel|,7,40,other_events,arm0,Dasatinib 100 mg + Docetaxel 75 mg/m^2,4,34
Hypersensitivity,Immune_system_disorders,NCT00439517,https://clinicaltrials.gov/show/NCT00439517,Previously_Untreated_Metastatic_Colorectal_Cancer,UFOX_+_Cetuximab|FOLFOX4_+_Cetuximab|,11,301,other_events,arm1,FOLFOX4 + Cetuximab,8,150
Hypersensitivity,Immune_system_disorders,NCT00439517,https://clinicaltrials.gov/show/NCT00439517,Previously_Untreated_Metastatic_Colorectal_Cancer,UFOX_+_Cetuximab|FOLFOX4_+_Cetuximab|,11,301,other_events,arm0,UFOX + Cetuximab,3,151
Hypersensitivity,Immune_system_disorders,NCT00439647,https://clinicaltrials.gov/show/NCT00439647,Male_Osteoporosis,Zoledronic_acid_5_mg_iv|Placebo|,1,588,serious_events,arm0,Zoledronic Acid,1,588
Hypersensitivity,Immune_system_disorders,NCT00439946,https://clinicaltrials.gov/show/NCT00439946,Pulmonary_Arterial_Hypertension,treprostinil|Crono_Five_ambulatory_pump|,1,8,other_events,arm0,Treprostinil,1,8
Hypersensitivity,Immune_system_disorders,NCT00440011,https://clinicaltrials.gov/show/NCT00440011,Glaucoma|Ocular_Hypertension|,bimatoprost_0.03_PERCENT_eye_drops|travoprost_0.004_PERCENT_eye_drops|,1,131,other_events,arm0,Bimatoprost,1,131
Hypersensitivity,Immune_system_disorders,NCT00439777,https://clinicaltrials.gov/show/NCT00439777,Pulmonary_Embolism,Rivaroxaban_(Xarelto_BAY59-7939)|Enoxaparin_overlapping_with_and_followed_by_VKA|,1,2412,serious_events,arm0,Rivaroxaban (Xarelto BAY59-7939),1,2412
Hypersensitivity,Immune_system_disorders,NCT00440310,https://clinicaltrials.gov/show/NCT00440310,Liver_Metastases|Colorectal_Neoplasms|Neoplasm_Metastasis|Neoplasm_Recurrence_Local|,Talaporfin_sodium|Percutaneous_placement_of_device_in_liver_metastases|Interstitial_light_emitting_diodes|FOLFOX4_regimen|FOLFIRI_regimen|,2,222,serious_events,arm0,Litx + Chemotherapy,2,222
Hypersensitivity,Immune_system_disorders,NCT00440947,https://clinicaltrials.gov/show/NCT00440947,Infection_Human_Immunodeficiency_Virus_I|HIV_Infection|,Abacavir_(ABC)/lamivudine_(3TC)_+_atazanavir_(ATV)_+_ritonavir_(/r)|Abacavir_(ABC)/lamivudine_(3TC)_+_atazanavir_(ATV)|,3,904,serious_events,arm2,ABC/3TC + ATV/r: Randomization Phase,1,209
Hypersensitivity,Immune_system_disorders,NCT00440947,https://clinicaltrials.gov/show/NCT00440947,Infection_Human_Immunodeficiency_Virus_I|HIV_Infection|,Abacavir_(ABC)/lamivudine_(3TC)_+_atazanavir_(ATV)_+_ritonavir_(/r)|Abacavir_(ABC)/lamivudine_(3TC)_+_atazanavir_(ATV)|,3,904,serious_events,arm0,ABC/3TC + ATV/r: Induction Phase,1,515
Hypersensitivity,Immune_system_disorders,NCT00440947,https://clinicaltrials.gov/show/NCT00440947,Infection_Human_Immunodeficiency_Virus_I|HIV_Infection|,Abacavir_(ABC)/lamivudine_(3TC)_+_atazanavir_(ATV)_+_ritonavir_(/r)|Abacavir_(ABC)/lamivudine_(3TC)_+_atazanavir_(ATV)|,3,904,serious_events,arm4,ABC/3TC + ATV/r: Extension Phase,1,180
Hypersensitivity,Immune_system_disorders,NCT00441337,https://clinicaltrials.gov/show/NCT00441337,Carcinoma_Non-Small-Cell_Lung|Colorectal_Cancer|Malignant_Melanoma|Renal_Cancer|Prostate_Cancer|,MDX-1106,1,6,other_events,arm2,3 mg/kg Nivolumab,1,6
Hypersensitivity,General_disorders,NCT00444600,https://clinicaltrials.gov/show/NCT00444600,Diabetic_Retinopathy|Diabetic_Macular_Edema|,Triamcinolone_Acetonide_+_laser|Ranibizumab_+_laser|Sham_injection_+_laser|Ranibizumab_+_deferred_laser|,1,135,serious_events,arm3,Triamcinolone + Prompt Laser,1,135
Hypersensitivity,Immune_system_disorders,NCT00444457,https://clinicaltrials.gov/show/NCT00444457,Vaccines_Pneumococcal,13-valent_Pneumococcal_Conjugate_Vaccine|7vPnC|,1,483,other_events,arm1,Infant Series 13vPnC (Pilot Lot 2),1,483
Hypersensitivity,Immune_system_disorders,NCT00445939,https://clinicaltrials.gov/show/NCT00445939,Crohn's_Disease,adalimumab|adalimumab|placebo|,1,12,other_events,arm4,80/40 mg + 40/40 mg,1,12
HYPERSENSITIVITY,Immune_system_disorders,NCT00446030,https://clinicaltrials.gov/show/NCT00446030,Breast_Neoplasms,Docetaxel|Doxorubicin|Carboplatin|Cyclophosphamide|Trastuzumab|Bevacizumab|,3,34,other_events,arm1,Stratum 2: TCH + Bevacizumab,3,34
Hypersensitivity,Immune_system_disorders,NCT00447057,https://clinicaltrials.gov/show/NCT00447057,Histological_or_Cytological_Diagnosis_of_Locally_Advanced_or_Metastatic_NSCLC_of_Nonsquamous_Histology_and_Not_Amenable_to_Curative_Therapy.,Pemetrexed|Erlotinib|Pemetrexed|Erlotinib|,1,102,serious_events,arm1,Pemetrexed + Erlotinib (Nonsquamous and Squamous),1,102
Hypersensitivity,Immune_system_disorders,NCT00448591,https://clinicaltrials.gov/show/NCT00448591,Breast_Cancer,bevacizumab_[Avastin]|Taxane-based_chemotherapy|,3,2264,serious_events,arm0,Bevacizumab,3,2264
Hypersensitivity,Immune_system_disorders,NCT00449644,https://clinicaltrials.gov/show/NCT00449644,Tuberculosis,TMC207|Placebo|Background_regimen_(BR)_for_MDR-TB_(multi-drug_resistant_tuberculosis)|,1,81,serious_events,arm3,Placebo / BR (Stage 2),1,81
HYPERSENSITIVITY,Immune_system_disorders,NCT00451451,https://clinicaltrials.gov/show/NCT00451451,Relapsing-Remitting_Multiple_Sclerosis,BG00012|Placebo|Glatiramer_Acetate|,1,351,serious_events,arm4,Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD),1,351
Hypersensitivity,Immune_system_disorders,NCT00453999,https://clinicaltrials.gov/show/NCT00453999,Influenza,Peramivir_200_mg|Peramivir_400_mg|Oseltamivir|,1,46,other_events,arm2,Oseltamivir,1,46
Hypersensitivity,Immune_system_disorders,NCT00454649,https://clinicaltrials.gov/show/NCT00454649,Neoplasms,Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_1)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_2)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_3)|Axitinib_+_Paclitaxel_(Cohort_4)|Axitinib_+_Docetaxel_+_Carboplatin_(Cohort_4a)|Axitinib_+_Docetaxel_(Cohort_5)|Axitinib_+_Capecitabine_(Cohort_6)|Axitinib_+_Capecitabine_(Cohort_7)|Axitinib_+_Gemcitabine_+_Cisplatin_(Cohort_8)|Axitinib_+_Pemetrexed_+_Cisplatin_(Cohort_9)|,3,11,serious_events,arm0,Axitinib + Paclitaxel + Carboplatin (Cohort 1),1,3
Hypersensitivity,Immune_system_disorders,NCT00454649,https://clinicaltrials.gov/show/NCT00454649,Neoplasms,Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_1)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_2)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_3)|Axitinib_+_Paclitaxel_(Cohort_4)|Axitinib_+_Docetaxel_+_Carboplatin_(Cohort_4a)|Axitinib_+_Docetaxel_(Cohort_5)|Axitinib_+_Capecitabine_(Cohort_6)|Axitinib_+_Capecitabine_(Cohort_7)|Axitinib_+_Gemcitabine_+_Cisplatin_(Cohort_8)|Axitinib_+_Pemetrexed_+_Cisplatin_(Cohort_9)|,3,11,other_events,arm0,Axitinib + Paclitaxel + Carboplatin (Cohort 1),1,3
Hypersensitivity,Immune_system_disorders,NCT00454649,https://clinicaltrials.gov/show/NCT00454649,Neoplasms,Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_1)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_2)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_3)|Axitinib_+_Paclitaxel_(Cohort_4)|Axitinib_+_Docetaxel_+_Carboplatin_(Cohort_4a)|Axitinib_+_Docetaxel_(Cohort_5)|Axitinib_+_Capecitabine_(Cohort_6)|Axitinib_+_Capecitabine_(Cohort_7)|Axitinib_+_Gemcitabine_+_Cisplatin_(Cohort_8)|Axitinib_+_Pemetrexed_+_Cisplatin_(Cohort_9)|,3,11,other_events,arm1,Axitinib + Paclitaxel + Carboplatin (Cohort 2),1,5
Hypersensitivity,Immune_system_disorders,NCT00455195,https://clinicaltrials.gov/show/NCT00455195,Pompe_Disease_(Late-Onset)|Glycogen_Storage_Disease_Type_II_(GSD-II)|Glycogenesis_Type_II|Acid_Maltase_Deficiency_(AMD)|,alglucosidase_alfa,10,318,other_events,arm1,Placebo/Alglucosidase Alfa,1,26
Hypersensitivity,Immune_system_disorders,NCT00455195,https://clinicaltrials.gov/show/NCT00455195,Pompe_Disease_(Late-Onset)|Glycogen_Storage_Disease_Type_II_(GSD-II)|Glycogenesis_Type_II|Acid_Maltase_Deficiency_(AMD)|,alglucosidase_alfa,10,318,other_events,arm0,Alglucosidase Alfa/Alglucosidase Alfa,2,60
Hypersensitivity,Immune_system_disorders,NCT00455195,https://clinicaltrials.gov/show/NCT00455195,Pompe_Disease_(Late-Onset)|Glycogen_Storage_Disease_Type_II_(GSD-II)|Glycogenesis_Type_II|Acid_Maltase_Deficiency_(AMD)|,alglucosidase_alfa,10,318,serious_events,arm0,Alglucosidase Alfa/Alglucosidase Alfa,2,60
Hypersensitivity,Immune_system_disorders,NCT00455195,https://clinicaltrials.gov/show/NCT00455195,Pompe_Disease_(Late-Onset)|Glycogen_Storage_Disease_Type_II_(GSD-II)|Glycogenesis_Type_II|Acid_Maltase_Deficiency_(AMD)|,alglucosidase_alfa,10,318,serious_events,arm2,Overall,2,86
Hypersensitivity,Immune_system_disorders,NCT00455195,https://clinicaltrials.gov/show/NCT00455195,Pompe_Disease_(Late-Onset)|Glycogen_Storage_Disease_Type_II_(GSD-II)|Glycogenesis_Type_II|Acid_Maltase_Deficiency_(AMD)|,alglucosidase_alfa,10,318,other_events,arm2,Overall,3,86
hypersensitivity,Immune_system_disorders,NCT00456508,https://clinicaltrials.gov/show/NCT00456508,Hereditary_Angioedema,ecallantide,1,147,serious_events,arm0,Treatment,1,147
Hypersensitivity,Immune_system_disorders,NCT00457392,https://clinicaltrials.gov/show/NCT00457392,Carcinoma_Non-Small_Cell_Lung,erlotinib|sunitinib|erlotinib|placebo|,1,477,other_events,arm1,Erlotinib,1,477
Hypersensitivity,Immune_system_disorders,NCT00459108,https://clinicaltrials.gov/show/NCT00459108,Adult_Primary_Hepatocellular_Carcinoma|Advanced_Adult_Primary_Liver_Cancer|Recurrent_Adult_Primary_Liver_Cancer|,dasatinib,2,50,serious_events,arm0,Oral Dasatinib,1,25
Hypersensitivity,Immune_system_disorders,NCT00459108,https://clinicaltrials.gov/show/NCT00459108,Adult_Primary_Hepatocellular_Carcinoma|Advanced_Adult_Primary_Liver_Cancer|Recurrent_Adult_Primary_Liver_Cancer|,dasatinib,2,50,other_events,arm0,Oral Dasatinib,1,25
Hypersensitivity,Immune_system_disorders,NCT00460265,https://clinicaltrials.gov/show/NCT00460265,Recurrent_and/or_Metastatic_Head_and_Neck_Cancer,ARM_2|ARM_1|,2,325,serious_events,arm0,Panitumumab Plus Chemotherapy,2,325
Hypersensitivity,Immune_system_disorders,NCT00460408,https://clinicaltrials.gov/show/NCT00460408,Macular_Degeneration,Macugen,1,403,other_events,arm0,Macugen,1,403
Hypersensitivity,Immune_system_disorders,NCT00461032,https://clinicaltrials.gov/show/NCT00461032,Asthma,montelukast|Comparator:_Placebo|,2,566,other_events,arm1,Montelukast 5 mg,2,566
Hypersensitivity,Immune_system_disorders,NCT00460603,https://clinicaltrials.gov/show/NCT00460603,Colorectal_Neoplasms,bevacizumab|AG-013726|AG-013736_(axitinib)|,5,129,other_events,arm9,Phase 2: Axitinib + FOLFOX,1,39
Hypersensitivity,Immune_system_disorders,NCT00460603,https://clinicaltrials.gov/show/NCT00460603,Colorectal_Neoplasms,bevacizumab|AG-013726|AG-013736_(axitinib)|,5,129,other_events,arm10,Phase 2: Bevacizumab + FOLFOX,1,43
Hypersensitivity,Immune_system_disorders,NCT00460603,https://clinicaltrials.gov/show/NCT00460603,Colorectal_Neoplasms,bevacizumab|AG-013726|AG-013736_(axitinib)|,5,129,serious_events,arm4,Phase 1: Axitinib + FOLFOX (Cohort 5),1,6
Hypersensitivity,Immune_system_disorders,NCT00460603,https://clinicaltrials.gov/show/NCT00460603,Colorectal_Neoplasms,bevacizumab|AG-013726|AG-013736_(axitinib)|,5,129,other_events,arm11,Phase 2: Axitinib + Bevacizumab + FOLFOX,2,41
Hypersensitivity,Immune_system_disorders,NCT00461097,https://clinicaltrials.gov/show/NCT00461097,Hypersensitivity|Immediate_Hypersensitivity|Food_Hypersensitivity|,Egg_oral_immunotherapy|Control_Group|,5,76,other_events,arm0,Egg Oral Immunotherapy (OIT) 0-2 Years,4,40
Hypersensitivity,Immune_system_disorders,NCT00461097,https://clinicaltrials.gov/show/NCT00461097,Hypersensitivity|Immediate_Hypersensitivity|Food_Hypersensitivity|,Egg_oral_immunotherapy|Control_Group|,5,76,other_events,arm2,Egg Oral Immunotherapy (OIT) 2-4 Years,1,36
Hypersensitivity,Immune_system_disorders,NCT00466947,https://clinicaltrials.gov/show/NCT00466947,Pneumonia_&_AOM_Caused_by_S._Pneumoniae_&_H._Influenzae,Pneumococcal_conjugate_vaccine_GSK1024850A|Havrix|Engerix-B|Infanrix_hexa|GSK_Biologicals'_DTPa-IPV/Hib_vaccine|,654,30811,serious_events,arm1,Control Group,6,11799
Hypersensitivity,Immune_system_disorders,NCT00466947,https://clinicaltrials.gov/show/NCT00466947,Pneumonia_&_AOM_Caused_by_S._Pneumoniae_&_H._Influenzae,Pneumococcal_conjugate_vaccine_GSK1024850A|Havrix|Engerix-B|Infanrix_hexa|GSK_Biologicals'_DTPa-IPV/Hib_vaccine|,654,30811,serious_events,arm0,Synflorix Group,5,11798
Hypersensitivity,Immune_system_disorders,NCT00466947,https://clinicaltrials.gov/show/NCT00466947,Pneumonia_&_AOM_Caused_by_S._Pneumoniae_&_H._Influenzae,Pneumococcal_conjugate_vaccine_GSK1024850A|Havrix|Engerix-B|Infanrix_hexa|GSK_Biologicals'_DTPa-IPV/Hib_vaccine|,654,30811,other_events,arm0,Synflorix Group,315,3602
Hypersensitivity,Immune_system_disorders,NCT00466947,https://clinicaltrials.gov/show/NCT00466947,Pneumonia_&_AOM_Caused_by_S._Pneumoniae_&_H._Influenzae,Pneumococcal_conjugate_vaccine_GSK1024850A|Havrix|Engerix-B|Infanrix_hexa|GSK_Biologicals'_DTPa-IPV/Hib_vaccine|,654,30811,other_events,arm1,Control Group,328,3612
Hypersensitivity,Immune_system_disorders,NCT00471146,https://clinicaltrials.gov/show/NCT00471146,Carcinoma_Pancreatic_Ductal,AG-013736|Gemcitabine|Gemcitabine|placebo|,3,613,other_events,arm0,Axitinib + Gemcitabine,2,304
Hypersensitivity,Immune_system_disorders,NCT00471146,https://clinicaltrials.gov/show/NCT00471146,Carcinoma_Pancreatic_Ductal,AG-013736|Gemcitabine|Gemcitabine|placebo|,3,613,other_events,arm1,Placebo + Gemcitabine,1,309
Hypersensitivity,Immune_system_disorders,NCT00473889,https://clinicaltrials.gov/show/NCT00473889,Stage_IIIB_or_IV_Non-Small_Cell_Lung_Cancer,vorinostat|Comparator:_paclitaxel|Comparator:_carboplatin|Comparator:_placebo|,1,124,serious_events,arm1,Placebo + Paclitaxel + Carboplatin,1,124
Hypersensitivity,Immune_system_disorders,NCT00474903,https://clinicaltrials.gov/show/NCT00474903,Barrett_Esophagus|Esophageal_Cancer|,acetylsalicylic_acid|esomeprazole_magnesium|placebo|,1,30,other_events,arm0,Arm I (Placebo Esomeprazole Magnesium),1,30
Hypersensitivity,Immune_system_disorders,NCT00475423,https://clinicaltrials.gov/show/NCT00475423,Idiopathic_Thrombocytopenic_Purpura,rituximab_[MabThera/Rituxan],1,122,other_events,arm0,Rituximab 1000 mg,1,122
Hypersensitivity,Immune_system_disorders,NCT00477269,https://clinicaltrials.gov/show/NCT00477269,Pulmonary_Arterial_Hypertension,Imatinib_mesylate|Placebo|,1,22,serious_events,arm2,Extension - STI571,1,22
Hypersensitivity,Immune_system_disorders,NCT00477750,https://clinicaltrials.gov/show/NCT00477750,Multiple_Myeloma_and_Plasma_Cell_Neoplasm,lenalidomide|melphalan|prednisone|,1,26,other_events,arm0,Treatment (Lenalidomide Melphalan Prednisone),1,26
Hypersensitivity,Immune_system_disorders,NCT00477594,https://clinicaltrials.gov/show/NCT00477594,Lipid_Metabolism_Inborn_Errors|Hypercholesterolemia_Autosomal_Dominant|Hyperlipidemias|Metabolic_Diseases|Hyperlipoproteinemia_Type_II|Metabolism_Inborn_Errors|Genetic_Diseases_Inborn|Infant_Newborn_Diseases|Metabolic_Disorder|Congenital_Abnormalities|Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemias|Lipid_Metabolism_Disorders|,mipomersen_sodium,1,16,other_events,arm0,Mipomersen 200 mg Per Week,1,16
Hypersensitivity,Immune_system_disorders,NCT00478231,https://clinicaltrials.gov/show/NCT00478231,Acquired_Immunodeficiency_Syndrome|HIV_Infection|,Maraviroc,5,206,other_events,arm0,Maraviroc,5,206
Hypersensitivity,Immune_system_disorders,NCT00479713,https://clinicaltrials.gov/show/NCT00479713,Hypercholesterolemia,ezetimibe_(+)_simvastatin|Comparator_:_rosuvastatin_calcium|Comparator:_Placebo_(unspecified)|Comparator:_Placebo_(unspecified)|,1,312,other_events,arm0,Ezetemibe + Simvastatin,1,312
Hypersensitivity,Immune_system_disorders,NCT00481078,https://clinicaltrials.gov/show/NCT00481078,Recurrent_Non-small_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|Stage_IV_Non-small_Cell_Lung_Cancer|,vorinostat|paclitaxel|carboplatin|placebo|laboratory_biomarker_analysis|,2,32,other_events,arm1,Arm II (Placebo Paclitaxel Carboplatin),2,32
Hypersensitivity,Immune_system_disorders,NCT00485173,https://clinicaltrials.gov/show/NCT00485173,Degenerative_Disc_Disease,INFUSEå¨_Bone_Graft/PEEK_Spacer/Anterior_Cervical_Plate,3,710,other_events,arm0,INFUSEå¨ Bone Graft,2,224
Hypersensitivity,Immune_system_disorders,NCT00485173,https://clinicaltrials.gov/show/NCT00485173,Degenerative_Disc_Disease,INFUSEå¨_Bone_Graft/PEEK_Spacer/Anterior_Cervical_Plate,3,710,serious_events,arm1,Historical Control,1,486
Hypersensitivity,Immune_system_disorders,NCT00486759,https://clinicaltrials.gov/show/NCT00486759,B-cell_Lymphoma,Bevacizumab|Rituximab|CHOP|Placebo|,3,781,serious_events,arm1,Placebo + Rituximab + CHOP,2,386
Hypersensitivity,Immune_system_disorders,NCT00486759,https://clinicaltrials.gov/show/NCT00486759,B-cell_Lymphoma,Bevacizumab|Rituximab|CHOP|Placebo|,3,781,serious_events,arm0,Bevacizumab + Rituximab + CHOP,1,395
Hypersensitivity,Immune_system_disorders,NCT00488475,https://clinicaltrials.gov/show/NCT00488475,Rheumatoid_Arthritis,etanercept,13,4871,other_events,arm0,Etanercept,13,4871
Hypersensitivity,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,5,79,other_events,arm6,Pemetrexed 500 + Carboplatin AUC 6 (Phase 2),1,66
Hypersensitivity,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,5,79,other_events,arm5,Pemetrexed 900 + Carboplatin AUC 6 (Phase 1),1,3
Hypersensitivity,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,5,79,other_events,arm1,Pemetrexed 600 + Carboplatin AUC 5 (Phase 1),1,3
Hypersensitivity,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,5,79,other_events,arm0,Pemetrexed 500 + Carboplatin AUC 5 (Phase 1),1,4
Hypersensitivity,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,5,79,other_events,arm3,Pemetrexed 700 + Carboplatin AUC 6 (Phase 1),1,3
Hypersensitivity,Immune_system_disorders,NCT00494780,https://clinicaltrials.gov/show/NCT00494780,Lymphoma_Follicular,Ofatumumab|Cyclophosphamide|Doxorubicin|Vincristine|Prednisolone_Prednisone_or_equivalent|,2,58,serious_events,arm1,1000 mg Ofatumumab + CHOP,1,29
Hypersensitivity,Immune_system_disorders,NCT00494780,https://clinicaltrials.gov/show/NCT00494780,Lymphoma_Follicular,Ofatumumab|Cyclophosphamide|Doxorubicin|Vincristine|Prednisolone_Prednisone_or_equivalent|,2,58,serious_events,arm0,500 mg Ofatumumab + CHOP,1,29
Hypersensitivity,Immune_system_disorders,NCT00497796,https://clinicaltrials.gov/show/NCT00497796,Cytomegalovirus_Infections,maribavir|ganciclovir|,1,147,serious_events,arm0,Maribavir 100 mg BID,1,147
Hypersensitivity,Immune_system_disorders,NCT00500357,https://clinicaltrials.gov/show/NCT00500357,Vaccines_Pneumococcal_Conjugate_Vaccine,13-valent_Pneumococcal_Conjugate_Vaccine,1,304,other_events,arm2,13vPnC-AlPO4 (After Vax 1 Core Study),1,304
Hypersensitivity,Immune_system_disorders,NCT00508924,https://clinicaltrials.gov/show/NCT00508924,Coronary_Artery_Disease|Angina_Unstable|,Argatroban|Argatroban|Argatroban|Heparin|,1,38,serious_events,arm1,ARG300,1,38
Hypersensitivity,Immune_system_disorders,NCT00509041,https://clinicaltrials.gov/show/NCT00509041,Malignant_Mesothelioma,dasatinib,1,43,other_events,arm0,Dasatinib,1,43
Hypersensitivity,Immune_system_disorders,NCT00511238,https://clinicaltrials.gov/show/NCT00511238,Multiple_Myeloma,carfilzomib|carfilzomib|,1,266,serious_events,arm1,Carfilzomib (A1),1,266
Hypersensitivity,Immune_system_disorders,NCT00511433,https://clinicaltrials.gov/show/NCT00511433,Contraception,NOMAC-E2|DRSP-EE|,1,16,other_events,arm1,DRSP-EE,1,16
Hypersensitivity,Immune_system_disorders,NCT00512148,https://clinicaltrials.gov/show/NCT00512148,Neurogenic_Bladder,Autologous_neobladder_construct,1,7,other_events,arm0,Safety Population,1,7
Hypersensitivity,Immune_system_disorders,NCT00513292,https://clinicaltrials.gov/show/NCT00513292,HER2/Neu_Positive|Stage_IA_Breast_Cancer|Stage_IB_Breast_Cancer|Stage_II_Breast_Cancer|Stage_IIIA_Breast_Cancer|,Cyclophosphamide|Epirubicin_Hydrochloride|Laboratory_Biomarker_Analysis|Paclitaxel|Therapeutic_Conventional_Surgery|Trastuzumab|,6,280,other_events,arm0,Arm A,2,138
Hypersensitivity,Immune_system_disorders,NCT00513292,https://clinicaltrials.gov/show/NCT00513292,HER2/Neu_Positive|Stage_IA_Breast_Cancer|Stage_IB_Breast_Cancer|Stage_II_Breast_Cancer|Stage_IIIA_Breast_Cancer|,Cyclophosphamide|Epirubicin_Hydrochloride|Laboratory_Biomarker_Analysis|Paclitaxel|Therapeutic_Conventional_Surgery|Trastuzumab|,6,280,other_events,arm1,Arm B,4,142
Hypersensitivity,Immune_system_disorders,NCT00514943,https://clinicaltrials.gov/show/NCT00514943,Head_and_Neck_Neoplasms|Carcinoma_Squamous_Cell|,BIBW_2992|Cetuximab|,1,60,serious_events,arm1,Cetuximab mg/m2 - Stage 1,1,60
Hypersensitivity,Immune_system_disorders,NCT00515203,https://clinicaltrials.gov/show/NCT00515203,Idiopathic_Thrombocytopenic_Purpura|Thrombocytopenia_in_Pediatric_Subjects_With_Immune_(Idiopathic)_Thrombocytopenic_Purpura_(ITP)|Thrombocytopenia_in_Subjects_With_Immune_(Idiopathic)_Thrombocytopenic_Purpura_(ITP)|,Placebo|AMG_531|,1,5,other_events,arm0,Placebo,1,5
Hypersensitivity,Immune_system_disorders,NCT00516217,https://clinicaltrials.gov/show/NCT00516217,Lymphoma,galiximab,1,29,serious_events,arm0,Galaximab,1,29
Hypersensitivity,Immune_system_disorders,NCT00517634,https://clinicaltrials.gov/show/NCT00517634,Asthma,FP|SFC|Placebo|,2,45,other_events,arm2,SFC 50/100 BID,1,22
Hypersensitivity,Immune_system_disorders,NCT00517634,https://clinicaltrials.gov/show/NCT00517634,Asthma,FP|SFC|Placebo|,2,45,other_events,arm1,FP 100 mcg BID,1,23
Hypersensitivity,Immune_system_disorders,NCT00518115,https://clinicaltrials.gov/show/NCT00518115,Diabetes_Mellitus_Type_2,Albiglutide_(GSK716155)_or_exenatide,2,35,serious_events,arm8,Albiglutide 50 mg Every 4 Weeks,2,35
Hypersensitivity,Immune_system_disorders,NCT00520741,https://clinicaltrials.gov/show/NCT00520741,Epilepsy,Lacosamide|Lacosamide|,1,319,serious_events,arm1,Lacosamide 400 mg/Day,1,319
Hypersensitivity,Immune_system_disorders,NCT00522275,https://clinicaltrials.gov/show/NCT00522275,Partial_Epilepsies,lacosamide,1,308,serious_events,arm0,Lacosamide,1,308
Hypersensitivity,Immune_system_disorders,NCT00524459,https://clinicaltrials.gov/show/NCT00524459,Breast_Cancer,docetaxel|pegylated_liposomal_doxorubicin_hydrochloride|conventional_surgery|neoadjuvant_therapy|,1,6,serious_events,arm0,DOXIL (Pegylated Liposomal Doxorubicin) and Docetaxel,1,6
Hypersensitivity,Immune_system_disorders,NCT00525798,https://clinicaltrials.gov/show/NCT00525798,Osteoporosis,SMC021_Oral_calcitonin|SMC021_Placebo|,1,2331,serious_events,arm1,Placebo,1,2331
HYPERSENSITIVITY,Immune_system_disorders,NCT00526474,https://clinicaltrials.gov/show/NCT00526474,Atherosclerosis|Ischemia|Myocardial_Infarction|Cerebrovascular_Accident|Peripheral_Arterial_Disease|,Vorapaxar|Placebo|,7,26352,serious_events,arm1,Vorapaxar,1,13186
HYPERSENSITIVITY,Immune_system_disorders,NCT00526474,https://clinicaltrials.gov/show/NCT00526474,Atherosclerosis|Ischemia|Myocardial_Infarction|Cerebrovascular_Accident|Peripheral_Arterial_Disease|,Vorapaxar|Placebo|,7,26352,serious_events,arm0,Placebo,6,13166
HYPERSENSITIVITY,Immune_system_disorders,NCT00527735,https://clinicaltrials.gov/show/NCT00527735,Lung_Cancer|Small_Cell_Lung_Cancer|Carcinoma_Non-Small-Cell_Lung|,Ipilimumab|Placebo|Paclitaxel|Carboplatin|,3,203,serious_events,arm1,Placebo/Ipilimumab+ Paclitaxel/Carboplatin (Sequential) NSCLC,1,67
HYPERSENSITIVITY,Immune_system_disorders,NCT00527735,https://clinicaltrials.gov/show/NCT00527735,Lung_Cancer|Small_Cell_Lung_Cancer|Carcinoma_Non-Small-Cell_Lung|,Ipilimumab|Placebo|Paclitaxel|Carboplatin|,3,203,serious_events,arm2,Placebo + Paclitaxel/Carboplatin NSCLC,1,65
HYPERSENSITIVITY,Immune_system_disorders,NCT00527735,https://clinicaltrials.gov/show/NCT00527735,Lung_Cancer|Small_Cell_Lung_Cancer|Carcinoma_Non-Small-Cell_Lung|,Ipilimumab|Placebo|Paclitaxel|Carboplatin|,3,203,serious_events,arm0,Ipilimubab+Paclitaxel/Carboplatin (Concurrent) NSCLC,1,71
HYPERSENSITIVITY,Immune_system_disorders,NCT00527943,https://clinicaltrials.gov/show/NCT00527943,Atherosclerosis|Myocardial_Ischemia|Myocardial_Infarction|,Vorapaxar|Placebo|,4,12887,serious_events,arm1,Vorapaxar,3,6446
HYPERSENSITIVITY,Immune_system_disorders,NCT00527943,https://clinicaltrials.gov/show/NCT00527943,Atherosclerosis|Myocardial_Ischemia|Myocardial_Infarction|,Vorapaxar|Placebo|,4,12887,serious_events,arm0,Placebo,1,6441
Hypersensitivity,Immune_system_disorders,NCT00528567,https://clinicaltrials.gov/show/NCT00528567,Breast_Cancer,Bevacizumab|Standard_adjuvant_chemotherapy|,1,1271,serious_events,arm1,Chemotherapy (0-18 Months),1,1271
Hypersensitivity,Immune_system_disorders,NCT00529659,https://clinicaltrials.gov/show/NCT00529659,Sarcopenia,Comparator:_MK-0773|Comparator:_Placebo|,1,81,other_events,arm0,MK-0773,1,81
Hypersensitivity,Immune_system_disorders,NCT00531960,https://clinicaltrials.gov/show/NCT00531960,Non-Small_Cell_Lung_Cancer,Erlotinib|Bevacizumab|Standard_platinum-based_chemotherapy|,1,60,other_events,arm0,Bevacizumab + Chemotherapy,1,60
Hypersensitivity,Immune_system_disorders,NCT00532883,https://clinicaltrials.gov/show/NCT00532883,Hemoglobin_SC_Disease,Hydroxyurea|Magnesium_Pidolate|Placebo_Pills_and_Placebo_Liquid|,2,22,other_events,arm0,Hydroxyurea/Magnesium Pidolate,1,11
Hypersensitivity,Immune_system_disorders,NCT00532883,https://clinicaltrials.gov/show/NCT00532883,Hemoglobin_SC_Disease,Hydroxyurea|Magnesium_Pidolate|Placebo_Pills_and_Placebo_Liquid|,2,22,other_events,arm3,Placebo/Placebo,1,11
Hypersensitivity,Immune_system_disorders,NCT00534417,https://clinicaltrials.gov/show/NCT00534417,Metastatic_Breast_Cancer,capecitabine|fulvestrant|,1,41,other_events,arm0,Treatment Group: Capecitabine/Fulvestrant,1,41
Hypersensitivity,Immune_system_disorders,NCT00534833,https://clinicaltrials.gov/show/NCT00534833,Diphtheria|Tetanus|Pertussis|Hepatitis_B|Haemophilus_Influenzae_Type_b|,DTaP-HB-PRP~T_vaccine|Tritanrix-HepB/Hib‰ã¢|Oral_Polio_Vaccine|,1,182,serious_events,arm0,Group 1: DTaP-Hep B-PRP~T + OPV,1,182
Hypersensitivity,Immune_system_disorders,NCT00535145,https://clinicaltrials.gov/show/NCT00535145,Schizophrenia|Schizoaffective_Disorder|Psychotic_Disorders|,Treatment_as_usual_(TAU)_Paliperidone_ER,1,84,other_events,arm1,Paliperidone ER Phase,1,84
Hypersensitivity,Immune_system_disorders,NCT00537394,https://clinicaltrials.gov/show/NCT00537394,HIV_Infections,Enfuvirtide|Raltegravir|Darunavir|Tipranavir|Etravirine|Maraviroc|,2,177,serious_events,arm1,Omit NRTIs (Randomized) to Individualized Regimen (cPSS > 2.0),2,177
Hypersensitivity,Immune_system_disorders,NCT00537511,https://clinicaltrials.gov/show/NCT00537511,Carcinoma_Small_Cell,Pomalidomide|Cisplatin|Etoposide|,4,32,other_events,arm4,Pomalidomide (Overall),2,22
Hypersensitivity,Immune_system_disorders,NCT00537511,https://clinicaltrials.gov/show/NCT00537511,Carcinoma_Small_Cell,Pomalidomide|Cisplatin|Etoposide|,4,32,other_events,arm0,Pomalidomide 1 mg,1,6
Hypersensitivity,Immune_system_disorders,NCT00537511,https://clinicaltrials.gov/show/NCT00537511,Carcinoma_Small_Cell,Pomalidomide|Cisplatin|Etoposide|,4,32,other_events,arm1,Pomalidomide 3 mg,1,4
Hypersensitivity,Immune_system_disorders,NCT00540228,https://clinicaltrials.gov/show/NCT00540228,Influenza|Influenza_Vaccines|,Influenza_Vaccine_GSK1247446A_-_4_different_formulations|Fluarix‰ã¢|,1,200,serious_events,arm0,GSK1247446A 1 Group,1,200
Hypersensitivity,Immune_system_disorders,NCT00541658,https://clinicaltrials.gov/show/NCT00541658,Postmenopausal_Osteoporosis,risedronate|risedronate|risedronate|,9,922,other_events,arm2,35 mg Before Breakfast,4,308
Hypersensitivity,Immune_system_disorders,NCT00541658,https://clinicaltrials.gov/show/NCT00541658,Postmenopausal_Osteoporosis,risedronate|risedronate|risedronate|,9,922,other_events,arm1,35 mg After Breakfast,2,307
Hypersensitivity,Immune_system_disorders,NCT00541658,https://clinicaltrials.gov/show/NCT00541658,Postmenopausal_Osteoporosis,risedronate|risedronate|risedronate|,9,922,other_events,arm0,5 mg Before Breakfast,3,307
Hypersensitivity,Immune_system_disorders,NCT00543543,https://clinicaltrials.gov/show/NCT00543543,Cervical_Cancer|Vulvar_Cancer|Vaginal_Cancer|Genital_Warts|Human_Papillomavirus_Infection|,Comparator:_GARDASIL|Experimental:_V503|,1,7071,serious_events,arm1,Mid-dose V503,1,7071
Hypersensitivity,Immune_system_disorders,NCT00544557,https://clinicaltrials.gov/show/NCT00544557,Ankylosing_Spondylitis,Etanercept,4,1685,other_events,arm0,Etanercept,4,1685
Hypersensitivity,Immune_system_disorders,NCT00545402,https://clinicaltrials.gov/show/NCT00545402,Liver_Transplantation,Mycophenolate_mofetil_adjusted_dose|Tacrolimus|Corticosteroids_IV|Mycophenolate_mofetil_Standard_dose|Corticosteroids_PO|,1,92,other_events,arm1,Fixed-Dose MMF + Tacrolimus + CS,1,92
Hypersensitivity,Immune_system_disorders,NCT00546000,https://clinicaltrials.gov/show/NCT00546000,Atopic_Dermatitis,Fluticasone_propionate_0.05_PERCENT_lotion,2,56,other_events,arm0,Experimental,2,56
Hypersensitivity,Immune_system_disorders,NCT00546351,https://clinicaltrials.gov/show/NCT00546351,Painful_Diabetic_Neuropathy,Lacosamide,1,621,serious_events,arm0,Lacosamide,1,621
HYPERSENSITIVITY,Immune_system_disorders,NCT00546364,https://clinicaltrials.gov/show/NCT00546364,Breast_Neoplasms,Ixabepilone_40_mg/m^2_+_Capecitabine_1000_mg/m^2|Ixabepilone_32_mg/m^2_+_Capecitabine_1000_mg/m^2|Docetaxel_75_mg/m^2_+_Capecitabine_1000_mg/m^2|,2,20,other_events,arm0,Docetaxel,2,20
Hypersensitivity,Immune_system_disorders,NCT00546754,https://clinicaltrials.gov/show/NCT00546754,Hypertension,losartan_potassium_(+)_hydrochlorothiazide|Comparator:_Valsartan_(+)_Hydrochlorothiazide|,2,383,other_events,arm1,Valsartan 80 mg/HCTZ 12.5 mg,2,383
HYPERSENSITIVITY,Immune_system_disorders,NCT00548548,https://clinicaltrials.gov/show/NCT00548548,Adenocarcinoma,Bevacizumab|Capecitabine|Cisplatin|Placebo|5-fluorouracil|,1,381,serious_events,arm1,Placebo,1,381
Hypersensitivity,Immune_system_disorders,NCT00549198,https://clinicaltrials.gov/show/NCT00549198,Infection_Human_Immunodeficiency_Virus_I|HIV_Infection|,Abacavir/lamivudine_and_efavirenz|Tenofovir/Emtricitabine_and_efavirenz|,3,192,serious_events,arm0,ABC/3TC FDC,3,192
Hypersensitivity,Immune_system_disorders,NCT00549757,https://clinicaltrials.gov/show/NCT00549757,Type_2_Diabetes_Mellitus|Cardiovascular_Disease|,Aliskiren|Placebo|,3,4285,serious_events,arm1,Core-phase: Placebo,3,4285
HYPERSENSITIVITY,Immune_system_disorders,NCT00550771,https://clinicaltrials.gov/show/NCT00550771,Breast_Neoplasm,doxorubicin_cyclophosphamide_paclitaxel_trastuzumab|PLD_cyclophosphamide_trastuzumab_paclitaxel|,12,179,other_events,arm1,Doxorubicin Based Regimen,3,59
HYPERSENSITIVITY,Immune_system_disorders,NCT00550771,https://clinicaltrials.gov/show/NCT00550771,Breast_Neoplasm,doxorubicin_cyclophosphamide_paclitaxel_trastuzumab|PLD_cyclophosphamide_trastuzumab_paclitaxel|,12,179,other_events,arm0,PLD Based Regimen,9,120
Hypersensitivity,Immune_system_disorders,NCT00551031,https://clinicaltrials.gov/show/NCT00551031,Influenza|Myxovirus_Infection|,Split_Inactivated_Trivalent_Influenza_Vaccine|Split_Inactivated_Trivalent_Influenza_Vaccine|Split_Inactivated_Trivalent_Influenza_Vaccine|Split_Inactivated_Trivalent_Influenza_Vaccine|Split_Inactivated_Trivalent_Influenza_Vaccine|,1,635,serious_events,arm1,Influenza Virus Vaccine Formulation 2,1,635
Hypersensitivity,Immune_system_disorders,NCT00553501,https://clinicaltrials.gov/show/NCT00553501,Lymphoma,epratuzumab|rituximab|,3,118,serious_events,arm0,Epratuzumab Plus Rituximab,1,59
Hypersensitivity,Immune_system_disorders,NCT00553501,https://clinicaltrials.gov/show/NCT00553501,Lymphoma,epratuzumab|rituximab|,3,118,other_events,arm0,Epratuzumab Plus Rituximab,2,59
Hypersensitivity,Immune_system_disorders,NCT00553631,https://clinicaltrials.gov/show/NCT00553631,Gaucher_Disease_Type_1,velaglucerase_alfa|imiglucerase|,2,17,other_events,arm0,Gene-Activated Human Glucocerebrosidase (GA-GCB),2,17
Hypersensitivity,Immune_system_disorders,NCT00553644,https://clinicaltrials.gov/show/NCT00553644,Recurrent_Mantle_Cell_Lymphoma,Bortezomib|Laboratory_Biomarker_Analysis|Lenalidomide|,1,53,other_events,arm0,Treatment (Antiangiogenesis Therapy Enzyme Inhibitor Therapy),1,53
hypersensitivity,Immune_system_disorders,NCT00554216,https://clinicaltrials.gov/show/NCT00554216,Obesity,VI-0521|VI-0521|Placebo_matched_phentermine/topiramate|,1,511,serious_events,arm2,VI-0521 Top,1,511
Hypersensitivity,Immune_system_disorders,NCT00555061,https://clinicaltrials.gov/show/NCT00555061,Skin_Infections_Bacterial,Retapamulin_Ointment_1_PERCENT,1,86,other_events,arm0,Retapamulin Ointment 1%,1,86
Hypersensitivity,Immune_system_disorders,NCT00555620,https://clinicaltrials.gov/show/NCT00555620,Stomach_Neoplasms,capecitabine|oxaliplatin|sunitinib_malate|capecitabine|cisplatin|sunitinib_malate|,2,23,other_events,arm3,SU 37.5 mg OXA 110 mg/m^2 CAP 1600 mg/m^2,2,23
Hypersensitivity,Immune_system_disorders,NCT00555906,https://clinicaltrials.gov/show/NCT00555906,Multiple_Myeloma,Bortezomib|Dexamethasone|PD_0332991|,1,30,serious_events,arm4,Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:ScheduleB),1,30
Hypersensitivity,Immune_system_disorders,NCT00556426,https://clinicaltrials.gov/show/NCT00556426,Pulmonary_Embolism|Venous_Thromboembolic_Disease|,Bard_Recovery_G2_Filter_System,1,100,other_events,arm0,All Patients Receiving the Filter,1,100
Hypersensitivity,General_disorders,NCT00556452,https://clinicaltrials.gov/show/NCT00556452,Leukemia|Hodgkin_Lymphoma|Non-Hodgkin_Lymphoma|Multiple_Myeloma|Myelodysplastic_Syndrome|,Clofarabine/Busulfan_x_4|Peripheral_blood_stem_cell_transplant|Total_Lymphoid_Irradiation|,1,46,other_events,arm0,Clo/Bu4,1,46
Hypersensitivity,Immune_system_disorders,NCT00557856,https://clinicaltrials.gov/show/NCT00557856,Advanced_Solid_Tumors,PF-03446962,1,68,serious_events,arm0,PF-03446962,1,68
Hypersensitivity,Immune_system_disorders,NCT00558896,https://clinicaltrials.gov/show/NCT00558896,Multiple_Myeloma_and_Plasma_Cell_Neoplasm,dexamethasone|pomalidomide|,1,60,other_events,arm4,Relapsed Myeloma (< 4 Prior Regimens): High Dose,1,60
Hypersensitivity,Immune_system_disorders,NCT00560235,https://clinicaltrials.gov/show/NCT00560235,Ewing's_Sarcoma_Family_of_Tumors,CP-751871,3,128,other_events,arm2,Figitumumab 30 mg/kg Dose Extension (Phase 1B),2,21
Hypersensitivity,Immune_system_disorders,NCT00560235,https://clinicaltrials.gov/show/NCT00560235,Ewing's_Sarcoma_Family_of_Tumors,CP-751871,3,128,other_events,arm6,Figitumumab 30mg/kg (Phase 2),1,107
Hypersensitivity,Immune_system_disorders,NCT00560573,https://clinicaltrials.gov/show/NCT00560573,Carcinoma_Non-Small-Cell_Lung,CP-751871|Cisplatin|Gemcitabine|Pemetrexed|,1,6,other_events,arm0,Figitumumab 6 mg/kg,1,6
Hypersensitivity,Immune_system_disorders,NCT00561470,https://clinicaltrials.gov/show/NCT00561470,Colorectal_Neoplasms|Neoplasm_Metastasis|,Placebo|Aflibercept_(ziv-aflibercept_AVE0005_VEGF_trap_ZALTRAPå¨)|FOLFIRI_(Irinotecan_5-Fluorouracil_and_Leucovorin)|FOLFIRI_(Irinotecan_5-Fluorouracil_and_Leucovorin)|,2,605,serious_events,arm0,Placebo/FOLFIRI,2,605
Hypersensitivity,Immune_system_disorders,NCT00561925,https://clinicaltrials.gov/show/NCT00561925,HIV_Infections,nevirapine_IR|nevirapine_XR|,1,1068,serious_events,arm0,NVP IR 200mg QD,1,1068
Hypersensitivity,Immune_system_disorders,NCT00562094,https://clinicaltrials.gov/show/NCT00562094,Erosive_Gastroesophageal_Reflux_Disease|Non-Erosive_Reflux_Disease|,Pantoprazole,1,8616,other_events,arm0,Pantoprazole,1,8616
Hypersensitivity,Immune_system_disorders,NCT00562328,https://clinicaltrials.gov/show/NCT00562328,Leukemia,Alemtuzumab|Rituximab|Sargramostim|,1,33,other_events,arm0,Alemtuzumab + Rituximab + GM-CSF,1,33
HYPERSENSITIVITY,Immune_system_disorders,NCT00565448,https://clinicaltrials.gov/show/NCT00565448,Nasopharyngeal_Neoplasms|Carcinoma|,docetaxel|cisplatin|5-fluorouracil|,5,100,other_events,arm1,Docetaxel /Cisplatin/5-FU,4,50
HYPERSENSITIVITY,Immune_system_disorders,NCT00565448,https://clinicaltrials.gov/show/NCT00565448,Nasopharyngeal_Neoplasms|Carcinoma|,docetaxel|cisplatin|5-fluorouracil|,5,100,serious_events,arm1,Docetaxel /Cisplatin/5-FU,1,50
Hypersensitivity,Immune_system_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,47,1211,other_events,arm0,Pertuzumab + Trastuzumab + Docetaxel,24,407
Hypersensitivity,Immune_system_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,47,1211,other_events,arm1,Placebo + Trastuzumab + Docetaxel,20,397
Hypersensitivity,Immune_system_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,47,1211,serious_events,arm0,Pertuzumab + Trastuzumab + Docetaxel,3,407
Hypersensitivity,Immune_system_disorders,NCT00570713,https://clinicaltrials.gov/show/NCT00570713,Pancreatic_Cancer,MORAb-009|Placebo|Gemcitabine|,1,73,serious_events,arm0,MORAb-009 Plus Gemcitabine (‰Û÷MORAb-009‰Ûª),1,73
Hypersensitivity,Immune_system_disorders,NCT00571649,https://clinicaltrials.gov/show/NCT00571649,Venous_Thromboembolism,Rivaroxaban_(Xarelto_BAY59-7939)|Enoxaparin|Rivaroxaban_placebo|Enoxaparin_placebo|,2,4001,serious_events,arm1,Enoxaparin,2,4001
Hypersensitivity,Immune_system_disorders,NCT00575588,https://clinicaltrials.gov/show/NCT00575588,Type_2_Diabetes,Metformin|Sulphonylurea|Saxagliptin|,2,858,serious_events,arm1,Glipizide + Metformin,1,430
Hypersensitivity,Immune_system_disorders,NCT00575588,https://clinicaltrials.gov/show/NCT00575588,Type_2_Diabetes,Metformin|Sulphonylurea|Saxagliptin|,2,858,serious_events,arm0,Saxagliptin + Metformin,1,428
Hypersensitivity,Immune_system_disorders,NCT00576901,https://clinicaltrials.gov/show/NCT00576901,Breast_Cancer,bevacizumab_[Avastin]|Docetaxel|Xeloda|,2,23,other_events,arm0,Bevacizumab+Docetaxel+Capecitabine,2,23
Hypersensitivity,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,7,394,other_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,4,197
Hypersensitivity,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,7,394,serious_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,3,197
Hypersensitivity,Immune_system_disorders,NCT00579501,https://clinicaltrials.gov/show/NCT00579501,LiposarcomaMyxoid,Trabectedin|Dexamethasone|,1,29,other_events,arm0,Trabectedin,1,29
Hypersensitivity,Immune_system_disorders,NCT00587990,https://clinicaltrials.gov/show/NCT00587990,Stem_Cell_Transplantation|Ventricular_Dysfunction_Left|,Lower_dose_mesenchymal_stem_cell_(MSC)_injection|Placebo|Higher_dose_MSC_injection|,1,3,serious_events,arm2,(3) Placebo Injection,1,3
Hypersensitivity,Immune_system_disorders,NCT00589563,https://clinicaltrials.gov/show/NCT00589563,Chronic_Myeloproliferative_Disorders|Graft_Versus_Host_Disease|Infection|Leukemia|Lymphoma|Multiple_Myeloma_and_Plasma_Cell_Neoplasm|Myelodysplastic_Syndromes|Myelodysplastic/Myeloproliferative_Neoplasms|Precancerous_Condition|Secondary_Myelofibrosis|Small_Intestine_Cancer|,anti-thymocyte_globulin|cyclophosphamide|etoposide|fludarabine_phosphate|melphalan|methotrexate|sirolimus|tacrolimus|allogeneic_hematopoietic_stem_cell_transplantation|hematopoietic_stem_cell_transplantation|nonmyeloablative_allogeneic_hematopoietic_stem_cell_transplantation|peripheral_blood_stem_cell_transplantation|total-body_irradiation|,3,31,other_events,arm0,All Patients,3,31
Hypersensitivity,Immune_system_disorders,NCT00589693,https://clinicaltrials.gov/show/NCT00589693,Ventilator-Associated_Pneumonia,Doripenem|Imipenem-Cilastatin|Placebo|,1,115,serious_events,arm0,Doripenem,1,115
Hypersensitivity,Immune_system_disorders,NCT00589979,https://clinicaltrials.gov/show/NCT00589979,Osteoarthritis_of_the_Knee,Lidoderm_(Lidocaine_5_PERCENT_Patch)|Placebo_Patch|,1,91,other_events,arm2,Double-Blind Active Treatment Period With Placebo,1,91
Hypersensitivity,Immune_system_disorders,NCT00594204,https://clinicaltrials.gov/show/NCT00594204,Smoking_Cessation,varenicline_tartrate_(CP-526_555-18)|Placebo|,1,390,serious_events,arm0,Varenicline,1,390
Hypersensitivity,Immune_system_disorders,NCT00594568,https://clinicaltrials.gov/show/NCT00594568,Alzheimer's_Disease,LY450139|Placebo|,1,507,serious_events,arm1,100 mg LY450139 - NT,1,507
Hypersensitivity,Immune_system_disorders,NCT00600756,https://clinicaltrials.gov/show/NCT00600756,Schizophrenic_Disorders,Quetiapine_XR|Risperidone|,1,402,serious_events,arm1,Risperidone,1,402
Hypersensitivity,Immune_system_disorders,NCT00602836,https://clinicaltrials.gov/show/NCT00602836,Leukemia|Lymphoma|,Rituximab|Cyclophosphamide|Lenalidomide|Pentostatin|,3,44,other_events,arm0,PCR-Lenalidomide,3,44
Hypersensitivity,Immune_system_disorders,NCT00603291,https://clinicaltrials.gov/show/NCT00603291,Obesity,Lorcaserin_10_mg_QD|Lorcaserin_10_mg_BID|Matching_Placebo|,1,252,serious_events,arm2,Matching Placebo,1,252
Hypersensitivity,Immune_system_disorders,NCT00603538,https://clinicaltrials.gov/show/NCT00603538,Carcinoma_Non-Small-Cell_Lung,CP-751871_+_carboplatin_+_paclitaxel,1,7,serious_events,arm1,CP-751871 10 mg/kg in Combination With Chemotherapy Agents,1,7
Hypersensitivity,Immune_system_disorders,NCT00603525,https://clinicaltrials.gov/show/NCT00603525,Arthritis_Rheumatoid,Ofatumumab|Placebo|,5,296,other_events,arm1,Ofatumumab 700 mg: DB and OL Periods,3,148
Hypersensitivity,Immune_system_disorders,NCT00603525,https://clinicaltrials.gov/show/NCT00603525,Arthritis_Rheumatoid,Ofatumumab|Placebo|,5,296,serious_events,arm1,Ofatumumab 700 mg: DB and OL Periods,2,148
Hypersensitivity,Immune_system_disorders,NCT00607048,https://clinicaltrials.gov/show/NCT00607048,Neoplasms,Paclitaxel_+_Carboplatin_+_CP-870893|Paclitaxel_+_Carboplatin_+_CP-870893|,2,12,serious_events,arm4,Schedule B - CP-870893 0.2 mg/kg (Escalation Cohort),1,6
Hypersensitivity,Immune_system_disorders,NCT00607048,https://clinicaltrials.gov/show/NCT00607048,Neoplasms,Paclitaxel_+_Carboplatin_+_CP-870893|Paclitaxel_+_Carboplatin_+_CP-870893|,2,12,other_events,arm4,Schedule B - CP-870893 0.2 mg/kg (Escalation Cohort),1,6
Hypersensitivity,Immune_system_disorders,NCT00609622,https://clinicaltrials.gov/show/NCT00609622,Colorectal_Neoplasms,sunitinib|mFOLFOX6|bevacizumab|mFOLFOX6|,7,189,other_events,arm1,Bevacizumab + mFOLFOX6,5,93
Hypersensitivity,Immune_system_disorders,NCT00609622,https://clinicaltrials.gov/show/NCT00609622,Colorectal_Neoplasms,sunitinib|mFOLFOX6|bevacizumab|mFOLFOX6|,7,189,other_events,arm0,Sunitinib + mFOLFOX6,2,96
Hypersensitivity,Immune_system_disorders,NCT00611455,https://clinicaltrials.gov/show/NCT00611455,Arthritis_Rheumatoid,ofatumumab|Placebo|,11,243,other_events,arm1,Ofatumumab 700 mg: DB and OL Periods,11,243
Hypersensitivity,Immune_system_disorders,NCT00615056,https://clinicaltrials.gov/show/NCT00615056,Colorectal_Neoplasms,Bevacizumab_(avastin)|FOLFIRI_(Irinotecan_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFIRI_(irinotecan_leucovorin_5-fluorouracil_[5FU])|Bevacizumab_(avastin)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|,7,122,other_events,arm1,Bevacizumab + FOLFIRI,1,51
Hypersensitivity,Immune_system_disorders,NCT00615056,https://clinicaltrials.gov/show/NCT00615056,Colorectal_Neoplasms,Bevacizumab_(avastin)|FOLFIRI_(Irinotecan_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFIRI_(irinotecan_leucovorin_5-fluorouracil_[5FU])|Bevacizumab_(avastin)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|,7,122,other_events,arm2,Axitinib + FOLFOX,5,36
Hypersensitivity,Immune_system_disorders,NCT00615056,https://clinicaltrials.gov/show/NCT00615056,Colorectal_Neoplasms,Bevacizumab_(avastin)|FOLFIRI_(Irinotecan_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFIRI_(irinotecan_leucovorin_5-fluorouracil_[5FU])|Bevacizumab_(avastin)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|,7,122,other_events,arm3,Bevacizumab + FOLFOX,1,35
hypersensitivity,Immune_system_disorders,NCT00615550,https://clinicaltrials.gov/show/NCT00615550,Preterm_Delivery|Short_Cervix|Short_Uterine_Cervical_Length|,progesterone|placebo|,1,224,serious_events,arm0,Placebo,1,224
Hypersensitivity,Psychiatric_disorders,NCT00616928,https://clinicaltrials.gov/show/NCT00616928,Influenza,Influenza_A_(H5N1)_Virus_Monovalent_Vaccine_Adjuvanted|Placebo|,1,371,serious_events,arm3,Placebo >64Y Group,1,371
Hypersensitivity,Immune_system_disorders,NCT00617084,https://clinicaltrials.gov/show/NCT00617084,Coronary_Artery_Disease,Medtronic_Endeavor_Resolute|Abbott_Xience_V|,3,1152,serious_events,arm1,2. XIENCE V - 12-13 Months,3,1152
Hypersensitivity,Immune_system_disorders,NCT00617773,https://clinicaltrials.gov/show/NCT00617773,Fallopian_Tube_Cancer|Ovarian_Cancer|Primary_Peritoneal_Cancer|,hu3S193,3,31,other_events,arm0,hu3S193,3,31
Hypersensitivity,Immune_system_disorders,NCT00617669,https://clinicaltrials.gov/show/NCT00617669,Prostate_Cancer,Docetaxel|ZD4054|Placebo|,2,1047,serious_events,arm0,ZD4054 + Docetaxel,1,522
Hypersensitivity,Immune_system_disorders,NCT00617669,https://clinicaltrials.gov/show/NCT00617669,Prostate_Cancer,Docetaxel|ZD4054|Placebo|,2,1047,serious_events,arm1,Placebo + Docetaxel,1,525
Hypersensitivity,Immune_system_disorders,NCT00621504,https://clinicaltrials.gov/show/NCT00621504,Bacterial_Pneumonia,Ceftaroline_fosamil_for_Injection|IV_Ceftriaxone|Placebo|Clarithromycin|,1,308,serious_events,arm1,IV Ceftriaxone,1,308
Hypersensitivity,Immune_system_disorders,NCT00622388,https://clinicaltrials.gov/show/NCT00622388,Lymphoma_Large-Cell_Diffuse,Ofatumumab,6,81,other_events,arm0,Ofatumumab,6,81
HYPERSENSITIVITY,Immune_system_disorders,NCT00622713,https://clinicaltrials.gov/show/NCT00622713,Alzheimer's_Disease,Rivastigmine_transdermal_patch,1,218,serious_events,arm0,Rivastigmine Transdermal Patch,1,218
Hypersensitivity,Immune_system_disorders,NCT00623727,https://clinicaltrials.gov/show/NCT00623727,Hemophilia_A,rFVIII-FS/pegylated_liposomes_(BAY79-4980)|rFVIII-FS/WFI_(BAY14-2222)|,1,67,serious_events,arm0,rFVIII-FS/Pegylated Liposomes (BAY79-4980) - Double Blind,1,67
Hypersensitivity,Immune_system_disorders,NCT00623766,https://clinicaltrials.gov/show/NCT00623766,Melanoma,Ipilimumab|Corticosteroid:_Betamethasone|Corticosteroid:_Dexamethasone|Corticosteroid:_Fludrocortisone|Corticosteroid:_Hydrocortisone|Corticosteroid:_Meprednisone|Corticosteroid:_Methylprednisolone|Corticosteroid:_Prednisolone|Corticosteroid:_Prednisone|Corticosteroid:_Triamcinolone|,1,21,serious_events,arm0,Ipilimumab 10 mg/kg IV in Corticosteroid-dependent Patients,1,21
Hypersensitivity,Immune_system_disorders,NCT00625183,https://clinicaltrials.gov/show/NCT00625183,Colorectal_Cancer,selenomethionine|capecitabine|oxaliplatin|laboratory_biomarker_analysis|pharmacological_study|adjuvant_therapy|neoadjuvant_therapy|therapeutic_conventional_surgery|radiation_therapy|,1,5,other_events,arm0,Capecitabine Oxaliplatin Selenomethionine and Radiation Ther,1,5
Hypersensitivity,Immune_system_disorders,NCT00625404,https://clinicaltrials.gov/show/NCT00625404,HIV_Infections,Truvada|Placebo|,10,2058,other_events,arm0,Truvada Arm,8,1025
Hypersensitivity,Immune_system_disorders,NCT00625404,https://clinicaltrials.gov/show/NCT00625404,HIV_Infections,Truvada|Placebo|,10,2058,other_events,arm1,Placebo Arm,2,1033
HYPERSENSITIVITY,Immune_system_disorders,NCT00627042,https://clinicaltrials.gov/show/NCT00627042,Hepatocellular_Carcinoma,Ramucirumab_(IMC-1121B),1,42,serious_events,arm0,Ramucirumab (IMC-1121B),1,42
Hypersensitivity,Immune_system_disorders,NCT00627523,https://clinicaltrials.gov/show/NCT00627523,Infant_Small_for_Gestational_Age,Genotropin_(PN-180307)_Somatropin|Control-no_treatment|,1,21,other_events,arm0,Genotropinå¨,1,21
Hypersensitivity,Immune_system_disorders,NCT00628901,https://clinicaltrials.gov/show/NCT00628901,Leiomyoma|Uterine_Fibroids|Uterine_Neoplasms|Menorrhagia|Leiomyomatosis|,Uterine_Fibroid_Embolization_(UFE)|Contour_SE‰ã¢_Microspheres|Embosphereå¨_Microspheres|,2,30,other_events,arm1,Embosphere Microspheres,2,30
hypersensitivity,Immune_system_disorders,NCT00631189,https://clinicaltrials.gov/show/NCT00631189,Type_IIa_and_IIb_Hypercholesterolaemia,Rosuvastatin|Pravastatin|Atorvastatin|,1,317,other_events,arm0,Initial Phase,1,317
Hypersensitivity,Immune_system_disorders,NCT00631410,https://clinicaltrials.gov/show/NCT00631410,Colorectal_Neoplasms,sunitinib_+_mFOLFOX6|sunitinib_+_mFOLFOX6|,1,6,other_events,arm0,Treatment Arm A 37.5 mg/Day (4/2),1,6
Hypersensitivity,Immune_system_disorders,NCT00632463,https://clinicaltrials.gov/show/NCT00632463,Upper_Respiratory_Tract_Infection|Lower_Respiratory_Tract_Infection|,RI-001|RI-001|RI-001|,1,7,other_events,arm0,1 (High Dose),1,7
HYPERSENSITIVITY,Immune_system_disorders,NCT00633464,https://clinicaltrials.gov/show/NCT00633464,Triple_Negative_Locally_Advanced_Non-resectable_Breast_Cancer|Metastatic_Breast_Cancer|,ixabepilone|ixabepilone_+_cetuximab|,4,77,other_events,arm0,Ixabepilone 40 mg/m^2,2,40
HYPERSENSITIVITY,Immune_system_disorders,NCT00633464,https://clinicaltrials.gov/show/NCT00633464,Triple_Negative_Locally_Advanced_Non-resectable_Breast_Cancer|Metastatic_Breast_Cancer|,ixabepilone|ixabepilone_+_cetuximab|,4,77,other_events,arm1,Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2,2,37
Hypersensitivity,Immune_system_disorders,NCT00632749,https://clinicaltrials.gov/show/NCT00632749,Leukemia_Myeloid_Acute,BI_811283_(d_1_and_15)|Cytarabine|BI_811283_(d1)|Cytarabine|,2,11,other_events,arm5,120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,1,7
Hypersensitivity,Immune_system_disorders,NCT00632749,https://clinicaltrials.gov/show/NCT00632749,Leukemia_Myeloid_Acute,BI_811283_(d_1_and_15)|Cytarabine|BI_811283_(d1)|Cytarabine|,2,11,other_events,arm7,40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,1,4
Hypersensitivity,Immune_system_disorders,NCT00635154,https://clinicaltrials.gov/show/NCT00635154,Multiple_Myeloma_and_Plasma_Cell_Neoplasm,Anakinra_(IL-1Ra)|Dexamethasone_acetate|,3,54,other_events,arm0,Anakinra With/Without Dexamethasone,3,54
Hypersensitivity,Immune_system_disorders,NCT00636168,https://clinicaltrials.gov/show/NCT00636168,High_Risk_Stage_III_Melanoma,ipilimumab|Placebo|,3,471,serious_events,arm0,Ipilimumab 10mg/kg,3,471
Hypersensitivity,Immune_system_disorders,NCT00641537,https://clinicaltrials.gov/show/NCT00641537,Relapsing-Remitting_Multiple_Sclerosis,Cladribine|Placebo|Cladribine|Cladribine|Placebo|,1,17,other_events,arm6,Cladribine 3.5 mg/kg/No Treatment,1,17
HYPERSENSITIVITY,Immune_system_disorders,NCT00643201,https://clinicaltrials.gov/show/NCT00643201,Venous_Thrombosis,Enoxaparin|warfarin|Placebo_for_apixaban|Placebo_for_enoxaparin|Placebo_for_warfarin|apixaban|,2,2676,serious_events,arm0,Apixaban,2,2676
Hypersensitivity,General_disorders,NCT00645333,https://clinicaltrials.gov/show/NCT00645333,Metastatic_Breast_Cancer,MK-0752_Docetaxel_Pegfilgrastim,2,30,serious_events,arm0,MK-0752,2,30
hypersensitivity,Immune_system_disorders,NCT00649389,https://clinicaltrials.gov/show/NCT00649389,Hypertension,Olmesartan_medoxomil|Amlodipine|Hydrochlorothiazide|,1,596,serious_events,arm0,OM40/AML10,1,596
Hypersensitivity,Immune_system_disorders,NCT00657709,https://clinicaltrials.gov/show/NCT00657709,Serogroup_B_Meningococcal_Meningitis,Serogroup_B_meningococcal_Vaccine_lot_1_(rMenB_Lot_1)|Serogroup_B_meningococcal_Vaccine_lot_2_(rMenB_Lot_2)|Serogroup_B_meningococcal_Vaccine_lot_3_(rMenB_Lot_3)|Infanrix_Hexa|Menjugate|Prevenar|,1,820,serious_events,arm2,rMenB Lot3,1,820
Hypersensitivity,Immune_system_disorders,NCT00661999,https://clinicaltrials.gov/show/NCT00661999,Anemia|Leukemia|Lymphoma|Lymphoproliferative_Disorder|Multiple_Myeloma_and_Plasma_Cell_Neoplasm|Precancerous_Condition|Unspecified_Adult_Solid_Tumor_Protocol_Specific|,darbepoetin_alfa|ferrous_sulfate|sodium_ferric_gluconate_complex_in_sucrose|placebo|,1,164,other_events,arm0,DA + IV Iron,1,164
Hypersensitivity,Immune_system_disorders,NCT00662831,https://clinicaltrials.gov/show/NCT00662831,Diabetic_Foot_Ulcer,Fragmin/_Dalteparin_Sodium|Placebo_for_Fragmin/_Dalteparin_Sodium|,1,184,other_events,arm0,Dalteparin,1,184
Hypersensitivity,Immune_system_disorders,NCT00666224,https://clinicaltrials.gov/show/NCT00666224,Multiple_Sclerosis,Glatiramer_Acetate_(DB)|Placebo|Glatiramer_Acetate_(OL)|,3,697,serious_events,arm2,Glatiramer Acetate (Entire Study),2,454
Hypersensitivity,Immune_system_disorders,NCT00666224,https://clinicaltrials.gov/show/NCT00666224,Multiple_Sclerosis,Glatiramer_Acetate_(DB)|Placebo|Glatiramer_Acetate_(OL)|,3,697,serious_events,arm1,Glatiramer Acetate (Double-blind Period),1,243
Hypersensitivity,Immune_system_disorders,NCT00669578,https://clinicaltrials.gov/show/NCT00669578,Chronic_Myeloproliferative_Disorders|Secondary_Myelofibrosis|,CC-4047,2,130,other_events,arm0,Phase II,1,65
Hypersensitivity,Immune_system_disorders,NCT00669578,https://clinicaltrials.gov/show/NCT00669578,Chronic_Myeloproliferative_Disorders|Secondary_Myelofibrosis|,CC-4047,2,130,serious_events,arm0,Phase II,1,65
Hypersensitivity,Immune_system_disorders,NCT00673049,https://clinicaltrials.gov/show/NCT00673049,Carcinoma_Large_Cell|Carcinoma_Non-Small-Cell_Lung|Carcinoma_Squamous_Cell|Carcinoma_Adenosquamous_Cell|,CP_751871_(Figitumumab)|Erlotinib|Erlotinib|,6,578,other_events,arm0,Figitumumab + Erlotinib,5,289
Hypersensitivity,Immune_system_disorders,NCT00673049,https://clinicaltrials.gov/show/NCT00673049,Carcinoma_Large_Cell|Carcinoma_Non-Small-Cell_Lung|Carcinoma_Squamous_Cell|Carcinoma_Adenosquamous_Cell|,CP_751871_(Figitumumab)|Erlotinib|Erlotinib|,6,578,serious_events,arm0,Figitumumab + Erlotinib,1,289
Hypersensitivity,Immune_system_disorders,NCT00676520,https://clinicaltrials.gov/show/NCT00676520,Coronary_Artery_Disease,XIENCE_Vå¨_Everolimus_Eluting_Coronary_Stent,2,4952,serious_events,arm0,Subjects Receiving the XIENCE V EECSS,2,4952
Hypersensitivity,Immune_system_disorders,NCT00678535,https://clinicaltrials.gov/show/NCT00678535,Gastric_Cancer,Cetuximab|Capecitabine|Cisplatin|,4,446,serious_events,arm0,Cetuximab Plus Capecitabine Plus Cisplatin,4,446
Hypersensitivity,Immune_system_disorders,NCT00678392,https://clinicaltrials.gov/show/NCT00678392,Kidney_Neoplasms,Axitinib_(AG-013736)|Sorafenib|,1,359,serious_events,arm0,Axitinib,1,359
Hypersensitivity,Immune_system_disorders,NCT00679341,https://clinicaltrials.gov/show/NCT00679341,Breast_Cancer,Trastuzumab_emtansine_[Kadcyla]|Trastuzumab|Docetaxel|,1,66,serious_events,arm1,Trastuzumab + Docetaxel,1,66
Hypersensitivity,Immune_system_disorders,NCT00680186,https://clinicaltrials.gov/show/NCT00680186,Thromboembolism,Warfarin|Dabigatran_etexilate|,2,1288,serious_events,arm1,Warfarin,2,1288
Hypersensitivity,Immune_system_disorders,NCT00680901,https://clinicaltrials.gov/show/NCT00680901,Neoplasms_Gastrointestinal_Tract,Lapatinib|Placebo|Capecitabine|Oxaliplatin|,1,270,serious_events,arm0,CapeOx + Lapatinib,1,270
Hypersensitivity,Immune_system_disorders,NCT00681863,https://clinicaltrials.gov/show/NCT00681863,Tourette_Syndrome,pramipexole_0.125_mg_BID|pramipexole_0.0625_mg_QD|pramipexole_0.125_mg_TID|pramipexole_0.25_mg_BID|pramipexole_0.0625_mg_BID|,4,45,other_events,arm0,Pramipexole,4,45
Hypersensitivity,Immune_system_disorders,NCT00683800,https://clinicaltrials.gov/show/NCT00683800,Vasomotor_Symptoms,desvenlafaxine_succinate_(DVS)_SR|Placebo|,12,2118,other_events,arm0,DVS SR 100 mg,7,1066
Hypersensitivity,Immune_system_disorders,NCT00683800,https://clinicaltrials.gov/show/NCT00683800,Vasomotor_Symptoms,desvenlafaxine_succinate_(DVS)_SR|Placebo|,12,2118,other_events,arm1,Placebo,5,1052
Hypersensitivity,Immune_system_disorders,NCT00684307,https://clinicaltrials.gov/show/NCT00684307,Nonvalvular_Atrial_Fibrillation,AZD0837|Vitamin-K_antagonist_at_INR_2-3|AZD0837|,1,152,serious_events,arm1,AZD0837 300 mg od,1,152
Hypersensitivity,Immune_system_disorders,NCT00684983,https://clinicaltrials.gov/show/NCT00684983,HER2/Neu_Positive|Stage_IIIB_Breast_Cancer|Stage_IIIC_Breast_Cancer|Stage_IV_Breast_Cancer|,Capecitabine|Cixutumumab|Laboratory_Biomarker_Analysis|Lapatinib_Ditosylate|Quality-of-Life_Assessment|,3,64,other_events,arm0,Arm A,2,19
Hypersensitivity,Immune_system_disorders,NCT00684983,https://clinicaltrials.gov/show/NCT00684983,HER2/Neu_Positive|Stage_IIIB_Breast_Cancer|Stage_IIIC_Breast_Cancer|Stage_IV_Breast_Cancer|,Capecitabine|Cixutumumab|Laboratory_Biomarker_Analysis|Lapatinib_Ditosylate|Quality-of-Life_Assessment|,3,64,other_events,arm1,Arm B,1,45
Hypersensitivity,Immune_system_disorders,NCT00688545,https://clinicaltrials.gov/show/NCT00688545,Arthritis_Juvenile_Rheumatoid,Celecoxib|nsNSAIDs|,1,225,other_events,arm1,nsNSAIDs,1,225
Hypersensitivity,Immune_system_disorders,NCT00688740,https://clinicaltrials.gov/show/NCT00688740,Breast_Cancer,Docetaxel|5-fluorouracil|Doxorubicin|Cyclophosphamide|,107,2224,serious_events,arm0,TAC (Docetaxel),4,744
Hypersensitivity,Immune_system_disorders,NCT00688740,https://clinicaltrials.gov/show/NCT00688740,Breast_Cancer,Docetaxel|5-fluorouracil|Doxorubicin|Cyclophosphamide|,107,2224,other_events,arm0,TAC (Docetaxel),82,744
Hypersensitivity,Immune_system_disorders,NCT00688740,https://clinicaltrials.gov/show/NCT00688740,Breast_Cancer,Docetaxel|5-fluorouracil|Doxorubicin|Cyclophosphamide|,107,2224,other_events,arm1,FAC (5-fluorouracil),21,736
HYPERSENSITIVITY,Immune_system_disorders,NCT00689221,https://clinicaltrials.gov/show/NCT00689221,Glioblastoma,Cilengitide|Temozolomide|Radiotherapy|,1,263,serious_events,arm0,Cilengitide + Temozolomide + Radiotherapy,1,263
Hypersensitivity,Immune_system_disorders,NCT00690430,https://clinicaltrials.gov/show/NCT00690430,Symptomatic_Refractory_Resistant_Carcinoid_Disease,Pasireotide|Octreotide|,1,6,other_events,arm3,Extension Phase Octreotide LAR,1,6
Hypersensitivity,Immune_system_disorders,NCT00695396,https://clinicaltrials.gov/show/NCT00695396,Myelodysplastic_Syndromes|Anemia|,Placebo|Epoetin_alfa|Placebo|Epoetin_alfa|,1,8,other_events,arm1,Epoetin Alfa 40000 IU,1,8
Hypersensitivity,Immune_system_disorders,NCT00698451,https://clinicaltrials.gov/show/NCT00698451,Ovarian_Neoplasms|Fallopian_Tube_Neoplasms|Peritoneal_Neoplasms|,doxorubicin_HCL_liposome;_bevacizumab;_carboplatin,5,54,other_events,arm0,DOXIL/CARBOPLATIN/BEVACIZUMAB,5,54
Hypersensitivity,Immune_system_disorders,NCT00699374,https://clinicaltrials.gov/show/NCT00699374,Carcinoma_Hepatocellular,sunitinib_malate|sorafenib|,1,542,serious_events,arm1,Sorafenib,1,542
Hypersensitivity,Immune_system_disorders,NCT00699491,https://clinicaltrials.gov/show/NCT00699491,Male_Breast_Cancer|Recurrent_Breast_Cancer|Stage_IV_Breast_Cancer|,cixutumumab|temsirolimus|laboratory_biomarker_analysis|,2,25,other_events,arm5,Phase II,1,22
Hypersensitivity,Immune_system_disorders,NCT00699491,https://clinicaltrials.gov/show/NCT00699491,Male_Breast_Cancer|Recurrent_Breast_Cancer|Stage_IV_Breast_Cancer|,cixutumumab|temsirolimus|laboratory_biomarker_analysis|,2,25,other_events,arm0,Dose Level 1,1,3
Hypersensitivity,Immune_system_disorders,NCT00700180,https://clinicaltrials.gov/show/NCT00700180,Non-Small_Cell_Lung_Cancer,bevacizumab_[Avastin]|bevacizumab_[Avastin]|Carboplatin-based_chemotherapy|,1,143,serious_events,arm1,Bevacizumab 15 mg Plus Chemotherapy,1,143
Hypersensitivity,Immune_system_disorders,NCT00700102,https://clinicaltrials.gov/show/NCT00700102,Colorectal_Cancer,Chemotherapy|Bevacizumab|,2,810,serious_events,arm1,Chemotherapy + Bevacizumab,1,401
Hypersensitivity,Immune_system_disorders,NCT00700102,https://clinicaltrials.gov/show/NCT00700102,Colorectal_Cancer,Chemotherapy|Bevacizumab|,2,810,serious_events,arm0,Chemotherapy,1,409
Hypersensitivity,Immune_system_disorders,NCT00699998,https://clinicaltrials.gov/show/NCT00699998,Acute_Coronary_Syndrome,Clopidogrel|Prasugrel|Commercially-available_Aspirin|,1,4617,serious_events,arm1,Clopidogrel,1,4617
hypersensitivity,Immune_system_disorders,NCT00702754,https://clinicaltrials.gov/show/NCT00702754,Cervical_Dystonia,Botulinum_Toxin_Type_B,1,502,serious_events,arm0,MYOBLOC Open Label Treatment,1,502
Hypersensitivity,Immune_system_disorders,NCT00703326,https://clinicaltrials.gov/show/NCT00703326,Breast_Cancer,ramucirumab_(IMC-1121B)|docetaxel|Placebo|,7,1134,serious_events,arm0,Ramucirumab (IMC-1121B) + Docetaxel,4,752
Hypersensitivity,Immune_system_disorders,NCT00703326,https://clinicaltrials.gov/show/NCT00703326,Breast_Cancer,ramucirumab_(IMC-1121B)|docetaxel|Placebo|,7,1134,serious_events,arm1,Placebo + Docetaxel,3,382
Hypersensitivity,Immune_system_disorders,NCT00704028,https://clinicaltrials.gov/show/NCT00704028,Anemia,Ferric_Carboxymaltose|Iron_Dextran|,8,156,serious_events,arm1,Iron Dextran,1,78
Hypersensitivity,Immune_system_disorders,NCT00704028,https://clinicaltrials.gov/show/NCT00704028,Anemia,Ferric_Carboxymaltose|Iron_Dextran|,8,156,other_events,arm1,Iron Dextran,7,78
Hypersensitivity,Immune_system_disorders,NCT00704730,https://clinicaltrials.gov/show/NCT00704730,Thyroid_Cancer,XL184|Placebo|,1,214,serious_events,arm0,XL184 (Cabozantinib),1,214
Hypersensitivity,Immune_system_disorders,NCT00704847,https://clinicaltrials.gov/show/NCT00704847,Osteoarthritis,Oral_Salmon_Calcitonin|Oral_Salmon_Calcitonin_(Placebo)|,2,508,serious_events,arm1,SMC021 Placebo,2,508
HYPERSENSITIVITY,Immune_system_disorders,NCT00706342,https://clinicaltrials.gov/show/NCT00706342,Purpura_Thrombocytopenic_Idiopathic,Fostamatinib_Disodium_/_R935788,1,18,other_events,arm0,R788 PO,1,18
Hypersensitivity,Immune_system_disorders,NCT00706797,https://clinicaltrials.gov/show/NCT00706797,Rheumatoid_Arthritis,etanercept_(EnbrelTM)|methotrexate|,1,71,other_events,arm1,ETN + MTX,1,71
Hypersensitivity,Immune_system_disorders,NCT00711828,https://clinicaltrials.gov/show/NCT00711828,Extranodal_Marginal_Zone_Lymphoma_of_Mucosa-Associated_Lymphoid_Tissue|Nodal_Marginal_Zone_Lymphoma|Recurrent_Grade_1_Follicular_Lymphoma|Recurrent_Grade_2_Follicular_Lymphoma|Recurrent_Mantle_Cell_Lymphoma|Recurrent_Small_Lymphocytic_Lymphoma|Refractory_Chronic_Lymphocytic_Leukemia|Splenic_Marginal_Zone_Lymphoma|Waldenstrom_Macroglobulinemia|,Bortezomib|Rituximab|Cyclophosphamide|Dexamethasone|Questionnaire_Administration|Quality-of-Life_Assessment|,1,21,other_events,arm0,Treatment,1,21
Hypersensitivity,Immune_system_disorders,NCT00712725,https://clinicaltrials.gov/show/NCT00712725,Migraine,MK3207-_2.5_mg|MK3207-_5_mg|MK3207-_10_mg|MK3207-_20_mg|MK3207-_50_mg|MK3207-_100_mg|Comparator:_placebo_(unspecified)|,1,142,serious_events,arm0,Placebo,1,142
Hypersensitivity,Immune_system_disorders,NCT00714493,https://clinicaltrials.gov/show/NCT00714493,Rheumatoid_Arthritis,Infliximab,1,203,serious_events,arm0,Infliximab,1,203
Hypersensitivity,Immune_system_disorders,NCT00715403,https://clinicaltrials.gov/show/NCT00715403,Neoplasms,BIBF_1120,1,6,other_events,arm4,200mg BID,1,6
Hypersensitivity,Immune_system_disorders,NCT00715884,https://clinicaltrials.gov/show/NCT00715884,Coronary_Artery_Disease|Coronary_Atherosclerosis|,CYPHERå¨_ELITE‰ã¢_Sirolimus-Eluting_Stent_System|CYPHERå¨_Bx_VELOCITYå¨_Sirolimus-eluting_Stent_System|,7,678,other_events,arm0,ELITE‰ã¢,6,452
Hypersensitivity,Immune_system_disorders,NCT00715884,https://clinicaltrials.gov/show/NCT00715884,Coronary_Artery_Disease|Coronary_Atherosclerosis|,CYPHERå¨_ELITE‰ã¢_Sirolimus-Eluting_Stent_System|CYPHERå¨_Bx_VELOCITYå¨_Sirolimus-eluting_Stent_System|,7,678,other_events,arm1,CYPHERå¨,1,226
Hypersensitivity,Immune_system_disorders,NCT00717522,https://clinicaltrials.gov/show/NCT00717522,Soft_Tissue_Sarcoma,Pomalidomide,1,7,other_events,arm0,Pomalidomide,1,7
Hypersensitivity,Immune_system_disorders,NCT00719563,https://clinicaltrials.gov/show/NCT00719563,Chronic_Myeloproliferative_Disorders|Fatigue|Leukemia|Lymphoma|Lymphoproliferative_Disorder|Multiple_Myeloma_and_Plasma_Cell_Neoplasm|Myelodysplastic_Syndromes|Myelodysplastic/Myeloproliferative_Neoplasms|Precancerous_Condition|Unspecified_Adult_Solid_Tumor_Protocol_Specific|,American_ginseng|placebo|,1,168,other_events,arm0,Ginseng,1,168
Hypersensitivity,Immune_system_disorders,NCT00719901,https://clinicaltrials.gov/show/NCT00719901,Refractory_Multiple_Myeloma|Stage_I_Multiple_Myeloma|Stage_II_Multiple_Myeloma|Stage_III_Multiple_Myeloma|,obatoclax_mesylate|bortezomib|laboratory_biomarker_analysis|,1,10,other_events,arm0,Treatment (Enzyme Inhibitor Therapy),1,10
Hypersensitivity,Immune_system_disorders,NCT00721396,https://clinicaltrials.gov/show/NCT00721396,Meningococcal_Infections,rMenB+OMV_NZ|combined_diphtheriatetanuspertussis+polio+Hepatitis_B+Haemophilus_influenzae_B_vaccine|Pneumococcal_vaccine|,1,312,serious_events,arm3,R234,1,312
Hypersensitivity,Immune_system_disorders,NCT00722371,https://clinicaltrials.gov/show/NCT00722371,Type_2_Diabetes_Mellitus,Sitagliptin_phosphate|Pioglitazone_hydrochloride|Matching_placebo_to_sitagliptin|Matching_placebo_to_pioglitazone|Metformin|,1,231,serious_events,arm5,Sitagliptin 100 mg/ Pioglitazone 30 mg,1,231
Hypersensitivity,Immune_system_disorders,NCT00723203,https://clinicaltrials.gov/show/NCT00723203,Leukemia,panobinostat|gene_expression_analysis|reverse_transcriptase-polymerase_chain_reaction|laboratory_biomarker_analysis|,1,16,other_events,arm0,Treatment (Panobinostat),1,16
HYPERSENSITIVITY,Immune_system_disorders,NCT00723957,https://clinicaltrials.gov/show/NCT00723957,Advanced/Metastatic_Non-Small_Cell_Lung_Cancer,Ixabepilone_32_mg/m^2|Paclitaxel_200_mg/m^2|Carboplatin_(area_under_the_concentration_curve_[AUC]_6)|,8,191,other_events,arm1,Paclitaxel 200 mg/m^2 + Carboplatin (AUC 6),6,96
HYPERSENSITIVITY,Immune_system_disorders,NCT00723957,https://clinicaltrials.gov/show/NCT00723957,Advanced/Metastatic_Non-Small_Cell_Lung_Cancer,Ixabepilone_32_mg/m^2|Paclitaxel_200_mg/m^2|Carboplatin_(area_under_the_concentration_curve_[AUC]_6)|,8,191,other_events,arm0,Ixabepilone 32 mg/m^2 + Carboplatin (AUC),2,95
Hypersensitivity,Immune_system_disorders,NCT00725985,https://clinicaltrials.gov/show/NCT00725985,Multiple_Sclerosis,Cladribine|Cladribine|Placebo|Rebifå¨_new_formulation_(RNF)|,1,16,other_events,arm8,Placebo Rebif Cladribine 3.5 mg/kg (LTFU),1,16
Hypersensitivity,Immune_system_disorders,NCT00726453,https://clinicaltrials.gov/show/NCT00726453,Coronary_Artery_Disease,Resolute_Zotarolimus-Eluting_Coronary_Stent,1,1402,serious_events,arm0,Primary Enrollment Group,1,1402
HYPERSENSITIVITY,Immune_system_disorders,NCT00727311,https://clinicaltrials.gov/show/NCT00727311,Hepatitis_C_Chronic|Hepatitis_C|,PegIntron_(peginterferon_alfa-2b;_SCH_54031)_injector|Rebetol_(ribavirin;_SCH_18908)|,2,2302,serious_events,arm0,All Participants,2,2302
Hypersensitivity,Immune_system_disorders,NCT00737061,https://clinicaltrials.gov/show/NCT00737061,Reproductive_Sterilization,Adiana_Transcervical_Sterilization_System,44,645,other_events,arm0,Adiana Permanent Contraception System,44,645
Hypersensitivity,Immune_system_disorders,NCT00738374,https://clinicaltrials.gov/show/NCT00738374,Lymphocytic_Leukemia_Chronic,rituximab_[MabThera/Rituxan]|chlorambucil|,2,131,other_events,arm1,CLB + R: Maintenance Treatment,1,34
Hypersensitivity,Immune_system_disorders,NCT00738374,https://clinicaltrials.gov/show/NCT00738374,Lymphocytic_Leukemia_Chronic,rituximab_[MabThera/Rituxan]|chlorambucil|,2,131,other_events,arm0,CLB + R: Induction Treatment,1,97
Hypersensitivity,Immune_system_disorders,NCT00739934,https://clinicaltrials.gov/show/NCT00739934,Candidiasis|Candidemia|,voriconazole_(Vfend),1,40,other_events,arm0,Voriconazole IV,1,40
Hypersensitivity,Immune_system_disorders,NCT00744757,https://clinicaltrials.gov/show/NCT00744757,Myelodysplastic_Syndrome,Decitabine,2,37,other_events,arm0,Decitabine,2,37
Hypersensitivity,Immune_system_disorders,NCT00750880,https://clinicaltrials.gov/show/NCT00750880,Rheumatoid_Arthritis,tocilizumab_[RoActemra/Actemra],2,1681,serious_events,arm0,Tocilizumab 8 mg/kg,2,1681
Hypersensitivity,Immune_system_disorders,NCT00751400,https://clinicaltrials.gov/show/NCT00751400,Pain,Naproxen_Sodium_ER_(BAYH6689),1,485,other_events,arm0,Naproxen Sodium ER (BAYH6689),1,485
Hypersensitivity,Immune_system_disorders,NCT00753272,https://clinicaltrials.gov/show/NCT00753272,Influenza,GSK_Bio's_influenza_vaccine_GSK2186877A|Fluarix_TM|,12,43695,serious_events,arm1,Fluarix Group,5,21802
Hypersensitivity,Immune_system_disorders,NCT00753272,https://clinicaltrials.gov/show/NCT00753272,Influenza,GSK_Bio's_influenza_vaccine_GSK2186877A|Fluarix_TM|,12,43695,serious_events,arm0,FluNG Group,7,21893
Hypersensitivity,Immune_system_disorders,NCT00753688,https://clinicaltrials.gov/show/NCT00753688,Sarcoma_Soft_Tissue,PAZOPANIB|Placebo|,1,240,serious_events,arm1,Pazopanib,1,240
Hypersensitivity,Immune_system_disorders,NCT00754559,https://clinicaltrials.gov/show/NCT00754559,Rheumatoid_Arthritis,Tocilizumab,5,286,other_events,arm0,Tocilizumab,5,286
Hypersensitivity,Immune_system_disorders,NCT00754572,https://clinicaltrials.gov/show/NCT00754572,Rheumatoid_Arthritis,tocilizumab_[RoActemra/Actemra]|methotrexate|,1,418,serious_events,arm0,Tocilizumab,1,418
Hypersensitivity,Immune_system_disorders,NCT00757172,https://clinicaltrials.gov/show/NCT00757172,Adenocarcinoma_of_the_Gastroesophageal_Junction|Esophageal_Cancer|,panitumumab|cisplatin|docetaxel|neoadjuvant_therapy|therapeutic_conventional_surgery|radiation_therapy|,13,70,other_events,arm0,Docetaxel + Cisplatin + Panitumumab + RT,13,70
Hypersensitivity,Immune_system_disorders,NCT00757705,https://clinicaltrials.gov/show/NCT00757705,Schizophrenia,Paliperidone_ER,6,299,other_events,arm0,Paliperidone Extended Release (ER),6,299
HYPERSENSITIVITY,Immune_system_disorders,NCT00758043,https://clinicaltrials.gov/show/NCT00758043,Hepatitis_C,telaprevir|ribavirin|peginterferon_alfa-2a|,1,118,serious_events,arm2,T12PR48 (eRVR-),1,118
Hypersensitivity,Immune_system_disorders,NCT00762034,https://clinicaltrials.gov/show/NCT00762034,Non-small_Cell_Lung_Cancer,Pemetrexed|Pemetrexed|Paclitaxel|Carboplatin|Bevacizumab|Bevacizumab|,1,292,serious_events,arm1,Pem/Carbo/Bev; Maintenance Phase,1,292
Hypersensitivity,Immune_system_disorders,NCT00765102,https://clinicaltrials.gov/show/NCT00765102,Multiple_Myeloma,Bortezomib|Romidepsin|,1,32,serious_events,arm0,Romidepsin + Bortezomib,1,32
Hypersensitivity,Immune_system_disorders,NCT00765076,https://clinicaltrials.gov/show/NCT00765076,Influenza_Infection,GSK_Biologicals'_influenza_vaccine_GSK2186877A|GSK_Biologicals'_Fluarix|,1,50,serious_events,arm2,Fluarix Young Group,1,50
Hypersensitivity,Immune_system_disorders,NCT00770146,https://clinicaltrials.gov/show/NCT00770146,Hypercholesterolemia|Coronary_Heart_Disease|,Mipomersen_sodium|Placebo|,1,105,other_events,arm1,Mipomersen,1,105
Hypersensitivity,Immune_system_disorders,NCT00770315,https://clinicaltrials.gov/show/NCT00770315,Rhinitis_Allergic|Conjunctivitis|,Ambrosia_artemisiifolia_allergen_extract_(Amb_a_1-U)|Placebo|,1,194,serious_events,arm2,SCH 39641 12 Amb a 1-U,1,194
Hypersensitivity,Immune_system_disorders,NCT00770562,https://clinicaltrials.gov/show/NCT00770562,Idiopathic_Thrombocytopenic_Purpura,rituximab|Dexamethasone|,2,49,other_events,arm1,Arm B: Dexamethasone + Rituximab,2,49
Hypersensitivity,Immune_system_disorders,NCT00770809,https://clinicaltrials.gov/show/NCT00770809,HER2/Neu_Positive|Male_Breast_Carcinoma|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Stage_IIIB_Breast_Cancer|Stage_IIIC_Breast_Cancer|,Lapatinib_Ditosylate|Trastuzumab|Paclitaxel|Laboratory_Biomarker_Analysis|,35,525,other_events,arm2,Arm III (TL),8,65
Hypersensitivity,Immune_system_disorders,NCT00770809,https://clinicaltrials.gov/show/NCT00770809,HER2/Neu_Positive|Male_Breast_Carcinoma|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Stage_IIIB_Breast_Cancer|Stage_IIIC_Breast_Cancer|,Lapatinib_Ditosylate|Trastuzumab|Paclitaxel|Laboratory_Biomarker_Analysis|,35,525,other_events,arm0,Arm I (THL),11,115
Hypersensitivity,Immune_system_disorders,NCT00770809,https://clinicaltrials.gov/show/NCT00770809,HER2/Neu_Positive|Male_Breast_Carcinoma|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Stage_IIIB_Breast_Cancer|Stage_IIIC_Breast_Cancer|,Lapatinib_Ditosylate|Trastuzumab|Paclitaxel|Laboratory_Biomarker_Analysis|,35,525,serious_events,arm0,Arm I (THL),1,115
Hypersensitivity,Immune_system_disorders,NCT00770809,https://clinicaltrials.gov/show/NCT00770809,HER2/Neu_Positive|Male_Breast_Carcinoma|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Stage_IIIB_Breast_Cancer|Stage_IIIC_Breast_Cancer|,Lapatinib_Ditosylate|Trastuzumab|Paclitaxel|Laboratory_Biomarker_Analysis|,35,525,other_events,arm1,Arm II (TH),14,115
Hypersensitivity,Immune_system_disorders,NCT00770809,https://clinicaltrials.gov/show/NCT00770809,HER2/Neu_Positive|Male_Breast_Carcinoma|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Stage_IIIB_Breast_Cancer|Stage_IIIC_Breast_Cancer|,Lapatinib_Ditosylate|Trastuzumab|Paclitaxel|Laboratory_Biomarker_Analysis|,35,525,serious_events,arm1,Arm II (TH),1,115
Hypersensitivity,Immune_system_disorders,NCT00771810,https://clinicaltrials.gov/show/NCT00771810,Thrombocytopenia|Neutropenia|Lymphopenia|Anemia|,TXA127|TXA127|Placebo|,8,34,other_events,arm1,TXA127 100 ug/kg,1,11
Hypersensitivity,Immune_system_disorders,NCT00771810,https://clinicaltrials.gov/show/NCT00771810,Thrombocytopenia|Neutropenia|Lymphopenia|Anemia|,TXA127|TXA127|Placebo|,8,34,other_events,arm2,TXA127 300 ug/kg,2,13
Hypersensitivity,Immune_system_disorders,NCT00771810,https://clinicaltrials.gov/show/NCT00771810,Thrombocytopenia|Neutropenia|Lymphopenia|Anemia|,TXA127|TXA127|Placebo|,8,34,other_events,arm0,Placebo,5,10
Hypersensitivity,Immune_system_disorders,NCT00771927,https://clinicaltrials.gov/show/NCT00771927,Epilepsies_Partial,Lacosamide,1,493,other_events,arm1,Other AED,1,493
Hypersensitivity,Immune_system_disorders,NCT00777179,https://clinicaltrials.gov/show/NCT00777179,NSCLC,Vandetanib|Placebo|,5,42,other_events,arm1,Placebo,5,42
Hypersensitivity,Immune_system_disorders,NCT00777153,https://clinicaltrials.gov/show/NCT00777153,Recurrent_Glioblastoma,Cediranib|Cediranib|Lomustine_Chemotherapy|Placebo_Cediranib|,1,123,serious_events,arm1,Cediranib 20mg + Lomustine 110mg,1,123
Hypersensitivity,Immune_system_disorders,NCT00778102,https://clinicaltrials.gov/show/NCT00778102,Colorectal_Cancer,5-FU|5-FU|5-FU|Irinotecan|Leucovorin|Leucovorin|Oxaliplatin|bevacizumab_[Avastin]|,6,77,other_events,arm0,Bevacizumab + mFOLFOX-6,3,37
Hypersensitivity,Immune_system_disorders,NCT00778102,https://clinicaltrials.gov/show/NCT00778102,Colorectal_Cancer,5-FU|5-FU|5-FU|Irinotecan|Leucovorin|Leucovorin|Oxaliplatin|bevacizumab_[Avastin]|,6,77,other_events,arm1,Bevacizumab + FOLFOXIRI,3,40
HYPERSENSITIVITY,Immune_system_disorders,NCT00781391,https://clinicaltrials.gov/show/NCT00781391,Stroke|Atrial_Fibrillation|Embolism|,warfarin_tablets|Edoxaban_tablets_(high_dose_regimen-60mg)|Edoxaban_tablets_(low_dose_regimen-30mg)|placebo_warfarin|placebo_edoxaban|,5,21026,serious_events,arm1,High Dose Edoxaban/Placebo Warfarin,2,7012
HYPERSENSITIVITY,Immune_system_disorders,NCT00781391,https://clinicaltrials.gov/show/NCT00781391,Stroke|Atrial_Fibrillation|Embolism|,warfarin_tablets|Edoxaban_tablets_(high_dose_regimen-60mg)|Edoxaban_tablets_(low_dose_regimen-30mg)|placebo_warfarin|placebo_edoxaban|,5,21026,serious_events,arm0,Warfarin/Placebo Edoxaban,1,7012
HYPERSENSITIVITY,Immune_system_disorders,NCT00781391,https://clinicaltrials.gov/show/NCT00781391,Stroke|Atrial_Fibrillation|Embolism|,warfarin_tablets|Edoxaban_tablets_(high_dose_regimen-60mg)|Edoxaban_tablets_(low_dose_regimen-30mg)|placebo_warfarin|placebo_edoxaban|,5,21026,serious_events,arm2,Low Dose Edoxaban/Placebo Warfarin,2,7002
Hypersensitivity,Immune_system_disorders,NCT00784875,https://clinicaltrials.gov/show/NCT00784875,Primary_Insomnia|Secondary_Insomnia|,LY2624803|LY2624803|Placebo|zolpidem|,1,94,other_events,arm11,Period D - Zolpidem 5 or 10 mg,1,94
Hypersensitivity,Immune_system_disorders,NCT00785291,https://clinicaltrials.gov/show/NCT00785291,Estrogen_Receptor_Negative|Estrogen_Receptor_Positive|HER2/Neu_Negative|HER2/Neu_Positive|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Progesterone_Receptor_Positive|Recurrent_Breast_Carcinoma|Stage_IIIC_Breast_Cancer_AJCC_v6|Stage_IV_Breast_Cancer|,Paclitaxel|Paclitaxel_Albumin-Stabilized_Nanoparticle_Formulation|Ixabepilone|Bevacizumab|Questionnaire_Administration|Laboratory_Biomarker_Analysis|,75,1548,other_events,arm0,Arm A (Paclitaxel),23,272
Hypersensitivity,Immune_system_disorders,NCT00785291,https://clinicaltrials.gov/show/NCT00785291,Estrogen_Receptor_Negative|Estrogen_Receptor_Positive|HER2/Neu_Negative|HER2/Neu_Positive|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Progesterone_Receptor_Positive|Recurrent_Breast_Carcinoma|Stage_IIIC_Breast_Cancer_AJCC_v6|Stage_IV_Breast_Cancer|,Paclitaxel|Paclitaxel_Albumin-Stabilized_Nanoparticle_Formulation|Ixabepilone|Bevacizumab|Questionnaire_Administration|Laboratory_Biomarker_Analysis|,75,1548,serious_events,arm0,Arm A (Paclitaxel),3,272
Hypersensitivity,Immune_system_disorders,NCT00785291,https://clinicaltrials.gov/show/NCT00785291,Estrogen_Receptor_Negative|Estrogen_Receptor_Positive|HER2/Neu_Negative|HER2/Neu_Positive|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Progesterone_Receptor_Positive|Recurrent_Breast_Carcinoma|Stage_IIIC_Breast_Cancer_AJCC_v6|Stage_IV_Breast_Cancer|,Paclitaxel|Paclitaxel_Albumin-Stabilized_Nanoparticle_Formulation|Ixabepilone|Bevacizumab|Questionnaire_Administration|Laboratory_Biomarker_Analysis|,75,1548,serious_events,arm1,Arm B (Nab-paclitaxel),2,264
Hypersensitivity,Immune_system_disorders,NCT00785291,https://clinicaltrials.gov/show/NCT00785291,Estrogen_Receptor_Negative|Estrogen_Receptor_Positive|HER2/Neu_Negative|HER2/Neu_Positive|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Progesterone_Receptor_Positive|Recurrent_Breast_Carcinoma|Stage_IIIC_Breast_Cancer_AJCC_v6|Stage_IV_Breast_Cancer|,Paclitaxel|Paclitaxel_Albumin-Stabilized_Nanoparticle_Formulation|Ixabepilone|Bevacizumab|Questionnaire_Administration|Laboratory_Biomarker_Analysis|,75,1548,serious_events,arm2,Arm C (Ixabepilone),2,238
Hypersensitivity,Immune_system_disorders,NCT00785291,https://clinicaltrials.gov/show/NCT00785291,Estrogen_Receptor_Negative|Estrogen_Receptor_Positive|HER2/Neu_Negative|HER2/Neu_Positive|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Progesterone_Receptor_Positive|Recurrent_Breast_Carcinoma|Stage_IIIC_Breast_Cancer_AJCC_v6|Stage_IV_Breast_Cancer|,Paclitaxel|Paclitaxel_Albumin-Stabilized_Nanoparticle_Formulation|Ixabepilone|Bevacizumab|Questionnaire_Administration|Laboratory_Biomarker_Analysis|,75,1548,other_events,arm2,Arm C (Ixabepilone),17,238
Hypersensitivity,Immune_system_disorders,NCT00785291,https://clinicaltrials.gov/show/NCT00785291,Estrogen_Receptor_Negative|Estrogen_Receptor_Positive|HER2/Neu_Negative|HER2/Neu_Positive|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Progesterone_Receptor_Positive|Recurrent_Breast_Carcinoma|Stage_IIIC_Breast_Cancer_AJCC_v6|Stage_IV_Breast_Cancer|,Paclitaxel|Paclitaxel_Albumin-Stabilized_Nanoparticle_Formulation|Ixabepilone|Bevacizumab|Questionnaire_Administration|Laboratory_Biomarker_Analysis|,75,1548,other_events,arm1,Arm B (Nab-paclitaxel),28,264
Hypersensitivity,Immune_system_disorders,NCT00786643,https://clinicaltrials.gov/show/NCT00786643,Colorectal_Cancer,5-Fluorouracil|Leucovorin_(LV)|Gamma-Interferon-1b_(IFN-ë_)|Bevacizumab|,1,20,other_events,arm0,Stratum 1,1,20
Hypersensitivity,Immune_system_disorders,NCT00787891,https://clinicaltrials.gov/show/NCT00787891,Gastroesophageal_Reflux_Disease_(GERD),rabeprazole|rabeprazole|,1,62,other_events,arm1,Rabeprazole 1.0 mg/kg (Short-term Double-blinde Phase),1,62
Hypersensitivity,Immune_system_disorders,NCT00789685,https://clinicaltrials.gov/show/NCT00789685,Acute_Lung_Injury|Acute_Respiratory_Distress_Syndrome|,Interferon_Beta,1,37,serious_events,arm0,Safety Population,1,37
Hypersensitivity,Immune_system_disorders,NCT00789828,https://clinicaltrials.gov/show/NCT00789828,Tuberous_Sclerosis|Subependymal_Giant_Cell_Astrocytoma|,Everolimus|Placebo|,1,78,serious_events,arm0,Everolimus,1,78
Hypersensitivity,Immune_system_disorders,NCT00790218,https://clinicaltrials.gov/show/NCT00790218,Hepatocellular_Carcinoma,CF102,1,6,other_events,arm0,CF102 1mg,1,6
Hypersensitivity,Immune_system_disorders,NCT00790400,https://clinicaltrials.gov/show/NCT00790400,Tuberous_Sclerosis_Complex_(TSC)|Lymphangioleiomyomatosis_(LAM)|,Everolimus_(RAD001)|Placebo|,1,79,serious_events,arm0,Everolimus,1,79
Hypersensitivity,Immune_system_disorders,NCT00791492,https://clinicaltrials.gov/show/NCT00791492,Familial_Amyloid_Polyneuropathy|ATTR-PN|,Fx-1006A,1,44,serious_events,arm0,Tafamidis-Tafamidis,1,44
Hypersensitivity,Immune_system_disorders,NCT00796666,https://clinicaltrials.gov/show/NCT00796666,Pulmonary_Arterial_Hypertension|Pulmonary_Hypertension|,Sitaxsentan|Sitaxsentan_and_Sildenafil|,1,66,serious_events,arm0,Sitaxsentan and Placebo,1,66
Hypersensitivity,Immune_system_disorders,NCT00796991,https://clinicaltrials.gov/show/NCT00796991,Advanced_Melanoma,Ipilimumab|Carboplatin|Paclitaxel|Dacarbazine|,7,40,other_events,arm0,Paclitaxel Carboplatin Ipilimumab,6,20
Hypersensitivity,Immune_system_disorders,NCT00796991,https://clinicaltrials.gov/show/NCT00796991,Advanced_Melanoma,Ipilimumab|Carboplatin|Paclitaxel|Dacarbazine|,7,40,other_events,arm2,Ipilimumab,1,20
Hypersensitivity,Immune_system_disorders,NCT00798707,https://clinicaltrials.gov/show/NCT00798707,Major_Depressive_Disorder,Desvenlafaxine_Succinate_Sustained-Release_(DVS_SR)|Desvenlafaxine_Succinate_Sustained-Release_(DVS_SR)|placebo|,1,232,other_events,arm1,DVS SR 25 mg,1,232
Hypersensitivity,Immune_system_disorders,NCT00800683,https://clinicaltrials.gov/show/NCT00800683,Diabetes_Mellitus_Type_2,BI_1356|placebo|,1,65,serious_events,arm0,Placebo,1,65
Hypersensitivity,Immune_system_disorders,NCT00802737,https://clinicaltrials.gov/show/NCT00802737,Leukaemia_Lymphocytic_Chronic,Ofatumumab,2,17,other_events,arm0,2000 mg Ofatumumab + DR,2,17
Hypersensitivity,Immune_system_disorders,NCT00805194,https://clinicaltrials.gov/show/NCT00805194,Carcinoma_Non-Small-Cell_Lung,placebo_plus_docetaxel|BIBF_1120_plus_docetaxel|,3,655,serious_events,arm1,Placebo Plus Docetaxel,3,655
Hypersensitivity,Immune_system_disorders,NCT00809965,https://clinicaltrials.gov/show/NCT00809965,Acute_Coronary_Syndrome|Myocardial_Infarction|Myocardial_Ischemia|Unstable_Angina|,Rivaroxaban_2.5_mg|Rivaroxaban_5_mg|Placebo|Standard_of_care|,2,10225,serious_events,arm1,Rivaroxaban 2.5 mg Bid,1,5115
Hypersensitivity,Immune_system_disorders,NCT00809965,https://clinicaltrials.gov/show/NCT00809965,Acute_Coronary_Syndrome|Myocardial_Infarction|Myocardial_Ischemia|Unstable_Angina|,Rivaroxaban_2.5_mg|Rivaroxaban_5_mg|Placebo|Standard_of_care|,2,10225,serious_events,arm2,Rivaroxaban 5 mg Bid,1,5110
Hypersensitivity,Immune_system_disorders,NCT00811954,https://clinicaltrials.gov/show/NCT00811954,HIV_Infection,Emtricitabine/tenofovir_disoproxil_fumarate|Raltegravir|Darunavir|Ritonavir|Atazanavir|,1,603,serious_events,arm1,Arm B: RAL + FTC/TDF,1,603
Hypersensitivity,Immune_system_disorders,NCT00816595,https://clinicaltrials.gov/show/NCT00816595,Leukemia|Lymphoma|,bevacizumab|pegfilgrastim|rituximab|cyclophosphamide|pentostatin|,2,66,other_events,arm1,Arm B: Pentostatin Cyclophosphamide and Rituximab,1,33
Hypersensitivity,Immune_system_disorders,NCT00816595,https://clinicaltrials.gov/show/NCT00816595,Leukemia|Lymphoma|,bevacizumab|pegfilgrastim|rituximab|cyclophosphamide|pentostatin|,2,66,other_events,arm0,Arm A: Pentostatin Cyclophosphamide Rituximab and Avastin,1,33
Hypersensitivity,Immune_system_disorders,NCT00818207,https://clinicaltrials.gov/show/NCT00818207,Smoking_Cessation|Insurance_Coverage|,Full_Smoking_Cessation_Treatment_Coverage_(100_PERCENT)|No_Smoking_Cessation_Treatment_Coverage_(0_PERCENT)|,1,696,serious_events,arm0,Reimbursement for Smoking Cessation Therapy (SCT),1,696
Hypersensitivity,Immune_system_disorders,NCT00819247,https://clinicaltrials.gov/show/NCT00819247,Prostate_Cancer,Degarelix,1,46,serious_events,arm1,Degarelix 40/40 + 40,1,46
hypersensitivity,Immune_system_disorders,NCT00819234,https://clinicaltrials.gov/show/NCT00819234,Obesity,Placebo|Pramlintide_and_Metreleptin|,1,14,other_events,arm5,360 mcg Pramlintide + 2.5 mg Metreleptin - Prior Mono+2.5,1,14
Hypersensitivity,Immune_system_disorders,NCT00819780,https://clinicaltrials.gov/show/NCT00819780,Colon_Cancer|Colorectal_Cancer|Rectal_Cancer|Metastatic_Colorectal_Cancer|,Panitumumab|Bevacizumab|mFOLFOX6|,1,139,serious_events,arm0,Panitumumab Plus mFOLFOX6,1,139
Hypersensitivity,Immune_system_disorders,NCT00820755,https://clinicaltrials.gov/show/NCT00820755,Non-Small_Cell_Lung_Cancer_(NSCLC),Cetuximab_plus_Platinum-based_Doublet_Chemotherapy|Cetuximab_500_mg/m^2|Cetuximab_250_mg/m^2|,2,583,serious_events,arm0,Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy,2,583
Hypersensitivity,Immune_system_disorders,NCT00822900,https://clinicaltrials.gov/show/NCT00822900,Traumatic_Brain_Injury,Progesterone,1,442,other_events,arm0,Progesterone,1,442
Hypersensitivity,Immune_system_disorders,NCT00823979,https://clinicaltrials.gov/show/NCT00823979,HIV-1,UK-453061_Dose_1|UK-453061_Dose_2|Etravirine|,1,34,other_events,arm2,Etravirine 200 mg,1,34
Hypersensitivity,Immune_system_disorders,NCT00824421,https://clinicaltrials.gov/show/NCT00824421,HIV-1,UK-453_061|UK-453_061|EFV_+TVA|,1,65,serious_events,arm0,Lersivirine 500 mg,1,65
Hypersensitivity,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,25,1438,serious_events,arm2,Platinum Pemetrexed Cetuximab (Arm C),2,130
Hypersensitivity,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,25,1438,serious_events,arm1,Platinum Gemcitabine Cetuximab (Arm B),2,236
Hypersensitivity,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,25,1438,other_events,arm0,Paclitaxel Carboplatin Cetuximab (Arm A),10,235
Hypersensitivity,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,25,1438,other_events,arm1,Platinum Gemcitabine Cetuximab (Arm B),4,236
Hypersensitivity,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,25,1438,serious_events,arm0,Paclitaxel Carboplatin Cetuximab (Arm A),4,235
Hypersensitivity,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,25,1438,other_events,arm2,Platinum Pemetrexed Cetuximab (Arm C),2,130
Hypersensitivity,Immune_system_disorders,NCT00829166,https://clinicaltrials.gov/show/NCT00829166,Breast_Cancer,Trastuzumab_emtansine_[Kadcyla]|Lapatinib|Capecitabine|,1,490,serious_events,arm0,Trastuzumab Emtansine,1,490
Hypersensitivity,Immune_system_disorders,NCT00834678,https://clinicaltrials.gov/show/NCT00834678,Breast_Cancer,bendamustine|erlotinib|Maintenance_erlotinib|,2,11,other_events,arm0,Bendamustine and Erlotinib,2,11
Hypersensitivity,Immune_system_disorders,NCT00838513,https://clinicaltrials.gov/show/NCT00838513,Atypical_Hemolytic_Uremic_Syndrome,eculizumab,4,20,other_events,arm0,Eculizumab,4,20
Hypersensitivity,Immune_system_disorders,NCT00838578,https://clinicaltrials.gov/show/NCT00838578,Colorectal_Cancer,KRN330|Irinotecan|,2,44,other_events,arm2,Phase 2: KRN330 Weekly + IRI Biweekly,2,44
Hypersensitivity,Immune_system_disorders,NCT00838903,https://clinicaltrials.gov/show/NCT00838903,Diabetes_Mellitus_Type_2,albiglutide|sitagliptin|glimepiride|metformin|placebo_albiglutide|placebo_sitagliptin|placebo_glimepiride|,1,302,serious_events,arm1,Sitagliptin 100 mg Plus Metformin,1,302
Hypersensitivity,Immune_system_disorders,NCT00844428,https://clinicaltrials.gov/show/NCT00844428,Atypical_Hemolytic_Uremic_Syndrome,eculizumab,4,20,other_events,arm0,Eculizumab,4,20
Hypersensitivity,Immune_system_disorders,NCT00844545,https://clinicaltrials.gov/show/NCT00844545,Atypical_Hemolytic_Uremic_Syndrome,Eculizumab,1,17,other_events,arm0,Eculizumab,1,17
Hypersensitivity,Immune_system_disorders,NCT00844844,https://clinicaltrials.gov/show/NCT00844844,Atypical_Hemolytic_Uremic_Syndrome,Eculizumab,1,17,other_events,arm0,Eculizumab,1,17
Hypersensitivity,Immune_system_disorders,NCT00845832,https://clinicaltrials.gov/show/NCT00845832,Rheumatoid_Arthritis,Placebo|rituximab_[MabThera/Rituxan]|tocilizumab_[RoActemra/Actemra]|,2,12,other_events,arm1,Rituximab (0.5 g) + TCZ (2 mg/kg),1,9
Hypersensitivity,Immune_system_disorders,NCT00845832,https://clinicaltrials.gov/show/NCT00845832,Rheumatoid_Arthritis,Placebo|rituximab_[MabThera/Rituxan]|tocilizumab_[RoActemra/Actemra]|,2,12,other_events,arm0,Placebo + TCZ (8 mg/kg),1,3
Hypersensitivity,Immune_system_disorders,NCT00846846,https://clinicaltrials.gov/show/NCT00846846,Coronary_Artery_Disease_Autosomal_Dominant_1,Endeavorå¨_Zotarolimus_Eluting_Coronary_Stent_System,3,1018,serious_events,arm0,Endeavor,3,1018
Hypersensitivity,Immune_system_disorders,NCT00847145,https://clinicaltrials.gov/show/NCT00847145,Meningococcal_Disease,1a_-_rMenB+OMV_NZ_and_routine_vaccines|1b_-_rMenB+OMV_NZ_and_routine_vaccines|2a_-_Routine_and_rMenB+OMV_NZ_vaccines|2b_-_rMenB+OMV_NZ_and_routine_vaccines|3a_-_rMenB+OMV_NZ_and_routine_vaccines|3b_-_1_dose_of_rMenB+OMV_NZ_plus_routine_infant_vaccinations|4a-_rMenB+OMV_NZ_and_routine_vaccines|4b_-_rMenB+OMV_NZ_and_routine_vaccines|,1,789,serious_events,arm1,12B13M,1,789
Hypersensitivity,Immune_system_disorders,NCT00850096,https://clinicaltrials.gov/show/NCT00850096,Type_2_Diabetes,Placebo_for_Nasulin|Nasulin|,1,47,other_events,arm1,Nasulin,1,47
HYPERSENSITIVITY,Immune_system_disorders,NCT00854308,https://clinicaltrials.gov/show/NCT00854308,Non-Small_Cell_Lung_Cancer,Erlotinib_HCl|MetMAb|placebo_(0.9__PERCENT_saline)|,1,67,serious_events,arm1,Placebo + Erlotinib,1,67
Hypersensitivity,Immune_system_disorders,NCT00855595,https://clinicaltrials.gov/show/NCT00855595,Papulopustular_Rosacea,Azelaic_acid_(Finacea_BAY39-6251)|Metronidazole_(Metrogel)|Doxycycline_(Oracea)|,1,101,other_events,arm1,Metronidazole (Metrogel) Plus Doxycycline (Oracea),1,101
Hypersensitivity,Immune_system_disorders,NCT00856583,https://clinicaltrials.gov/show/NCT00856583,Schizophrenia,Sertindole|Risperidone|,1,4905,serious_events,arm0,Sertindole,1,4905
Hypersensitivity,Immune_system_disorders,NCT00858637,https://clinicaltrials.gov/show/NCT00858637,Chronic_Kidney_Disease,MCI-196|Placebo_of_Simvastatin|Simvastatin|Placebo_of_MCI-196|,1,131,serious_events,arm1,Simvastatin (Active) + MCI-196 (Placebo)/ Comparion Phase,1,131
HYPERSENSITIVITY,Immune_system_disorders,NCT00860067,https://clinicaltrials.gov/show/NCT00860067,Healthy_or_Stable_Underlying_Chronic_Medical_Condition,Q/LAIV_(MEDI3250)|FluMist/B/Yamagata|FluMist/B/Victoria|,1,598,serious_events,arm1,All FluMist,1,598
Hypersensitivity,Immune_system_disorders,NCT00862836,https://clinicaltrials.gov/show/NCT00862836,Ovarian_Cancer,Vandetanib,1,14,other_events,arm0,Vandetanib 100 mg,1,14
Hypersensitivity,Immune_system_disorders,NCT00861705,https://clinicaltrials.gov/show/NCT00861705,Estrogen_Receptor_Negative|HER2/Neu_Negative|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Triple-Negative_Breast_Carcinoma|,Bevacizumab|Carboplatin|Cyclophosphamide|Doxorubicin_Hydrochloride|Laboratory_Biomarker_Analysis|Paclitaxel|,40,766,serious_events,arm1,Arm 2 (Pac + Bev --> ddAC + Bev),1,108
Hypersensitivity,Immune_system_disorders,NCT00861705,https://clinicaltrials.gov/show/NCT00861705,Estrogen_Receptor_Negative|HER2/Neu_Negative|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Triple-Negative_Breast_Carcinoma|,Bevacizumab|Carboplatin|Cyclophosphamide|Doxorubicin_Hydrochloride|Laboratory_Biomarker_Analysis|Paclitaxel|,40,766,serious_events,arm3,Arm 4 (Pac + Carboplatin + Bev --> ddAC + Bev),1,112
Hypersensitivity,Immune_system_disorders,NCT00861705,https://clinicaltrials.gov/show/NCT00861705,Estrogen_Receptor_Negative|HER2/Neu_Negative|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Triple-Negative_Breast_Carcinoma|,Bevacizumab|Carboplatin|Cyclophosphamide|Doxorubicin_Hydrochloride|Laboratory_Biomarker_Analysis|Paclitaxel|,40,766,other_events,arm0,Arm 1 (Pac --> ddAC),8,108
Hypersensitivity,Immune_system_disorders,NCT00861705,https://clinicaltrials.gov/show/NCT00861705,Estrogen_Receptor_Negative|HER2/Neu_Negative|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Triple-Negative_Breast_Carcinoma|,Bevacizumab|Carboplatin|Cyclophosphamide|Doxorubicin_Hydrochloride|Laboratory_Biomarker_Analysis|Paclitaxel|,40,766,other_events,arm2,Arm 3 (Pac + Carboplatin --> ddAC),6,109
Hypersensitivity,Immune_system_disorders,NCT00861705,https://clinicaltrials.gov/show/NCT00861705,Estrogen_Receptor_Negative|HER2/Neu_Negative|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Triple-Negative_Breast_Carcinoma|,Bevacizumab|Carboplatin|Cyclophosphamide|Doxorubicin_Hydrochloride|Laboratory_Biomarker_Analysis|Paclitaxel|,40,766,other_events,arm3,Arm 4 (Pac + Carboplatin + Bev --> ddAC + Bev),12,112
Hypersensitivity,Immune_system_disorders,NCT00861705,https://clinicaltrials.gov/show/NCT00861705,Estrogen_Receptor_Negative|HER2/Neu_Negative|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Triple-Negative_Breast_Carcinoma|,Bevacizumab|Carboplatin|Cyclophosphamide|Doxorubicin_Hydrochloride|Laboratory_Biomarker_Analysis|Paclitaxel|,40,766,serious_events,arm2,Arm 3 (Pac + Carboplatin --> ddAC),1,109
Hypersensitivity,Immune_system_disorders,NCT00861705,https://clinicaltrials.gov/show/NCT00861705,Estrogen_Receptor_Negative|HER2/Neu_Negative|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Triple-Negative_Breast_Carcinoma|,Bevacizumab|Carboplatin|Cyclophosphamide|Doxorubicin_Hydrochloride|Laboratory_Biomarker_Analysis|Paclitaxel|,40,766,other_events,arm1,Arm 2 (Pac + Bev --> ddAC + Bev),11,108
Hypersensitivity,Immune_system_disorders,NCT00864253,https://clinicaltrials.gov/show/NCT00864253,Malignant_Melanoma,ABI-007|Dacarbazine|,2,258,serious_events,arm1,Dacarbazine Arm B,2,258
Hypersensitivity,Immune_system_disorders,NCT00865709,https://clinicaltrials.gov/show/NCT00865709,Metastatic_Colorectal_Cancer,Sorafenib_(Nexavar_BAY43-9006)_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|Matching_placebo_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|,2,202,serious_events,arm1,Matching Placebo + mFOLFOX6,1,101
Hypersensitivity,Immune_system_disorders,NCT00865709,https://clinicaltrials.gov/show/NCT00865709,Metastatic_Colorectal_Cancer,Sorafenib_(Nexavar_BAY43-9006)_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|Matching_placebo_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|,2,202,serious_events,arm3,Matching Placebo + mFOLFOX6 (OS Update),1,101
Hypersensitivity,Immune_system_disorders,NCT00867009,https://clinicaltrials.gov/show/NCT00867009,Non-Small-Cell_Lung_Cancer,Pemetrexed|Cisplatin|Cetuximab|,4,226,other_events,arm0,Pem/Cis + Cet,3,113
Hypersensitivity,Immune_system_disorders,NCT00867009,https://clinicaltrials.gov/show/NCT00867009,Non-Small-Cell_Lung_Cancer,Pemetrexed|Cisplatin|Cetuximab|,4,226,serious_events,arm0,Pem/Cis + Cet,1,113
Hypersensitivity,Immune_system_disorders,NCT00868530,https://clinicaltrials.gov/show/NCT00868530,Hemophilia_A,Xyntha,1,53,other_events,arm0,Xyntha,1,53
Hypersensitivity,Immune_system_disorders,NCT00868959,https://clinicaltrials.gov/show/NCT00868959,Bipolar_Depression,lurasidone,1,813,serious_events,arm0,Lurasidone,1,813
Hypersensitivity,Immune_system_disorders,NCT00878800,https://clinicaltrials.gov/show/NCT00878800,Dose_Escalation:_Solid_Tumors|MTD:_Soft_Tissue_Sarcomas|,PXD101|Doxorubicin|,4,34,serious_events,arm2,Cohort 3: BelDox IV (800/75),1,9
Hypersensitivity,Immune_system_disorders,NCT00878800,https://clinicaltrials.gov/show/NCT00878800,Dose_Escalation:_Solid_Tumors|MTD:_Soft_Tissue_Sarcomas|,PXD101|Doxorubicin|,4,34,other_events,arm2,Cohort 3: BelDox IV (800/75),1,9
Hypersensitivity,Immune_system_disorders,NCT00878800,https://clinicaltrials.gov/show/NCT00878800,Dose_Escalation:_Solid_Tumors|MTD:_Soft_Tissue_Sarcomas|,PXD101|Doxorubicin|,4,34,other_events,arm4,MTD Expansion: BelDox IV (1000/75),2,16
Hypersensitivity,Immune_system_disorders,NCT00884949,https://clinicaltrials.gov/show/NCT00884949,MPS_IV_A,BMN_110,2,40,other_events,arm4,Entire Study,1,20
Hypersensitivity,Immune_system_disorders,NCT00884949,https://clinicaltrials.gov/show/NCT00884949,MPS_IV_A,BMN_110,2,40,other_events,arm0,0.1 mg/kg/Week,1,20
Hypersensitivity,Immune_system_disorders,NCT00885755,https://clinicaltrials.gov/show/NCT00885755,Breast_Cancer,Standard_taxane_therapy|capecitabine_[Xeloda]|trastuzumab_[Herceptin]|,2,33,other_events,arm0,All Participants,2,33
Hypersensitivity,Immune_system_disorders,NCT00887341,https://clinicaltrials.gov/show/NCT00887341,Rheumatoid_Arthritis,tocilizumab_[RoActemra/Actemra]|tocilizumab_[RoActemra/Actemra]|,1,39,other_events,arm1,Tocilizumab 31 Minute Infusions,1,39
Hypersensitivity,Immune_system_disorders,NCT00900731,https://clinicaltrials.gov/show/NCT00900731,Chronic_Obstructive_Pulmonary_Disease,Indacaterol_150_ë_g|Tiotropium_18_ë_g|Placebo_to_indacaterol|Placebo_to_tiotropium|,1,794,serious_events,arm0,Indacaterol 150 ë_g,1,794
HYPERSENSITIVITY,Immune_system_disorders,NCT00900627,https://clinicaltrials.gov/show/NCT00900627,Neoplasms|Breast_Neoplasms|Breast_Cancer|,AZD8931|Paclitaxel|Placebo|,1,95,other_events,arm5,Placebo + Paclitaxel,1,95
Hypersensitivity,Immune_system_disorders,NCT00903006,https://clinicaltrials.gov/show/NCT00903006,Breast_Cancer,Fulvestrant|MK-0646|Dasatinib|,1,3,other_events,arm1,Group 2: Fulvestrant + Dasatinib,1,3
Hypersensitivity,Immune_system_disorders,NCT00906399,https://clinicaltrials.gov/show/NCT00906399,Relapsing_Multiple_Sclerosis,BIIB017_(peginterferon_beta-1a)|Placebo|,1,513,serious_events,arm2,Year 1: Peginterferon Beta-1a Q2W,1,513
Hypersensitivity,Immune_system_disorders,NCT00908037,https://clinicaltrials.gov/show/NCT00908037,Purpura_Thrombocytopaenic_Idiopathic,eltrombopag|Placebo|,1,65,other_events,arm3,Part 2/ 3 (Eltrombopag Open-Label Period),1,65
Hypersensitivity,Immune_system_disorders,NCT00915278,https://clinicaltrials.gov/show/NCT00915278,Advanced_Non-Hematologic_Malignancies,PF-04605412,4,22,other_events,arm1,PF-04605412 11.25 mg,2,5
Hypersensitivity,Immune_system_disorders,NCT00915278,https://clinicaltrials.gov/show/NCT00915278,Advanced_Non-Hematologic_Malignancies,PF-04605412,4,22,other_events,arm5,PF-04605412 136 mg,1,9
Hypersensitivity,Immune_system_disorders,NCT00915278,https://clinicaltrials.gov/show/NCT00915278,Advanced_Non-Hematologic_Malignancies,PF-04605412,4,22,serious_events,arm0,PF-04605412 7.5 mg,1,8
Hypersensitivity,Immune_system_disorders,NCT00924352,https://clinicaltrials.gov/show/NCT00924352,Metastatic_Breast_Cancer,Dasatinib|Ixabepilone|,3,56,other_events,arm0,Ixabepilone + Dasatinib,3,56
HYPERSENSITIVITY,Immune_system_disorders,NCT00924443,https://clinicaltrials.gov/show/NCT00924443,Acute_Myeloid_Leukemia,clofarabine,2,66,other_events,arm0,Clofarabine,2,66
Hypersensitivity,Immune_system_disorders,NCT00924638,https://clinicaltrials.gov/show/NCT00924638,Cryptogenic_Symptomatic_Transient_Ischemic_Attack|Cryptogenic_Ischemic_Stroke|,Revealå¨_XT_Insertable_Cardiac_Monitor,1,221,serious_events,arm0,Continuous Monitoring,1,221
Hypersensitivity,Immune_system_disorders,NCT00925938,https://clinicaltrials.gov/show/NCT00925938,Cervical_Priming,misoprostol|placebo|,1,25,other_events,arm1,MVPI 800 Mcg,1,25
Hypersensitivity,General_disorders,NCT00930969,https://clinicaltrials.gov/show/NCT00930969,Coronary_Artery_Disease,ICD,1,175,serious_events,arm0,ICD Indicated,1,175
Hypersensitivity,Immune_system_disorders,NCT00933686,https://clinicaltrials.gov/show/NCT00933686,Fibromyalgia,Saizenå¨|Placebo_and_Saizenå¨|,1,55,other_events,arm0,Saizenå¨,1,55
Hypersensitivity,Immune_system_disorders,NCT00936897,https://clinicaltrials.gov/show/NCT00936897,Postmenopausal_Osteoporosis,Ibandronate|Denosumab|,1,410,serious_events,arm0,Ibandronate 150 mg PO QM,1,410
Hypersensitivity,Immune_system_disorders,NCT00937560,https://clinicaltrials.gov/show/NCT00937560,Ovarian_Cancer,Bevacizumab|Paclitaxel|Carboplatin|,1,189,serious_events,arm0,Bevacizumab + Paclitaxel + Carboplatin,1,189
Hypersensitivity,Immune_system_disorders,NCT00938015,https://clinicaltrials.gov/show/NCT00938015,Arthritis_Psoriatic,Questionnaire|Questionnaire|,2,301,other_events,arm0,Etanercept,2,301
Hypersensitivity,Immune_system_disorders,NCT00939783,https://clinicaltrials.gov/show/NCT00939783,Alzheimer's_Disease,Dimebon,1,648,serious_events,arm0,Dimebon,1,648
Hypersensitivity,Immune_system_disorders,NCT00941733,https://clinicaltrials.gov/show/NCT00941733,Critical_Lower_Limb_Ischemia,IN.PACT_Amphirion|Standard_PTA|,2,239,serious_events,arm0,Drug Eluting Balloon,2,239
Hypersensitivity,Immune_system_disorders,NCT00943111,https://clinicaltrials.gov/show/NCT00943111,Gaucher_Disease_Type_1,Eliglustat_tartrate|Imiglucerase|,1,106,other_events,arm0,Eliglustat,1,106
Hypersensitivity,Immune_system_disorders,NCT00943735,https://clinicaltrials.gov/show/NCT00943735,Overactive_Bladder,Fesoterodine|Your_Way|,1,774,other_events,arm0,Fesoterodine 4 mg or 8 mg,1,774
Hypersensitivity,Immune_system_disorders,NCT00948389,https://clinicaltrials.gov/show/NCT00948389,Glioblastoma,Dasatinib|Lomustine|,1,6,other_events,arm0,Dasatinib 100 mg QD/100 mg BID + Lomustine 110 mg/m^2,1,6
Hypersensitivity,Immune_system_disorders,NCT00948675,https://clinicaltrials.gov/show/NCT00948675,Advanced_Non-Small_Cell_Lung_Cancer,Pemetrexed|Carboplatin|Paclitaxel|Bevacizumab|,1,166,serious_events,arm1,Paclitaxel + Carboplatin + Bevacizumab,1,166
Hypersensitivity,Immune_system_disorders,NCT00949884,https://clinicaltrials.gov/show/NCT00949884,Hypertension,olmesartan_medoxomil|Placebo|losartan_potassium|,1,469,other_events,arm2,Losartan,1,469
Hypersensitivity,Immune_system_disorders,NCT00950755,https://clinicaltrials.gov/show/NCT00950755,Lymphoma_Non-Hodgkin|Non-Hodgkin's_Lymphoma|,tositumomab_and_Iodine_I_131_tositumomab_(anti-B1_antibody),1,41,other_events,arm0,TST and Iodine I 131 TST,1,41
Hypersensitivity,Immune_system_disorders,NCT00951275,https://clinicaltrials.gov/show/NCT00951275,Rheumatoid_Arthritis,tocilizumab_[RoActemra/Actemra]|Standard_DMARDs_(Disease_Modifying_Anti_Rheumatic_Drugs)|,1,105,other_events,arm0,Tocilizumab 8 mg/kg,1,105
Hypersensitivity,Immune_system_disorders,NCT00953706,https://clinicaltrials.gov/show/NCT00953706,Cystic_Fibrosis,Ivacaftor|Placebo|,1,5,other_events,arm2,Placebo/Ivacaftor ‰ÛÒ Part B,1,5
Hypersensitivity,Immune_system_disorders,NCT00963235,https://clinicaltrials.gov/show/NCT00963235,HIV_Infections|Pneumococcal_Infections|,13-valent_pneumococcal_conjugate_vaccine|Blood_draw|,1,329,other_events,arm3,13vPnC (After Dose 3 Blood Draw),1,329
Hypersensitivity,Immune_system_disorders,NCT00975806,https://clinicaltrials.gov/show/NCT00975806,Renal_Cell_Carcinoma,Lenalidomide_(CC-5013)_in_combination_with_sunitinib|Lenalidomide|Sunitinib|,1,7,serious_events,arm1,Cohort F,1,7
Hypersensitivity,Immune_system_disorders,NCT00977106,https://clinicaltrials.gov/show/NCT00977106,Rheumatoid_Arthritis,tocilizumab_[RoActemra/Actemra]|placebo|tocilizumab_[RoActemra/Actemra]|,1,50,other_events,arm1,Placebo Tocilizumab,1,50
Hypersensitivity,Immune_system_disorders,NCT00981045,https://clinicaltrials.gov/show/NCT00981045,Iron_Deficiency_Anemia|Impaired_Renal_Function|,Ferric_Carboxymaltose_(FCM)|Iron_Sucrose_(Venofer)|,1,1276,serious_events,arm0,Ferric Carboxymaltose (FCM),1,1276
Hypersensitivity,Immune_system_disorders,NCT00980655,https://clinicaltrials.gov/show/NCT00980655,Vaccines_Pneumococcal_Conjugate_Vaccine,13vPnC|23vPS|,2,221,other_events,arm1,13vPnC Dose 3 Blood Draw to 13vPnC Dose 4,2,221
Hypersensitivity,Immune_system_disorders,NCT00982007,https://clinicaltrials.gov/show/NCT00982007,Iron_Deficiency_Anemia,Ferric_Carboxymaltose_(FCM)|Ferrous_Sulfate_Tablets|IV_Iron_(standard_of_care)|Ferric_Carboxymaltose_(FCM)|,3,245,serious_events,arm3,Cohort 2 (Group D) - IV Iron (Standard of Care),3,245
Hypersensitivity,Immune_system_disorders,NCT00982657,https://clinicaltrials.gov/show/NCT00982657,Solid_Tumor,CVX-060_+_sunitinib|CVX-060_+_sunitinib|CVX-060_+_sunitinib|CVX-060_+_sunitinib|CVX-060_+_sunitinib|Sunitinib|,1,12,other_events,arm0,CVX-060 6 mg/kg + Sunitinib 50 mg,1,12
Hypersensitivity,Immune_system_disorders,NCT00984568,https://clinicaltrials.gov/show/NCT00984568,Colitis_Ulcerative,Infliximab|Prednisolone|5-aminosalicylic_acid|Azathioprine|,2,15,other_events,arm0,Top-Hold,2,15
Hypersensitivity,Immune_system_disorders,NCT00985959,https://clinicaltrials.gov/show/NCT00985959,Multiple_Myeloma,JNJ-26866138_0.7_mg/m2|JNJ-26866138_1.0_mg/m2|JNJ-26866138_1.3_mg/m2|Melphalan|Prednisolone|,9,93,other_events,arm1,Phase I - JNJ-26866138 1.0 mg/m2 Group,1,6
Hypersensitivity,Immune_system_disorders,NCT00985959,https://clinicaltrials.gov/show/NCT00985959,Multiple_Myeloma,JNJ-26866138_0.7_mg/m2|JNJ-26866138_1.0_mg/m2|JNJ-26866138_1.3_mg/m2|Melphalan|Prednisolone|,9,93,other_events,arm3,Phase II - JNJ-26866138 1.3 mg/m2 Group,8,87
Hypersensitivity,Immune_system_disorders,NCT00986362,https://clinicaltrials.gov/show/NCT00986362,Vitrectomy,Ocriplasmin|Placebo|,1,16,other_events,arm0,Ocriplasmin,1,16
Hypersensitivity,Immune_system_disorders,NCT00986154,https://clinicaltrials.gov/show/NCT00986154,Venous_Thromboembolism|Deep_Vein_Thrombosis_(DVT)|Pulmonary_Embolism_(PE)|Thromboembolism|Venous_Thrombosis|,edoxaban_tosylate(DU-176b)|low_molecular_weight_heparin/unfractionated_heparin|warfarin|,2,8240,serious_events,arm0,Heparin/Edoxaban Tosylate,1,4118
Hypersensitivity,Immune_system_disorders,NCT00986154,https://clinicaltrials.gov/show/NCT00986154,Venous_Thromboembolism|Deep_Vein_Thrombosis_(DVT)|Pulmonary_Embolism_(PE)|Thromboembolism|Venous_Thrombosis|,edoxaban_tosylate(DU-176b)|low_molecular_weight_heparin/unfractionated_heparin|warfarin|,2,8240,serious_events,arm1,Heparin/Warfarin,1,4122
Hypersensitivity,Immune_system_disorders,NCT00987935,https://clinicaltrials.gov/show/NCT00987935,Carcinoma_Hepatocellular,Sorafenib|BIBF_1120|,1,16,other_events,arm6,Phase I Group II Nintedanib 200 mg Bid,1,16
Hypersensitivity,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,72,2092,serious_events,arm1,Lenalidomide/Docetaxel/Prednisone (DPL),3,525
Hypersensitivity,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,72,2092,serious_events,arm0,Docetaxel/Prednisone/Placebo (DP),1,521
Hypersensitivity,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,72,2092,other_events,arm0,Docetaxel/Prednisone/Placebo (DP),20,521
Hypersensitivity,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,72,2092,other_events,arm1,Lenalidomide/Docetaxel/Prednisone (DPL),48,525
Hypersensitivity,Immune_system_disorders,NCT00991341,https://clinicaltrials.gov/show/NCT00991341,Cardiac_Surgery|Erythrocyte_Transfusion|,Red_blood_cell_units_stored_<=_10_days|Red_blood_cell_units_stored_>=_21_days|,1,538,other_events,arm0,Shorter-storage Red Blood Cell Units,1,538
Hypersensitivity,Immune_system_disorders,NCT00996203,https://clinicaltrials.gov/show/NCT00996203,Rheumatoid_Arthritis,tocilizumab_[RoActemra/Actemra]|DMARDs_(disease-modifying_antirheumatic_drugs)|,1,201,other_events,arm0,Tocilizumab,1,201
Hypersensitivity,Immune_system_disorders,NCT00996437,https://clinicaltrials.gov/show/NCT00996437,Vitreous_Hemorrhage|Proliferative_Diabetic_Retinopathy|,Ranibizumab|Saline|,1,136,other_events,arm1,Saline Injection,1,136
Hypersensitivity,Immune_system_disorders,NCT00997503,https://clinicaltrials.gov/show/NCT00997503,Coronary_Artery_Disease,TAXUS_LibertÌ©_Paclitaxel-Eluting_Coronary_Stent|prasugrel|placebo|aspirin|,7,8398,serious_events,arm0,TAXUS LibertÌ©: Overall Enrolled Population,3,4199
Hypersensitivity,Immune_system_disorders,NCT00997503,https://clinicaltrials.gov/show/NCT00997503,Coronary_Artery_Disease,TAXUS_LibertÌ©_Paclitaxel-Eluting_Coronary_Stent|prasugrel|placebo|aspirin|,7,8398,other_events,arm0,TAXUS LibertÌ©: Overall Enrolled Population,4,4199
Hypersensitivity,Immune_system_disorders,NCT01001377,https://clinicaltrials.gov/show/NCT01001377,Metastatic_Colorectal_Cancer,Cetuximab|Panitumumab|,3,999,serious_events,arm1,Panitumumab,1,496
Hypersensitivity,Immune_system_disorders,NCT01001377,https://clinicaltrials.gov/show/NCT01001377,Metastatic_Colorectal_Cancer,Cetuximab|Panitumumab|,3,999,serious_events,arm0,Cetuximab,2,503
Hypersensitivity,Immune_system_disorders,NCT01004159,https://clinicaltrials.gov/show/NCT01004159,Colorectal_Cancer,cetuximab_with_irinotecan,1,20,serious_events,arm0,Cetuximab With Irinotecan,1,20
Hypersensitivity,Immune_system_disorders,NCT01004003,https://clinicaltrials.gov/show/NCT01004003,Carcinoma_Hepatocellular,Sorafenib|BIBF_1120|,1,4,other_events,arm2,Phase I Group 1 200mg Nintedanib Bid,1,4
Hypersensitivity,Immune_system_disorders,NCT01006980,https://clinicaltrials.gov/show/NCT01006980,Malignant_Melanoma,RO5185426|dacarbazine|,1,282,serious_events,arm1,Dacarbazine,1,282
Hypersensitivity,Immune_system_disorders,NCT01012674,https://clinicaltrials.gov/show/NCT01012674,Cerebral_Arterial_Diseases,Dotarem|TOF_MRA|,1,187,serious_events,arm0,Dotarem-enhanced MRA,1,187
Hypersensitivity,Immune_system_disorders,NCT01014208,https://clinicaltrials.gov/show/NCT01014208,Lymphoma_Large-Cell_Diffuse,OFATUMUMAB_+_DHAP|RITUXIMAB_+_DHAP|,1,222,serious_events,arm1,Ofatumumab + Chemotherapy,1,222
Hypersensitivity,Immune_system_disorders,NCT01015118,https://clinicaltrials.gov/show/NCT01015118,Ovarian_Neoplasms|Peritoneal_Neoplasms|,Placebo|Paclitaxel|BIBF_1120|Carboplatin|Paclitaxel|Carboplatin|,85,2704,other_events,arm0,Nintedanib,53,902
Hypersensitivity,Immune_system_disorders,NCT01015118,https://clinicaltrials.gov/show/NCT01015118,Ovarian_Neoplasms|Peritoneal_Neoplasms|,Placebo|Paclitaxel|BIBF_1120|Carboplatin|Paclitaxel|Carboplatin|,85,2704,serious_events,arm0,Nintedanib,1,902
Hypersensitivity,Immune_system_disorders,NCT01015118,https://clinicaltrials.gov/show/NCT01015118,Ovarian_Neoplasms|Peritoneal_Neoplasms|,Placebo|Paclitaxel|BIBF_1120|Carboplatin|Paclitaxel|Carboplatin|,85,2704,serious_events,arm1,Placebo,1,450
Hypersensitivity,Immune_system_disorders,NCT01015118,https://clinicaltrials.gov/show/NCT01015118,Ovarian_Neoplasms|Peritoneal_Neoplasms|,Placebo|Paclitaxel|BIBF_1120|Carboplatin|Paclitaxel|Carboplatin|,85,2704,other_events,arm1,Placebo,30,450
Hypersensitivity,Immune_system_disorders,NCT01015287,https://clinicaltrials.gov/show/NCT01015287,Acute_Coronary_Syndromes,Placebo|Prasugrel|,3,6029,serious_events,arm0,Non Pre-treatment,1,1996
Hypersensitivity,Immune_system_disorders,NCT01015287,https://clinicaltrials.gov/show/NCT01015287,Acute_Coronary_Syndromes,Placebo|Prasugrel|,3,6029,other_events,arm0,Non Pre-treatment,1,1996
Hypersensitivity,Immune_system_disorders,NCT01015287,https://clinicaltrials.gov/show/NCT01015287,Acute_Coronary_Syndromes,Placebo|Prasugrel|,3,6029,other_events,arm1,Pre-treatment,1,2037
Hypersensitivity,General_disorders,NCT01018992,https://clinicaltrials.gov/show/NCT01018992,Stress_Disorders_Post-Traumatic,GSK561679|Placebo|,4,128,other_events,arm0,GSK561679,1,63
Hypersensitivity,General_disorders,NCT01018992,https://clinicaltrials.gov/show/NCT01018992,Stress_Disorders_Post-Traumatic,GSK561679|Placebo|,4,128,other_events,arm1,Placebo,3,65
Hypersensitivity,Immune_system_disorders,NCT01026818,https://clinicaltrials.gov/show/NCT01026818,Erectile_Dysfunction,Tadalafil|Placebo|,2,722,other_events,arm1,Tadalafil 5 mg OaD (Double-Blind Period/Washout Period),1,139
Hypersensitivity,Immune_system_disorders,NCT01026818,https://clinicaltrials.gov/show/NCT01026818,Erectile_Dysfunction,Tadalafil|Placebo|,2,722,other_events,arm0,Screen - BNSRP,1,583
Hypersensitivity,Immune_system_disorders,NCT01027650,https://clinicaltrials.gov/show/NCT01027650,Macular_Edema|Retinal_Vein_Occlusion|,AGN208397_intravitreal_injection|dexamethasone_intravitreal_implant|,1,6,other_events,arm1,Stage 1 Cohort 3,1,6
Hypersensitivity,Immune_system_disorders,NCT01032291,https://clinicaltrials.gov/show/NCT01032291,Colorectal_Cancer,cetuximab|lenalidomide|,1,29,serious_events,arm1,Lenalidomide + Cetuximab (Safety Lead-in and Proof of Concept),1,29
Hypersensitivity,Immune_system_disorders,NCT01044498,https://clinicaltrials.gov/show/NCT01044498,Rheumatoid_Arthritis,Tocilizumab|Ortho-Novumå¨_1/35|,1,23,serious_events,arm0,Tocilizumab 8 mg/kg + Ortho-Novumå¨ 1/35 (Group 1),1,23
Hypersensitivity,Immune_system_disorders,NCT01049945,https://clinicaltrials.gov/show/NCT01049945,Refractory_Multiple_Myeloma,bendamustine_hydrochloride|lenalidomide|dexamethasone|,5,55,other_events,arm3,Phase I Dose Level 4,1,6
Hypersensitivity,Immune_system_disorders,NCT01049945,https://clinicaltrials.gov/show/NCT01049945,Refractory_Multiple_Myeloma,bendamustine_hydrochloride|lenalidomide|dexamethasone|,5,55,other_events,arm5,Phase II Dose Level 4,4,49
Hypersensitivity,Immune_system_disorders,NCT01050634,https://clinicaltrials.gov/show/NCT01050634,Post_Menopausal_Women_With_Early_Breast_Cancer,Aromasin_(exemestane),1,924,other_events,arm0,Observational,1,924
Hypersensitivity,Immune_system_disorders,NCT01057693,https://clinicaltrials.gov/show/NCT01057693,Diabetic_Neuropathy_Painful,pregabalin_(Lyrica)|Placebo|,1,665,other_events,arm0,Pregabalin SB,1,665
Hypersensitivity,Immune_system_disorders,NCT01069419,https://clinicaltrials.gov/show/NCT01069419,Rheumatoid_Arthritis,Null,1,1111,serious_events,arm0,Cimzia,1,1111
Hypersensitivity,Immune_system_disorders,NCT01069627,https://clinicaltrials.gov/show/NCT01069627,Malignant_Melanoma,bevacizumab_[Avastin]|fotemustine|,1,20,other_events,arm0,Bevacizumab + Fotemustine,1,20
Hypersensitivity,Immune_system_disorders,NCT01073631,https://clinicaltrials.gov/show/NCT01073631,Serious_Fungal_Infections,voriconazole_tablet,1,543,other_events,arm0,Vfend,1,543
Hypersensitivity,Immune_system_disorders,NCT01076972,https://clinicaltrials.gov/show/NCT01076972,Human_Immunodeficiency_Virus,Lopinavir/ritonavir_(Kaletra),1,1184,serious_events,arm0,Lopinavir/Ritonavir Group,1,1184
Hypersensitivity,Immune_system_disorders,NCT01077375,https://clinicaltrials.gov/show/NCT01077375,Fibromyalgia,Placebo|Milnacipran|,1,85,serious_events,arm1,Milnacipran,1,85
Hypersensitivity,Immune_system_disorders,NCT01076959,https://clinicaltrials.gov/show/NCT01076959,Rheumatoid_Arthritis,Null,1,7740,serious_events,arm0,Humira,1,7740
Hypersensitivity,Immune_system_disorders,NCT01077739,https://clinicaltrials.gov/show/NCT01077739,Colorectal_Cancer,fluorouracil_(5FU)|leucovorin|bevacizumab_[Avastin]|capecitabine_[Xeloda]|oxaliplatin|,1,50,other_events,arm1,Bevacizumab + FOLFOX,1,50
Hypersensitivity,Immune_system_disorders,NCT01078116,https://clinicaltrials.gov/show/NCT01078116,Rheumatoid_Arthritis,Null,1,124,other_events,arm0,Adalimumab Treatment,1,124
Hypersensitivity,Immune_system_disorders,NCT01078675,https://clinicaltrials.gov/show/NCT01078675,Familial_Hypercholesterolaemia,rosuvastatin_calcium|rosuvastatin_calcium|rosuvastatin_calcium|,4,197,other_events,arm0,Rosuvastatin,4,197
Hypersensitivity,Immune_system_disorders,NCT01079182,https://clinicaltrials.gov/show/NCT01079182,Ankylosing_Spondylitis,Null,6,4681,other_events,arm0,Ankylosing Spondylitis,6,4681
Hypersensitivity,Immune_system_disorders,NCT01081041,https://clinicaltrials.gov/show/NCT01081041,Head_and_Neck_Cancer,Cetuximab|Cisplatin|Carboplatin|5-Fluorouracil|,1,33,serious_events,arm0,Part 1: Safety Lead-In (Cetuximab Cis or Carbo 5-FU),1,33
Hypersensitivity,Immune_system_disorders,NCT01088399,https://clinicaltrials.gov/show/NCT01088399,Hypopituitarism|Pituitary_Insufficiency|Growth_Hormone_Deficiency_Adult|,Somatropin_(rDNA_origin),3,9689,serious_events,arm1,Untreated,2,1269
Hypersensitivity,Immune_system_disorders,NCT01088399,https://clinicaltrials.gov/show/NCT01088399,Hypopituitarism|Pituitary_Insufficiency|Growth_Hormone_Deficiency_Adult|,Somatropin_(rDNA_origin),3,9689,serious_events,arm0,Somatropin Treated,1,8420
Hypersensitivity,Immune_system_disorders,NCT01098240,https://clinicaltrials.gov/show/NCT01098240,Major_Depressive_Disorder,CP-601927|Placebo|,2,374,other_events,arm1,CP-601927 + ADT,1,77
Hypersensitivity,Immune_system_disorders,NCT01098240,https://clinicaltrials.gov/show/NCT01098240,Major_Depressive_Disorder,CP-601927|Placebo|,2,374,other_events,arm0,Open-Label ADT,1,297
Hypersensitivity,Immune_system_disorders,NCT01104662,https://clinicaltrials.gov/show/NCT01104662,Complicated_Skin_and_Skin_Structure_Infections|S._Aureus_Bacteremia|Renal_Impairment|,Vancomycin|Daptomycin|Semi-Synthetic_Penicillin|,1,4,other_events,arm3,Vancomycin or SSP Bacteremia Moderate Renal Impairment,1,4
Hypersensitivity,Immune_system_disorders,NCT01107886,https://clinicaltrials.gov/show/NCT01107886,Type_2_Diabetes_Mellitus,Saxagliptin|Placebo|,3,8280,serious_events,arm1,Saxagliptin,3,8280
Hypersensitivity,Immune_system_disorders,NCT01109524,https://clinicaltrials.gov/show/NCT01109524,Lung_Neoplasms|Carcinoma|Cancer_of_the_Lung|Non-Small-Cell_Lung_Carcinoma|,Cetuximab|Cisplatin|Vinorelbine|,5,60,other_events,arm0,Cetuximab + Cisplatin/Vinorelbine,5,60
Hypersensitivity,Immune_system_disorders,NCT01110421,https://clinicaltrials.gov/show/NCT01110421,Pneumonia_Bacterial|Community-Acquired_Infections|Nosocomial_Infection|Pneumonia_Ventilator-Associated|,Cefepime_placebo|Cefepime|Doripenem|Doripenem_placebo|Amoxicillin/clavulanate_potassium|,1,5,other_events,arm0,Doripenem,1,5
Hypersensitivity,Immune_system_disorders,NCT01117012,https://clinicaltrials.gov/show/NCT01117012,Cystic_Fibrosis,Ivacaftor,3,192,other_events,arm0,VX-770,3,192
Hypersensitivity,Immune_system_disorders,NCT01118845,https://clinicaltrials.gov/show/NCT01118845,Non-Hodgkin's_Lymphoma|Lymphoma_Large_Cell|Diffuse_Mantle_Cell_Lymphoma_Lymphoma|Follicular_Lymphoma|Large_B-Cell_Diffuse|,SyB_L-0501|Rituximab|,1,59,other_events,arm0,SyB L-0501,1,59
Hypersensitivity,Immune_system_disorders,NCT01120379,https://clinicaltrials.gov/show/NCT01120379,Chronic_Coronary_Occlusion|Vascular_Disease|Myocardial_Ischemia|Coronary_Artery_Stenosis|Coronary_Disease|Coronary_Artery_Disease|Coronary_Restenosis|,XIENCE_Vå¨_EECSS,1,4852,serious_events,arm0,XV-LTF Cohort,1,4852
Hypersensitivity,Immune_system_disorders,NCT01121393,https://clinicaltrials.gov/show/NCT01121393,Carcinoma_Non-Small-Cell_Lung|Adenocarcinoma|,Gemcitabine+Cisplatin|BIBW_2992|,1,239,serious_events,arm0,Afatinib 40mg,1,239
Hypersensitivity,Immune_system_disorders,NCT01121406,https://clinicaltrials.gov/show/NCT01121406,Ovarian_Neoplasms,Paclitaxel|Gemcitabine|Topotecan|Pegylated_liposomal_doxorubicin_(PLD)|BI_6727|,4,78,other_events,arm0,Volasertib (BI 6727),2,54
Hypersensitivity,Immune_system_disorders,NCT01121406,https://clinicaltrials.gov/show/NCT01121406,Ovarian_Neoplasms,Paclitaxel|Gemcitabine|Topotecan|Pegylated_liposomal_doxorubicin_(PLD)|BI_6727|,4,78,other_events,arm2,Cytotoxic to Volasertib Switch,2,24
Hypersensitivity,Immune_system_disorders,NCT01121575,https://clinicaltrials.gov/show/NCT01121575,Non_Small_Cell_Lung_Cancer,PF-02341066|PF-00299804|PF-02341066|PF-00299804|,1,6,serious_events,arm1,PF-02341066 200 mg BID/ PF-00299804 45 mg QD,1,6
Hypersensitivity,Immune_system_disorders,NCT01125774,https://clinicaltrials.gov/show/NCT01125774,Migraine,Telcagepant|Placebo|,1,2660,serious_events,arm0,Telcagepant 140 mg,1,2660
Hypersensitivity,Immune_system_disorders,NCT01126437,https://clinicaltrials.gov/show/NCT01126437,Pulmonary_Disease_Chronic_Obstructive,tiotropium_18_mcg|tiotropium_1.25_mcg_(2_actuations/day)|tiotropium_2.5_mcg_(2_actuations/day)|,5,17116,serious_events,arm0,Tiotropium 2.5 mcg and Placebo,2,5724
Hypersensitivity,Immune_system_disorders,NCT01126437,https://clinicaltrials.gov/show/NCT01126437,Pulmonary_Disease_Chronic_Obstructive,tiotropium_18_mcg|tiotropium_1.25_mcg_(2_actuations/day)|tiotropium_2.5_mcg_(2_actuations/day)|,5,17116,serious_events,arm1,Tiotropium 5 mcg and Placebo,2,5705
Hypersensitivity,Immune_system_disorders,NCT01126437,https://clinicaltrials.gov/show/NCT01126437,Pulmonary_Disease_Chronic_Obstructive,tiotropium_18_mcg|tiotropium_1.25_mcg_(2_actuations/day)|tiotropium_2.5_mcg_(2_actuations/day)|,5,17116,serious_events,arm2,Tiotropium 18 mcg and Placebo,1,5687
Hypersensitivity,Immune_system_disorders,NCT01132664,https://clinicaltrials.gov/show/NCT01132664,Metastatic_Breast_Cancer|HER2+_Breast_Cancer|,BKM120|Trastuzumab|Capecitabine|,3,68,other_events,arm1,Phase Ib Dose Escalation 100 mg/Day,1,12
Hypersensitivity,Immune_system_disorders,NCT01132664,https://clinicaltrials.gov/show/NCT01132664,Metastatic_Breast_Cancer|HER2+_Breast_Cancer|,BKM120|Trastuzumab|Capecitabine|,3,68,serious_events,arm4,BM Cohort 100 mg/Day,1,6
Hypersensitivity,Immune_system_disorders,NCT01132664,https://clinicaltrials.gov/show/NCT01132664,Metastatic_Breast_Cancer|HER2+_Breast_Cancer|,BKM120|Trastuzumab|Capecitabine|,3,68,other_events,arm2,Phase II Dose Expansion 100 mg/Day,1,50
Hypersensitivity,Immune_system_disorders,NCT01134107,https://clinicaltrials.gov/show/NCT01134107,Diabetes_Mellitus_Type_1,Insulin_Lispro_6_Day_(6D)|Insulin_Aspart_6_Day_(6D)|,2,127,other_events,arm0,Insulin Lispro 6D,2,127
Hypersensitivity,Immune_system_disorders,NCT01134627,https://clinicaltrials.gov/show/NCT01134627,Multiple_Sclerosis_Relapsing-Remitting,Minocycline|Placebo|,1,155,serious_events,arm1,Rebifå¨ + Placebo,1,155
Hypersensitivity,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,3,90,other_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,3,90
Hypersensitivity,Immune_system_disorders,NCT01137292,https://clinicaltrials.gov/show/NCT01137292,Invasive_Fungal_Infections,voriconazole_(VFENDå¨),1,177,other_events,arm0,Voriconazole,1,177
Hypersensitivity,Immune_system_disorders,NCT01139762,https://clinicaltrials.gov/show/NCT01139762,Benign_Prostatic_Hyperplasia|Enlarged_Prostate|,Tadalafil|Placebo|Finasteride|,1,345,other_events,arm1,Tadalafil,1,345
Hypersensitivity,Immune_system_disorders,NCT01143324,https://clinicaltrials.gov/show/NCT01143324,Degenerative_Lumbar_Spine_Causing_Back_and/or_Leg_Pain|Lumbar_Spine_Degeneration|,MAST‰ã¢_procedure,1,252,serious_events,arm0,MAST‰ã¢ Procedure,1,252
Hypersensitivity,Immune_system_disorders,NCT01144364,https://clinicaltrials.gov/show/NCT01144364,Non-Hodgkin's_Lymphoma,rituximab_[Mabthera/Rituxan],13,567,serious_events,arm0,Rituximab Induction (Induction Phase Only),1,233
Hypersensitivity,Immune_system_disorders,NCT01144364,https://clinicaltrials.gov/show/NCT01144364,Non-Hodgkin's_Lymphoma,rituximab_[Mabthera/Rituxan],13,567,other_events,arm0,Rituximab Induction (Induction Phase Only),11,233
Hypersensitivity,Immune_system_disorders,NCT01144364,https://clinicaltrials.gov/show/NCT01144364,Non-Hodgkin's_Lymphoma,rituximab_[Mabthera/Rituxan],13,567,other_events,arm2,Rituximab Induction Observation Maintenance (Follow-up Phase),1,101
Hypersensitivity,Immune_system_disorders,NCT01147302,https://clinicaltrials.gov/show/NCT01147302,Graft_Rejection,Placebo|C1_Esterase_Inhibitor_(Human)|,1,9,other_events,arm1,CINRYZE,1,9
HYPERSENSITIVITY,Immune_system_disorders,NCT01151215,https://clinicaltrials.gov/show/NCT01151215,Neoplasms|Breast_Neoplasms|Breast_Cancer|,AZD8931|anastrozole|Placebo|,2,120,other_events,arm1,AZD8931 40mg,2,120
Hypersensitivity,Immune_system_disorders,NCT01153815,https://clinicaltrials.gov/show/NCT01153815,Cerebrovascular_Accident,GSK1358820(Botulinum_toxin_type_A)|placebo|,1,83,other_events,arm0,Placebo,1,83
Hypersensitivity,Immune_system_disorders,NCT01153971,https://clinicaltrials.gov/show/NCT01153971,Non-Hodgkin's_Lymphoma,rituximab,1,47,other_events,arm0,Rituximab + Fludarabine + Cyclophosphamide,1,47
Hypersensitivity,Immune_system_disorders,NCT01157351,https://clinicaltrials.gov/show/NCT01157351,Schizophrenia,paliperidone|risperidone|haloperidole|perphenazine|aripiprazole|quetiapine|paliperidone_palmitate|olanzapine|,1,218,serious_events,arm1,Oral Antipsychotics,1,218
Hypersensitivity,Immune_system_disorders,NCT01159600,https://clinicaltrials.gov/show/NCT01159600,Diabetes_Mellitus_Type_2,Placebo_identical_to_BI_10773_high_dose|Placebo_identical_to_BI_10773_low_dose|BI_10773|BI_10773|Placebo_identical_to_BI_10773_low_dose|BI_10773|Placebo_identical_to_BI_10773_high_dose|,1,206,serious_events,arm0,Met: Placebo,1,206
Hypersensitivity,Immune_system_disorders,NCT01160744,https://clinicaltrials.gov/show/NCT01160744,Carcinoma_Non-Small-Cell_Lung,IMC-1121B_(ramucirumab)|Pemetrexed|Carboplatin_(AUC_6)|Cisplatin|Gemcitabine|Carboplatin_(AUC_5)|,1,69,serious_events,arm0,Pem + Carb or Cis (Non-Squamous),1,69
Hypersensitivity,Immune_system_disorders,NCT01169675,https://clinicaltrials.gov/show/NCT01169675,Neoplasms,BIBW_2992_low_dose|BIBW_2992_high_dose|pemetrexed|pemetrexed|BIBW_2992_high_dose_6_day|pemetrexed|pemetrexed|pemetrexed|pemetrexed|BIBW_2992_low_dose_6_day|BIBW_2992_medium_dose_6_day|BIBW_2992_medium_dose|,1,17,other_events,arm3,Pulsed Afatinib 60 mg,1,17
Hypersensitivity,Immune_system_disorders,NCT01171976,https://clinicaltrials.gov/show/NCT01171976,Diabetic_Macular_Edema,Ranibizumab,2,126,other_events,arm1,TE Ranibizumab 0.5 mg Alone,2,126
Hypersensitivity,Immune_system_disorders,NCT01175707,https://clinicaltrials.gov/show/NCT01175707,Complicated_Skin_or_Skin_Structure_Infection,Daptomycin|Vancomycin|,1,40,other_events,arm0,Daptomycin,1,40
Hypersensitivity,Immune_system_disorders,NCT01179191,https://clinicaltrials.gov/show/NCT01179191,Chronic_Disease|Pain|,morphine_sulfate_and_naltrexone_hydrochloride_(EMBEDA),1,684,other_events,arm0,EMBEDA,1,684
Hypersensitivity,Immune_system_disorders,NCT01179347,https://clinicaltrials.gov/show/NCT01179347,Cystic_Fibrosis,tiotropium_Respimatå¨_inhaler|Placebo_Respimatå¨_inhaler|,1,147,serious_events,arm2,Placebo Randomized Group Over the Open‰öÕLabel Period,1,147
Hypersensitivity,Immune_system_disorders,NCT01182428,https://clinicaltrials.gov/show/NCT01182428,Coronary_Artery_Stenosis|Coronary_Arteriosclerosis|Coronary_Artery_Disease|Coronary_Artery_Restenosis|Total_Coronary_Occlusion|Stent_Thrombosis|Vascular_Disease|Myocardial_Ischemia|,XIENCE_Vå¨/_XIENCE_PRIME‰ã¢|CYPHER_SELECT|,2,297,serious_events,arm0,XIENCE Vå¨ / XIENCE PRIMEå¨,2,297
Hypersensitivity,Infections_and_infestations,NCT01193582,https://clinicaltrials.gov/show/NCT01193582,Pneumococcal_Infections,Prevenar|Prevenar|Prevenar|Prevenar|,1,125,other_events,arm2,Group 3,1,125
hypersensitivity,Immune_system_disorders,NCT01193920,https://clinicaltrials.gov/show/NCT01193920,Streptococcal_Infections,Group_B_Streptococcus_Trivalent_Vaccine_-_20/20/20_ë_g|Saline_solution|Group_B_Streptococcus_Trivalent_Vaccine_-_0.5/0.5/0.5_ë_g|Group_B_Streptococcus_Trivalent_Vaccine_-_2.5/2.5/2.5_ë_g|Group_B_Streptococcus_Trivalent_Vaccine_-_5/5/5_ë_g|saline_solution|,1,79,serious_events,arm6,Infants 0.5/0.5/0.5 ë_g,1,79
Hypersensitivity,Immune_system_disorders,NCT01194414,https://clinicaltrials.gov/show/NCT01194414,Rheumatoid_Arthritis,tocilizumab_SC|tocilizumab_IV|placebo_to_tocilizumab_SC|placebo_to_tocilizumab_IV|Disease-modifying_antirheumatic_drugs_(DMARDs)|,3,1262,serious_events,arm1,Tocilizumab IV,1,631
Hypersensitivity,Immune_system_disorders,NCT01194414,https://clinicaltrials.gov/show/NCT01194414,Rheumatoid_Arthritis,tocilizumab_SC|tocilizumab_IV|placebo_to_tocilizumab_SC|placebo_to_tocilizumab_IV|Disease-modifying_antirheumatic_drugs_(DMARDs)|,3,1262,serious_events,arm0,Tocilizumab SC,2,631
Hypersensitivity,Immune_system_disorders,NCT01198548,https://clinicaltrials.gov/show/NCT01198548,Stage_IV_Colon_Cancer|Stage_IV_Rectal_Cancer|,leucovorin_calcium|bevacizumab|cholecalciferol|fluorouracil|oxaliplatin|pharmacological_study|,1,10,serious_events,arm0,Treatment (FOLXFOX Bevacizumab Cholecalciferol),1,10
Hypersensitivity,Immune_system_disorders,NCT01198756,https://clinicaltrials.gov/show/NCT01198756,Influenza_Human|Seasonal_Influenza|,Quadrivalent_seasonal_influenza_vaccine_GSK2282512A|Fluarix‰ã¢_VB|Fluarix‰ã¢_YB|Quadrivalent_seasonal_influenza_vaccine_GSK2282512A|,1,929,serious_events,arm1,Victoria Strain Fluarix Group,1,929
Hypersensitivity,Immune_system_disorders,NCT01207388,https://clinicaltrials.gov/show/NCT01207388,B-cell_Acute_Lymphoblastic_Leukemia,Blinatumomab,2,116,serious_events,arm0,Blinatumomab,2,116
Hypersensitivity,Immune_system_disorders,NCT01207648,https://clinicaltrials.gov/show/NCT01207648,Multiple_Sclerosis,Rebifå¨,1,307,serious_events,arm0,Retrospective Cohort,1,307
Hypersensitivity,Immune_system_disorders,NCT01209624,https://clinicaltrials.gov/show/NCT01209624,Low_Tension_Glaucoma,Null,2,902,other_events,arm0,Xalatanå¨,2,902
Hypersensitivity,Immune_system_disorders,NCT01209702,https://clinicaltrials.gov/show/NCT01209702,Spondylitis_Ankylosing,tocilizumab|Placebo|,1,260,serious_events,arm3,All Tocilizumab,1,260
hypersensitivity,Immune_system_disorders,NCT01222884,https://clinicaltrials.gov/show/NCT01222884,Chronic_Kidney_Disease_Stage_5_(Dialysis_Dependent),Monofer|Iron_sucrose|,1,230,serious_events,arm0,Iron Isomaltoside 1000,1,230
HYPERSENSITIVITY,Immune_system_disorders,NCT01225211,https://clinicaltrials.gov/show/NCT01225211,Cystic_Fibrosis,Lumacaftor|Ivacaftor|Lumacaftor_Placebo|Ivacaftor_Placebo|,1,23,serious_events,arm5,Cohort 2: LUM 200 mg qd ‰ÛÒ Period 1,1,23
Hypersensitivity,Immune_system_disorders,NCT01227395,https://clinicaltrials.gov/show/NCT01227395,HIV_Infection,Azithromycin,1,391,other_events,arm0,Azithromycin for Prophylaxis,1,391
Hypersensitivity,Immune_system_disorders,NCT01227824,https://clinicaltrials.gov/show/NCT01227824,Infection_Human_Immunodeficiency_Virus_I,GSK1349572_(dolutegravir)|raltegravir|GSK1349572_Placebo|ABC/3TC|TDF/FTC|raltegravir_Placebo|,1,411,serious_events,arm1,RTG 400 mg BID,1,411
Hypersensitivity,Immune_system_disorders,NCT01233869,https://clinicaltrials.gov/show/NCT01233869,Polycystic_Kidney_Autosomal_Dominant,Bosutinib|Bosutinib|Placebo|,6,145,other_events,arm0,Bosutinib 200 mg/Day,2,58
Hypersensitivity,Immune_system_disorders,NCT01233869,https://clinicaltrials.gov/show/NCT01233869,Polycystic_Kidney_Autosomal_Dominant,Bosutinib|Bosutinib|Placebo|,6,145,other_events,arm1,Bosutinib 400 mg/Day,1,31
Hypersensitivity,Immune_system_disorders,NCT01233869,https://clinicaltrials.gov/show/NCT01233869,Polycystic_Kidney_Autosomal_Dominant,Bosutinib|Bosutinib|Placebo|,6,145,other_events,arm3,Placebo,3,56
HYPERSENSITIVITY,Immune_system_disorders,NCT01242514,https://clinicaltrials.gov/show/NCT01242514,Rheumatoid_Arthritis,Fostamatinib|Fostamatinib|Fostamatinib|,2,1343,serious_events,arm0,FOSTA 100 MG BID,2,1343
Hypersensitivity,Immune_system_disorders,NCT01244061,https://clinicaltrials.gov/show/NCT01244061,Smoking_Cessation,Varenicline|Placebo|,2,494,serious_events,arm0,Varenicline,1,249
Hypersensitivity,Immune_system_disorders,NCT01244061,https://clinicaltrials.gov/show/NCT01244061,Smoking_Cessation,Varenicline|Placebo|,2,494,serious_events,arm1,Placebo,1,245
Hypersensitivity,Immune_system_disorders,NCT01245062,https://clinicaltrials.gov/show/NCT01245062,Melanoma,GSK1120212|Chemotherapy|,1,211,serious_events,arm0,Trametinib,1,211
Hypersensitivity,Immune_system_disorders,NCT01253525,https://clinicaltrials.gov/show/NCT01253525,Adenocarcinoma,Ramucirumab_(IMC-1121B_)|Paclitaxel|,1,6,other_events,arm0,Ramucirumab + Paclitaxel,1,6
Hypersensitivity,Immune_system_disorders,NCT01256086,https://clinicaltrials.gov/show/NCT01256086,Asthma,Formatris_24åµg|Formatris_12åµg|Foradil_P_24åµg|Foradil_P_12åµg|,1,42,other_events,arm3,12åµg Formoterol Aerolizer,1,42
Hypersensitivity,Immune_system_disorders,NCT01259713,https://clinicaltrials.gov/show/NCT01259713,Invasive_Fungal_Disease,Liposomal_amphotericin_B|Placebo|,1,237,serious_events,arm0,Liposomal Amphotericin B,1,237
Hypersensitivity,Immune_system_disorders,NCT01260350,https://clinicaltrials.gov/show/NCT01260350,Chronic_Hepatitis_C_Infection,SOF|RBV|PEG|LDV|GS-9669|LDV/SOF|,1,14,other_events,arm18,Group 20: LDV/SOF FDC+RBV 12 wk: GT 1 Hemophiliac,1,14
Hypersensitivity,Immune_system_disorders,NCT01264939,https://clinicaltrials.gov/show/NCT01264939,Chronic_Idiopathic_Urticaria,Omalizumab|Placebo|H1_antihistamine_H2_antihistamine_leukotriene_receptor_antagonist|Diphenhydramine|,1,83,serious_events,arm0,Placebo,1,83
Hypersensitivity,Immune_system_disorders,NCT01265784,https://clinicaltrials.gov/show/NCT01265784,Complicated_Intra-abdominal_Infection,TP-434|Ertapenem|Placebo|,1,30,other_events,arm2,Ertapenem 1 g q24h,1,30
Hypersensitivity,Immune_system_disorders,NCT01272219,https://clinicaltrials.gov/show/NCT01272219,Metabolism_and_Nutrition_Disorder|Obesity|,liraglutide|placebo|placebo|liraglutide|placebo|,1,487,serious_events,arm1,Liraglutide Placebo no Pre-diabetes,1,487
Hypersensitivity,Immune_system_disorders,NCT01275066,https://clinicaltrials.gov/show/NCT01275066,MPS_IV_A,BMN_110_Weekly|Placebo|BMN_110_Every_Other_Week|,8,234,other_events,arm2,BMN110 2.0 mg/kg/Week,2,58
Hypersensitivity,Immune_system_disorders,NCT01275066,https://clinicaltrials.gov/show/NCT01275066,MPS_IV_A,BMN_110_Weekly|Placebo|BMN_110_Every_Other_Week|,8,234,other_events,arm1,BMN110 2.0 mg/kg/Qow,4,59
Hypersensitivity,Immune_system_disorders,NCT01275066,https://clinicaltrials.gov/show/NCT01275066,MPS_IV_A,BMN_110_Weekly|Placebo|BMN_110_Every_Other_Week|,8,234,other_events,arm0,Placebo,1,59
Hypersensitivity,Immune_system_disorders,NCT01275066,https://clinicaltrials.gov/show/NCT01275066,MPS_IV_A,BMN_110_Weekly|Placebo|BMN_110_Every_Other_Week|,8,234,serious_events,arm2,BMN110 2.0 mg/kg/Week,1,58
Hypersensitivity,Immune_system_disorders,NCT01289041,https://clinicaltrials.gov/show/NCT01289041,Advanced_Endometrial_Cancer,BKM120,3,70,serious_events,arm0,All Patients,3,70
Hypersensitivity,Immune_system_disorders,NCT01289990,https://clinicaltrials.gov/show/NCT01289990,Diabetes_Mellitus_Type_2,BI_10773|Placebo|Placebo|Placebo|Placebo|Placebo|BI_10773|Placebo|Placebo|BI_10773|Placebo|Placebo|Placebo|BI_10773|BI_10773|BI_10773|Placebo|BI_10773|Placebo|Placebo|Placebo|Sitagliptin_100mg|BI_10773|Placebo|Placebo|Placebo|Placebo|Placebo|Placebo|Placebo|,1,206,serious_events,arm7,Empagliflozin 10 mg (Metformin),1,206
Hypersensitivity,Immune_system_disorders,NCT01297270,https://clinicaltrials.gov/show/NCT01297270,Hepatitis_C,BI201335|PegIFN/RBV|BI201335|Placebo|,1,262,serious_events,arm0,Faldaprevir 120mg and PegIFN/RBV,1,262
Hypersensitivity,Immune_system_disorders,NCT01299389,https://clinicaltrials.gov/show/NCT01299389,Schizophrenia,Paliperidone_palmitate|Placebo|,1,156,other_events,arm2,Placebo (Post-observational),1,156
Hypersensitivity,Immune_system_disorders,NCT01299480,https://clinicaltrials.gov/show/NCT01299480,Meningococcal_Vaccine,Vaccine|Vaccine|Vaccine|Vaccine|Vaccine|,1,144,serious_events,arm4,Group 5: rLP2086(2-6- Month)+ Saline(0-1- Month),1,144
Hypersensitivity,Immune_system_disorders,NCT01302067,https://clinicaltrials.gov/show/NCT01302067,Overactive_Bladder,Fesoterodine_8mg|Fesoterodine_4mg|Placebo|,1,779,other_events,arm2,Fesoterodine 8 mg,1,779
Hypersensitivity,Immune_system_disorders,NCT01302392,https://clinicaltrials.gov/show/NCT01302392,Multiple_Myeloma,Carfilzomib|Best_Supportive_Care|,1,153,serious_events,arm0,Best Supportive Care,1,153
Hypersensitivity,Immune_system_disorders,NCT01304706,https://clinicaltrials.gov/show/NCT01304706,Diabetic_Macular_Edema,Fluocinolone_Acetonide,2,120,other_events,arm0,Fluocinolone Acetonide,2,120
Hypersensitivity,Immune_system_disorders,NCT01309243,https://clinicaltrials.gov/show/NCT01309243,HIV-1_Infection,FTC/RPV/TDF|EFV/FTC/TDF|,1,392,serious_events,arm1,EFV/FTC/TDF,1,392
Hypersensitivity,Immune_system_disorders,NCT01313637,https://clinicaltrials.gov/show/NCT01313637,Pulmonary_Disease_Chronic_Obstructive,GSK573719/GW642444_125/25mcg|GSK573719_125mcg|GW642444_25mcg|Placebo_only|,1,403,serious_events,arm3,UMEC/VI 125/25 åµg,1,403
Hypersensitivity,Immune_system_disorders,NCT01314105,https://clinicaltrials.gov/show/NCT01314105,Ovarian_Neoplasms|Peritoneal_Neoplasms|,BIBF_1120_+_PLD_30_mg/m2_+_CBDCA_AUC5_mg/mLmin|BIBF_1120+_PLD_30_mg/m2_+_CBDCA_AUC5_mg/mLmin|BIBF_1120_+_PLD_30_mg/m2_+_CBDCA_AUC5_mg/mLmin|,2,14,serious_events,arm0,Nintedanib 150mg,1,7
Hypersensitivity,Immune_system_disorders,NCT01314105,https://clinicaltrials.gov/show/NCT01314105,Ovarian_Neoplasms|Peritoneal_Neoplasms|,BIBF_1120_+_PLD_30_mg/m2_+_CBDCA_AUC5_mg/mLmin|BIBF_1120+_PLD_30_mg/m2_+_CBDCA_AUC5_mg/mLmin|BIBF_1120_+_PLD_30_mg/m2_+_CBDCA_AUC5_mg/mLmin|,2,14,other_events,arm0,Nintedanib 150mg,1,7
Hypersensitivity,Immune_system_disorders,NCT01332994,https://clinicaltrials.gov/show/NCT01332994,Rheumatoid_Arthritis,rituximab_[MabThera/Rituxan]|tocilizumab_[RoActemra/Actemra]|tocilizumab_[RoActemra/Actemra]|,2,519,serious_events,arm0,TCZ/TCZ or TCZ/RTX,2,519
Hypersensitivity,Immune_system_disorders,NCT01333813,https://clinicaltrials.gov/show/NCT01333813,Hepatitis_B,Engerix-B‰ã¢_Kinder,1,297,serious_events,arm0,Engerix-B Kinder Group,1,297
Hypersensitivity,Immune_system_disorders,NCT01343888,https://clinicaltrials.gov/show/NCT01343888,Hepatitis_C,PegIFN/RBV|BI_201335|BI_201335|Placebo|,1,261,serious_events,arm1,Faldaprevir 240mg and PegIFN/RBV,1,261
Hypersensitivity,Immune_system_disorders,NCT01348100,https://clinicaltrials.gov/show/NCT01348100,Schizophrenia,Iloperidone_crystalline_formulation|Iloperidone_microparticle_formulation|Oral_iloperidone|,1,15,other_events,arm11,Iloperidone 250 mg Microparticle Formulation - Phase C Depot,1,15
Hypersensitivity,Immune_system_disorders,NCT01354431,https://clinicaltrials.gov/show/NCT01354431,Renal_Cell_Carcinoma,BMS-936558|BMS-936558|BMS-936558|,13,167,other_events,arm1,2.0 mg/kg Nivolumab,1,54
Hypersensitivity,Immune_system_disorders,NCT01354431,https://clinicaltrials.gov/show/NCT01354431,Renal_Cell_Carcinoma,BMS-936558|BMS-936558|BMS-936558|,13,167,other_events,arm2,10.0 mg/kg Nivolumab,9,54
Hypersensitivity,Immune_system_disorders,NCT01354431,https://clinicaltrials.gov/show/NCT01354431,Renal_Cell_Carcinoma,BMS-936558|BMS-936558|BMS-936558|,13,167,other_events,arm0,0.3 mg/kg Nivolumab,3,59
Hypersensitivity,Immune_system_disorders,NCT01361568,https://clinicaltrials.gov/show/NCT01361568,Postoperative_Pain,CR845|Placebo|CR845|Placebo|,1,13,other_events,arm5,Placebo-No Postoperative Treatment,1,13
Hypersensitivity,Immune_system_disorders,NCT01377480,https://clinicaltrials.gov/show/NCT01377480,Chagas_Disease,Posaconazole|Placebo_for_posaconazole|Benznidazole|,4,58,other_events,arm3,Benznidazole + Placebo,3,30
Hypersensitivity,Immune_system_disorders,NCT01377480,https://clinicaltrials.gov/show/NCT01377480,Chagas_Disease,Posaconazole|Placebo_for_posaconazole|Benznidazole|,4,58,other_events,arm2,Posaconazole + Benznidazole,1,28
Hypersensitivity,Immune_system_disorders,NCT01388647,https://clinicaltrials.gov/show/NCT01388647,HER-2_Positive_Breast_Cancer,eribulin|carboplatin|trastuzumab|,2,6,other_events,arm0,Eribulin 1.1 mg/m2,2,6
Hypersensitivity,Immune_system_disorders,NCT01394991,https://clinicaltrials.gov/show/NCT01394991,Anemia|Neoplasms|,Epoetin_alfa_450_IU/kg_once_a_week|Epoetin_alfa_150_IU/kg_3_times_a_week|Epoetin_alfa_450_IU/kg_once_a_week_(QW)|Epoetin_alfa_150_IU/kg_3_times_a_week_(TIW)|,1,242,serious_events,arm0,Epoetin Alfa QW,1,242
Hypersensitivity,Immune_system_disorders,NCT01415518,https://clinicaltrials.gov/show/NCT01415518,Chronic_Obstructive_Pulmonary_Disease_(COPD),Drug:_Budesonide/formoterol_(Symbicort_Turbuhaler|Drug:_ipratropium_(AtroventTM)|theophylline_SR|,1,293,other_events,arm0,Symbicort Turbuhaler + Ipratropium + Theophylline SR,1,293
Hypersensitivity,Immune_system_disorders,NCT01415531,https://clinicaltrials.gov/show/NCT01415531,Hypertension,Nebivolol|Placebo|,1,427,serious_events,arm1,Nebivolol,1,427
Hypersensitivity,Immune_system_disorders,NCT01419197,https://clinicaltrials.gov/show/NCT01419197,Breast_Cancer,Trastuzumab_emtansine|Treatment_of_physician's_choice|,1,403,serious_events,arm0,Trastuzumab Emtansine - Planned Treatment Period,1,403
Hypersensitivity,Immune_system_disorders,NCT01420081,https://clinicaltrials.gov/show/NCT01420081,Endometrial_Neoplasms,PF-05212384|PF-05212384|PF-05212384|,1,21,other_events,arm4,PF-05212384 154 mg (PI3K Basal),1,21
Hypersensitivity,Immune_system_disorders,NCT01424930,https://clinicaltrials.gov/show/NCT01424930,Prostate_Neoplasms|Prostate_Cancer|,Abiraterone|Prednisone|,2,25,other_events,arm1,Abiraterone+Prednisone (High-fat Meal),1,18
Hypersensitivity,Immune_system_disorders,NCT01424930,https://clinicaltrials.gov/show/NCT01424930,Prostate_Neoplasms|Prostate_Cancer|,Abiraterone|Prednisone|,2,25,other_events,arm0,Abiraterone+Prednisone (Low-fat Meal),1,7
hypersensitivity,Immune_system_disorders,NCT01427803,https://clinicaltrials.gov/show/NCT01427803,Pain,Naproxen_Sodium_ER_(BAYH6689),1,745,serious_events,arm0,Naproxen Sodium ER (BAYH6689),1,745
Hypersensitivity,Immune_system_disorders,NCT01437267,https://clinicaltrials.gov/show/NCT01437267,Typhoid_Fever,Vi-CRM197_vaccine|Pneumococcal_conjugate_vaccine|Vi_Polysaccharide_(PS)_vaccine|,2,20,other_events,arm4,Vi-CRM Infants,2,20
HYPERSENSITIVITY,Immune_system_disorders,NCT01438424,https://clinicaltrials.gov/show/NCT01438424,Hepatitis_B_Virus|HBV|,Entecavir|Lamivudine|,14,894,other_events,arm5,Lamovidine 100 mg,11,523
HYPERSENSITIVITY,Immune_system_disorders,NCT01438424,https://clinicaltrials.gov/show/NCT01438424,Hepatitis_B_Virus|HBV|,Entecavir|Lamivudine|,14,894,other_events,arm0,Adefovir 10 mg,2,35
HYPERSENSITIVITY,Immune_system_disorders,NCT01438424,https://clinicaltrials.gov/show/NCT01438424,Hepatitis_B_Virus|HBV|,Entecavir|Lamivudine|,14,894,other_events,arm3,Entecavir 0.5 mg,1,336
Hypersensitivity,Immune_system_disorders,NCT01440569,https://clinicaltrials.gov/show/NCT01440569,Acquired_Immunodeficiency_Syndrome|HIV_Infections|,COBI|DRV|NRTIs|,1,295,serious_events,arm0,Treatment-Naive,1,295
Hypersensitivity,Immune_system_disorders,NCT01453374,https://clinicaltrials.gov/show/NCT01453374,Opioid_Dependence,VIVITROL_380mg,1,27,serious_events,arm0,VIVITROL,1,27
Hypersensitivity,Immune_system_disorders,NCT01454531,https://clinicaltrials.gov/show/NCT01454531,Allergic_Rhinoconjunctivitis,AVANZ_Phleum_pratense,10,192,other_events,arm0,AVANZ Phleum Pratense,10,192
Hypersensitivity,Immune_system_disorders,NCT01462266,https://clinicaltrials.gov/show/NCT01462266,Type_2_Diabetes_Mellitus,Sitagliptin|Comparator:_Placebo|Insulin_Glargine|Metformin|,1,329,serious_events,arm1,Placebo,1,329
Hypersensitivity,Immune_system_disorders,NCT01466179,https://clinicaltrials.gov/show/NCT01466179,Acute_Lymphoblastic_Leukemia,Blinatumomab,2,189,serious_events,arm0,Blinatumomab,2,189
HYPERSENSITIVITY,Immune_system_disorders,NCT01468207,https://clinicaltrials.gov/show/NCT01468207,Hidradenitis_Suppurativa_(HS),adalimumab|placebo|,1,48,other_events,arm4,Adalimumab EW/Adalimumab EOW (Period 2),1,48
Hypersensitivity,Immune_system_disorders,NCT01478594,https://clinicaltrials.gov/show/NCT01478594,Colorectal_Cancer,Tivozanib|Bevacizumab|mFOLFOX6|,10,441,other_events,arm0,Tivozanib + mFOLFOX6,3,177
Hypersensitivity,Immune_system_disorders,NCT01478594,https://clinicaltrials.gov/show/NCT01478594,Colorectal_Cancer,Tivozanib|Bevacizumab|mFOLFOX6|,10,441,other_events,arm1,Bevacizumab + mFOLFOX6,6,87
Hypersensitivity,Immune_system_disorders,NCT01478594,https://clinicaltrials.gov/show/NCT01478594,Colorectal_Cancer,Tivozanib|Bevacizumab|mFOLFOX6|,10,441,serious_events,arm0,Tivozanib + mFOLFOX6,1,177
Hypersensitivity,Immune_system_disorders,NCT01500083,https://clinicaltrials.gov/show/NCT01500083,Indolent_Non-Hodgkin's_Lymphoma|Chronic_Lymphocytic_Leukemia|,Bendamustine_at_a_dose_of_100_mg/m2|Bendamustine_at_a_dose_of_120_mg/m2|,1,74,serious_events,arm1,Patients With iNHL,1,74
Hypersensitivity,Immune_system_disorders,NCT01525563,https://clinicaltrials.gov/show/NCT01525563,Irregular_Menstrual_Cycle,Null,1,1000,other_events,arm0,Subjects With Irregular Menstrual Cycle,1,1000
Hypersensitivity,Immune_system_disorders,NCT01526785,https://clinicaltrials.gov/show/NCT01526785,Pompe_Disease,Alglucosidase_alfa,5,113,other_events,arm0,Alglucosidase Alfa,5,113
Hypersensitivity,Immune_system_disorders,NCT01542788,https://clinicaltrials.gov/show/NCT01542788,Chronic_Hepatitis_C,SOF|RBV|Placebo_to_match_SOF|Placebo_to_match_RBV|,1,207,serious_events,arm0,SOF+RBV,1,207
Hypersensitivity,Immune_system_disorders,NCT01543178,https://clinicaltrials.gov/show/NCT01543178,Irritable_Bowel_Syndrome_With_Diarrhea,open-label_rifaximin|double-blind_placebo|double-blind_rifaximin|,1,2579,serious_events,arm0,Total Open-label Experience,1,2579
Hypersensitivity,Immune_system_disorders,NCT01559116,https://clinicaltrials.gov/show/NCT01559116,Pulmonary_Disease_Chronic_Obstructive,tiotropium_+_olodaterol|tiotropium|olodaterol|tiotropium|tiotropium_+_olodaterol|Placebo|Respimat|,1,138,serious_events,arm3,Tiotropium (5 åµg),1,138
Hypersensitivity,Immune_system_disorders,NCT01560403,https://clinicaltrials.gov/show/NCT01560403,Short_Bowel_Syndrome,Teduglutide,2,9,other_events,arm0,NT/PBOTED,2,9
Hypersensitivity,Immune_system_disorders,NCT01592045,https://clinicaltrials.gov/show/NCT01592045,Neuroblastoma,ch14.18_-NCI|ch14.18-UTC|Granulocyte-Macrophage_Colony-Stimulating_Factor_(GM-CSF)|Aldesleukin_(IL-2)|Isotretinoin|,5,54,other_events,arm0,UTC ch14.18,2,27
Hypersensitivity,Immune_system_disorders,NCT01592045,https://clinicaltrials.gov/show/NCT01592045,Neuroblastoma,ch14.18_-NCI|ch14.18-UTC|Granulocyte-Macrophage_Colony-Stimulating_Factor_(GM-CSF)|Aldesleukin_(IL-2)|Isotretinoin|,5,54,other_events,arm1,NCI ch14.18,3,27
Hypersensitivity,Immune_system_disorders,NCT01594749,https://clinicaltrials.gov/show/NCT01594749,Chemotherapy-Induced_Nausea_and_Vomiting_(CINV),Fosaprepitant_dimeglumine|Fosaprepitant_Placebo|Dexamethasone|Ondansetron|Dexamethasone_Placebo|Ondansetron_Placebo|Rescue_Therapy|,2,1001,serious_events,arm0,Fosaprepitant Regimen,1,504
Hypersensitivity,Immune_system_disorders,NCT01594749,https://clinicaltrials.gov/show/NCT01594749,Chemotherapy-Induced_Nausea_and_Vomiting_(CINV),Fosaprepitant_dimeglumine|Fosaprepitant_Placebo|Dexamethasone|Ondansetron|Dexamethasone_Placebo|Ondansetron_Placebo|Rescue_Therapy|,2,1001,serious_events,arm1,Control Regimen,1,497
Hypersensitivity,Immune_system_disorders,NCT01596088,https://clinicaltrials.gov/show/NCT01596088,Extravasations_of_Anthracycline_Anti-cancer_Agents,Dexrazoxane,1,2,other_events,arm0,Dexrazoxane,1,2
Hypersensitivity,Immune_system_disorders,NCT01597908,https://clinicaltrials.gov/show/NCT01597908,Melanoma,Dabrafenib|Vemurafenib|Trametinib|,1,349,serious_events,arm1,Vemurafenib,1,349
Hypersensitivity,Immune_system_disorders,NCT01604278,https://clinicaltrials.gov/show/NCT01604278,Chronic_Obstructive_Pulmonary_Disease_(COPD),NVA237_50_åµg_and_indacaterol_150_åµg|Placebo_to_NVA237_and_indacaterol_150_åµg|,1,226,serious_events,arm0,NVA237 + Indacaterol,1,226
Hypersensitivity,Immune_system_disorders,NCT01604941,https://clinicaltrials.gov/show/NCT01604941,Iron_Overload_Due_to_Repeated_Red_Blood_Cell_Transfusions,SPD602,1,12,other_events,arm0,SPD602 50mg/kg/Day,1,12
Hypersensitivity,Immune_system_disorders,NCT01614457,https://clinicaltrials.gov/show/NCT01614457,Cystic_Fibrosis,Ivacaftor|Placebo|,2,35,other_events,arm1,Placebo,2,35
Hypersensitivity,Immune_system_disorders,NCT01614470,https://clinicaltrials.gov/show/NCT01614470,Cystic_Fibrosis,Ivacaftor|Placebo|,1,36,other_events,arm2,Part 2: Ivacaftor,1,36
Hypersensitivity,Immune_system_disorders,NCT01649791,https://clinicaltrials.gov/show/NCT01649791,B-cell_Chronic_Lymphocytic_Leukemia|Chronic_Lymphocytic_Leukemia|Stage_0_Chronic_Lymphocytic_Leukemia|Stage_I_Chronic_Lymphocytic_Leukemia|Stage_II_Chronic_Lymphocytic_Leukemia|,lenalidomide|laboratory_biomarker_analysis|lymph_node_biopsy|bone_marrow_aspiration|pharmacological_study|flow_cytometry|,1,8,other_events,arm0,Treatment (Lenalidomide as Chemoprevention),1,8
Hypersensitivity,Immune_system_disorders,NCT01653158,https://clinicaltrials.gov/show/NCT01653158,Advanced_Non-Hematologic_Malignancies,CP-751871|Docetaxel|,1,3,other_events,arm2,CP-751871 0.8 mg/kg + Docetaxel,1,3
Hypersensitivity,Immune_system_disorders,NCT01656161,https://clinicaltrials.gov/show/NCT01656161,Prostate_Cancer,Triptorelin_embonate_22.5_mg,1,120,serious_events,arm0,Triptorelin Embonate 22.5 mg,1,120
Hypersensitivity,Immune_system_disorders,NCT01673178,https://clinicaltrials.gov/show/NCT01673178,Diabetes_Melliuts_Type_2,Placebo|25_mg_PF-05231023|50_mg_PF-05231023|100_mg_PF-05231023|150_mg_PF-05231023|,1,22,serious_events,arm3,PF-05231023 100 mg,1,22
Hypersensitivity,Immune_system_disorders,NCT01683266,https://clinicaltrials.gov/show/NCT01683266,Type_1_Diabetes_Mellitus,HOE901-U300_(Insulin_glargine_new_formulation)|Lantus_(Insulin_glargine)|,1,274,serious_events,arm0,HOE901-å_U300,1,274
Hypersensitivity,Immune_system_disorders,NCT01685801,https://clinicaltrials.gov/show/NCT01685801,Cystic_Fibrosis,Ivacaftor|Placebo-matched-to-ivacaftor_tablet|,1,21,other_events,arm2,Open-label Period: Ivacaftor,1,21
HYPERSENSITIVITY,Hepatobiliary_disorders,NCT01689519,https://clinicaltrials.gov/show/NCT01689519,Malignant_Melanoma,Placebo|Vemurafenib|Cobimetinib|,3,247,serious_events,arm1,Cobimetinib + Vemurafenib,3,247
Hypersensitivity,Immune_system_disorders,NCT01709513,https://clinicaltrials.gov/show/NCT01709513,Hypercholesterolemia,Atorvastatin|Ezetimibe|Alirocumab|Placebo|,1,124,serious_events,arm1,Ezetimibe,1,124
Hypersensitivity,General_disorders,NCT01720251,https://clinicaltrials.gov/show/NCT01720251,Allergic_Rhinitis|Rhinoconjunctivitis|,placebo|AllerT_low_dose|AllerT_full_dose|,1,82,serious_events,arm2,AllerT 100 åµg,1,82
Hypersensitivity,Immune_system_disorders,NCT01721759,https://clinicaltrials.gov/show/NCT01721759,Squamous_Cell_Non-small_Cell_Lung_Cancer,Nivolumab,1,117,serious_events,arm0,NivolumAB 3 mg/kg,1,117
Hypersensitivity,Immune_system_disorders,NCT01726335,https://clinicaltrials.gov/show/NCT01726335,Schizophrenia,Risperidone_prolonged_release,1,53,other_events,arm0,Risperidone Prolonged Release,1,53
Hypersensitivity,Immune_system_disorders,NCT01773473,https://clinicaltrials.gov/show/NCT01773473,Type_2_Diabetes_Mellitus,Insulin_Lispro_Mix25|Insulin_Lispro_Mix50|,1,196,other_events,arm1,Insulin Lispro Mix50,1,196
Hypersensitivity,Immune_system_disorders,NCT01786902,https://clinicaltrials.gov/show/NCT01786902,Idiopathic_Short_Stature,DA-3002,2,36,other_events,arm0,DA-3002 Treatment Group,2,36
Hypersensitivity,Immune_system_disorders,NCT01807923,https://clinicaltrials.gov/show/NCT01807923,Cystic_Fibrosis_Homozygous_for_the_F508del_CFTR_Mutation,Lumacaftor_Plus_Ivacaftor_Combination|Ivacaftor|Placebo|,1,184,other_events,arm0,Placebo,1,184
Hypersensitivity,Immune_system_disorders,NCT01808326,https://clinicaltrials.gov/show/NCT01808326,Leukaemia_Lymphoblastic,chlorambucil_tablets,1,5,other_events,arm0,Chlorambucil 10 mg/m^2,1,5
Hypersensitivity,Immune_system_disorders,NCT01848990,https://clinicaltrials.gov/show/NCT01848990,Type_1_Diabetes_Mellitus,Commercial_Hylenexå¨_recombinant_(hyaluronidase_human_injection)|Precommercial_Hylenex_recombinant_(hyaluronidase_human_injection)|Insulin_lispro|Insulin_aspart|Insulin_glulisine|,1,113,other_events,arm2,Standard Rapid-Acting Insulin CSII,1,113
Hypersensitivity,Immune_system_disorders,NCT01928940,https://clinicaltrials.gov/show/NCT01928940,Solid_Tumours,dabrafenib|trametinib|,1,6,other_events,arm0,Phase I: GSK2118436 150 mg + GSK1120212 2 mg,1,6
Hypersensitivity,Immune_system_disorders,NCT01958060,https://clinicaltrials.gov/show/NCT01958060,Healthy,BI_1034020|Placebo_to_BI_1034020|,1,6,other_events,arm4,BI 1034020 (50 mg/25 mL - iv),1,6
Hypersensitivity,Immune_system_disorders,NCT01990859,https://clinicaltrials.gov/show/NCT01990859,Melanoma,Ipilimumab,1,20,other_events,arm0,3 MG/KG IPILIMUMAB,1,20
Hypersensitivity,Immune_system_disorders,NCT01998906,https://clinicaltrials.gov/show/NCT01998906,Breast_Cancer,Trastuzumab|Doxorubicin|Paclitaxel|CMF|,10,326,other_events,arm2,HER2- C,5,99
Hypersensitivity,Immune_system_disorders,NCT01998906,https://clinicaltrials.gov/show/NCT01998906,Breast_Cancer,Trastuzumab|Doxorubicin|Paclitaxel|CMF|,10,326,other_events,arm0,HER2+ TC,1,115
Hypersensitivity,Immune_system_disorders,NCT01998906,https://clinicaltrials.gov/show/NCT01998906,Breast_Cancer,Trastuzumab|Doxorubicin|Paclitaxel|CMF|,10,326,other_events,arm1,HER2+ C,4,112
Hypersensitivity,Immune_system_disorders,NCT01998919,https://clinicaltrials.gov/show/NCT01998919,Non-Small_Cell_Lung_Cancer,erlotinib_[Tarceva]|placebo|gemcitabine|cisplatin|carboplatin|,1,79,other_events,arm0,Placebo Plus Chemotherapy,1,79
Hypersensitivity,Immune_system_disorders,NCT02005484,https://clinicaltrials.gov/show/NCT02005484,Gastric_Cancer,Trastuzumab,2,12,other_events,arm0,Trastuzumab Monotherapy,1,6
Hypersensitivity,Immune_system_disorders,NCT02005484,https://clinicaltrials.gov/show/NCT02005484,Gastric_Cancer,Trastuzumab,2,12,serious_events,arm0,Trastuzumab Monotherapy,1,6
Hypersensitivity,Immune_system_disorders,NCT02013817,https://clinicaltrials.gov/show/NCT02013817,Lymphocytic_Leukemia_Chronic,rituximab_[MabThera/Rituxan]|fludarabine|cyclophosphamide|,1,43,other_events,arm0,Rituximab Fludarabine Cyclophosphamide,1,43
Hypersensitivity,Immune_system_disorders,NCT02446990,https://clinicaltrials.gov/show/NCT02446990,Coronary_Artery_Disease.,Ivabradine|Placebo|,2,19083,serious_events,arm0,Ivabradine,1,9539
Hypersensitivity,Immune_system_disorders,NCT02446990,https://clinicaltrials.gov/show/NCT02446990,Coronary_Artery_Disease.,Ivabradine|Placebo|,2,19083,serious_events,arm1,Placebo,1,9544
Hypersensitivity,Immune_system_disorders,NCT02461290,https://clinicaltrials.gov/show/NCT02461290,Follicular_Lymphoma,Chemotherapy|Rituximab|,6,198,serious_events,arm0,Rituximab + Chemotherapy,2,99
Hypersensitivity,Immune_system_disorders,NCT02461290,https://clinicaltrials.gov/show/NCT02461290,Follicular_Lymphoma,Chemotherapy|Rituximab|,6,198,other_events,arm0,Rituximab + Chemotherapy,4,99